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Overview 
The liver is an important organ for homeostasis. Drugs can interfere with the functions of the 
liver, which can lead to drug induced liver injury. Drug induced liver injury is a form of 
acquired liver disease and is a major cause of safety-related withdrawal of drugs from the 
market. Additionally, it is a major cause of attrition during the drug development process. 
Therefore, new strategies are needed to identify and characterize interactions of new 
candidate drugs with hepatic transporters early in the developmental process. It is important to 
improve the currently available prediction methods to identify and mitigate potential 
compound-related safety issues. This will result in safer drugs and a more efficient drug 
development process. 
In the first part of this chapter, an overview of main liver functions is provided, with a focus 
on the enterohepatic cycling of bile acids, their biosynthesis and the most common bile acid 
transporters. Additionally, an introduction on drug induced liver injury is given. In the second 
part, molecular imaging and more specifically Single Photon Emission Tomography will be 
discussed, since these techniques will be used in this work to investigate drug-induced liver 
injury in a non-invasive manner.  
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Part I: The Liver 
Anatomy and physiology of the liver  
The liver is the biggest organ in the body and is functionally very complex. It is an important 
organ for homeostasis and its most important functions include glycogen storage, production 
of plasma proteins and bile acids, elimination of endogenous substances (e.g. cholesterol, 
bilirubin and their metabolites) and secretion of toxic compounds (e.g. drugs, carcinogens) 
(Kullak-Ublick et al., 2000; Wolkoff et al., 2003; Erlinger et al., 1996)  
 
Figure 1.1: Anatomy of the liver and surroundings  (adapted from www.urmc.rochester.edu) 
The liver is located in the right upper quadrant of the abdominal cavity and it overlies the 
gallbladder (Figure 1.1). It consists of a left and right lobe, which each have an independent 
vascular supply and duct drainage. The lobes, in turn, consists of lobules, that form the 
functional units of the liver (Roberts et al., 2002) (Figure 1.2).  
The blood circuit of the liver is a unique system with a double blood supply: venous blood 
from the gut, pancreas and the spleen and arterial blood from the hepatic artery are delivered 
to the liver via a highly branched network of fenestrated blood vessels known as the liver 
sinusoids. In the liver sinusoids, the blood mixture has a near-direct contact with the 
hepatocytes. Processed blood is delivered from the sinusoids to the central veins which empty 
into the vena cava inferior (Treyer et al., 2013) 
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Histologically, the liver comprises thousands of nearly identical lobules that are divided by 
sheets of connective tissue. The lobule is the structural and functional subunit of the liver and 
has a hexagonal structure, 2 mm in height and 1–1.3 mm in diameter (Figure 1.2). The lobule 
consists mainly of hepatocytes that are arranged radially in plates from the central vein to the 
portal triads. Hepatocytes account for approximately 65% of the nuclear population in the 
liver. They are polarized cells since they absorb substrates from the blood and secrete 
molecules in the bile (Treyer et al., 2013). They have basolateral (sinusoidal) and apical 
(canalicular) plasma membrane domains (Trauner et al., 2003). The sinusoids can be found 
between the hepatocyte plates, also arranged radially, and connect the vessels in the portal 
triad to the central vein, thus allowing nutrient and oxygen-rich blood to enter the lobule from 
the portal vessels and empty into the central vein. The hepatocyte sinusoidal membrane faces 
the small perisinusoidal space of Disse, which is located between the hepatocytes and the 
endothelium of the sinusoid and gives rise to a two-way exchange between the blood and 
hepatocytes (Figure 1.3). The sinusoid lumen houses the mononuclear phagocytic system, 
which comprises generally stationary Kupffer cells as well as some migrating macrophages. 
These cells play an essential role in host defense mechanisms and the removal of foreign 
small particles and substances that enter the liver (Esteller, 2008). 
Immediately under the liver, the gallbladder can be found. The gallbladder contains bile that 
is produced by hepatocytes and is collected in bile canaliculi, which merge to form bile 
ductules (Figure 1.2). These intrahepatic ducts (within the liver) drain into the left and right 
hepatic ducts, which merge to form the common hepatic duct. The cystic duct from the 
gallbladder joins with the common hepatic duct to form the common bile duct (Figure 1.1). 
Bile is a major excretion route for endogenous substances and secretion of toxic compounds 
(Hofmann et al., 2008). 
The biliary apparatus is a convergent system of canals that begins in the canaliculi, followed 
by the bile ducts, and ending with the common bile duct (choledochus) (Figure 1.2). Bile 
secretion depends on the function of membrane transport systems in hepatocytes and 
cholangiocytes and on the structural integrity of the biliary tree. The hepatocytes generate the 
primary bile in their canaliculi (Esteller, 2008). Biliary canaliculi are blind tubular structures 
that favor the formation of bile flow by means of osmotic gradients.  Osmosis is considered to 
be the major mechanism of water movement during bile formation. The osmotic gradient is 
provided by organic and inorganic solutes secreted into bile. Therefore, bile formation is 
intimately related to hepatobiliary transport of biliary constituents (Strazzabosco et al., 2008).  
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The cholangiocytes, which are epithelial cells that line intrahepatic bile ducts, account for 3 to 
5% of the liver cell population. They modify the canalicular bile by secretory and reabsorptive 
processes as bile passes through the bile ducts.  
 
Figure 1.2: Microanatomy of the liver. Overview of the hepatic functional subunits or lobules . (Stenvall et al., 
2014) 
 
Figure 1.3: Liver sinusoids and surrounding tissue. Liver sinusoids are lined with fenestrated endothelia and 
Kupffer cells. They are separated from hepatocytes by the space of Disse. Stellate cells embrace the sinusoids  
inside the space of Disse. The arrows display the flow in the vessel. Hepatocytes form hepatic cords (adapted 
from Frevert et al., 2004). 
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The enterohepatic cycle 
Bile formation is a unique feature of the liver and is vital for survival of the organism (Boyer, 
2013). Bile is a complex fluid that consists of approximately 95% water in which a number of 
endogenous molecules, including bile acids, bilirubin, phospholipid, cholesterol, proteins, 
peptides, amino acids, steroids, enzymes, vitamins and heavy metals, as well as exogenous 
drugs, xenobiotics and environmental toxins are dissolved (Figure 1.4). These compounds 
flow through the biliary tract into the small intestine (Pellicoro et al., 2007).  
The important functions of bile according to Boyer et al. (Boyer et al., 2013) are:  
1) Bile is the major excretory route for potentially harmful exogenous lipophilic 
substances and for other endogenous substrates such as bilirubin and bile acids whose 
molecular weights are >300 to 500 dalton (Da) and not readily filtered or excreted by 
the kidneys. 
2) Bile acids are the major organic components in bile and normally function to emulsify 
dietary fat, cholesterol and fat-soluble vitamins, and facilitate their intestinal 
absorption. 
3) Bile is the major elimination route of cholesterol. 
4) Bile protects the organism from enteric infections by excreting immunoglobulin A 
(IgA), inflammatory cytokines, and by stimulating the innate immune system in the 
intestine. 
5) Bile is an essential component of the cholehepatic and enterohepatic circulation. 
6) Many hormones and pheromones are excreted in bile. 
 
The main driving force of bile flow is the secretion of bile acids. The average bile flow in 
humans is 1.5 to 2.0 mL/min/kg body weight (Roberts et al., 2002). In healthy individuals, the 
basal concentrations of bile acids in peripheral blood are lower than 10 µM, whereas they are 
in the mM range in bile (Marin et al., 2016). These bile acids are synthesized in the liver from 
cholesterol or are taken up from the sinusoidal blood as part of the enterohepatic circulation, 
and are actively secreted into bile and stored in the gallbladder between meals. Upon food 
ingestion, the duodenum secretes cholecystokinine into the blood, which consequently leads 
to contraction of the gallbladder and release of bile into the intestines. In the small intestine, 
bile has a detergent function to keep fat-soluble compounds in solution for uptake (vitamins) 
or excretion (cholesterol, lipophilic toxins/drugs). In the bile, bile acids form mixed micelles 
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with phospholipids and these are the vehicles that carry cholesterol and other lipophilic 
compounds through the intestine.  
 
 
Figure 1.4: Composition of bile. BA=bile acids; PL=phospholipids; Chol=cholesterol; BP=biliary pigments; 
proteins (Esteller et al., 2008). 
 
Figure 1.5 displays the enterohepatic cycle of bile acids. The enterohepatic circulation 
maintains a bile acid pool size of approximately 2-4 g in humans, and 4 mg in mice. This pool 
cycles 3-4 times per day and as such, the intestinal bile acids absorbed may be as much as 30 
g per day in humans, and 20 mg/day in mice. This enterohepatic circulation of bile acids is an 
extremely efficient process, since less than 5% of the intestinal bile acids escapes reabsorption 
and is eliminated in the feces (Hulzebos et al., 2001; Hofmann et al., 1983; Dietschy et al., 
1993; Dietschy et al., 2002). Bile acids are highly albumin bound. However, bile acids in the 
sinusoidal blood are efficiently taken up by the hepatocytes from Disse’s space due to the 
existence of transporters in the basolateral membrane (Alrefai et al., 2007; Esteller et al., 
2008; Kullak-Ublick et al., 2000; Kosters et al., 2008). After their dissociation from albumin, 
bile acids are transported across the hepatocytes to the canaliculus. Bile acid uptake across the 
basolateral membrane of the hepatocytes is mainly mediated by the Na+-dependent 
Taurocholate Cotransporting Polypeptide (NTCP). Additionally, Organic Anion Transporting 
Polypeptides (OATPs) are also responsible for bile acid uptake in a Na+-independent manner. 
Efflux to the bile across the canalicular membrane occurs via the Bile Salt Export Pump 
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(BSEP) and Multidrug Resistance-associated Protein 2 (MRP2). The bile acids arrive in the 
intestinal lumen via the bile duct. Some of the excreted bile acids are deconjugated there by 
the action of the bacterial flora. 95% of bile acids are efficiently reabsorbed from the 
intestinal lumen via passive diffusion and actively via Na+-dependent Apical Sodium 
Dependent Bile Acid Transporter (ASBT). Whereas passive absorption occurs down the 
length of the intestine, active transport of bile acids is restricted to the ileum (Dawson et al., 
2009). The intracellular transport of bile acids across the enterocytes is facilitated by the Ileal 
Bile Acid Binding Protein (IBABP), followed by efflux through Organic Solute Transporter α 
and β (OSTα/OSTβ). Bile acids then re-enter the portal blood and complete the enterohepatic 
cycle. Hepatic conversion of cholesterol to bile acid balances fecal excretion and this process 
represents a major route of cholesterol elimination from the body. 
 
Figure 1.5: Enterohepatic circulation of bile acids (adapted from Alrefai et al., 2008). 
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Bile acid biosynthesis  
In the 1930s, the steroid structure of bile acids was finally established (Hofmann et al., 2014). 
The first ideas came from Nobel Prize winners Heinrich Wieland and Adolf Windaus 
(Wieland, 1928; Windaus, 1928). These two chemists had slowly developed the idea that both 
cholesterol and bile acids share a four-ring structure with a side chain of five carbon atoms for 
bile acids and eight carbons for cholesterol. However, the structures of the steroid nucleus 
shown in their Nobel lectures were not correct. The path to the correct structure came from 
Desmond Bernal, a physicist, who undertook X-ray diffraction studies of organic molecules. 
He studied cholesterol, among other things, and published his findings in Nature in 1932 
(Bernal, 1932). Finally, Rosenheim and King in London, and Wieland and Dane in Munich, 
published the application of Bernal’s pioneering studies to the extensive literature on bile acid 
structure (Rosenheim et al., 1934). Each group proposed the 
cyclopentanoperhydrophenanthrene structure for the steroid nucleus. Figure 1.6 shows the 
structure of chenodeoxycholic acid (CDCA) and the numbering system for the steroid nucleus 
and side chain that was proposed in the 1930s and has been used ever since.  
 
Figure 1.6: Numbering system of bile acids and bile alcohols (A). Frontal view of CDCA (B). The numbering 
system was developed in the 1930s when the steroid structure was finally established. (adapted from Hofmann et 
al., 2014) 
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Bile acid biosynthesis is an exclusively liver-specific process and starts from cholesterol and 
involves 17 different enzymes, many of which are preferentially expressed in the liver 
(Pellicoro et al., 2007). 
The biosynthesis can be subdivided into a classic or neutral and an alternative or acidic 
pathway. The products that derive from these pathways are the primary bile acids. The classic 
pathway results in the formation of the primary bile acid cholic acid (CA) and accounts for 
90% of bile acid synthesis. In contrast, the alternative pathway, which is initiated in the 
plasma, leads to formation of the primary bile acid CDCA. The most important difference 
between these two pathways is the order of reactions that transforms cholesterol to CA or 
CDCA and the cellular site where the first reactions take place. The chemical diversity of the 
bile acid pool is further expanded by the action of anaerobic bacteria in the gut, which convert 
primary bile acids into dozens of secondary bile acids (Hofmann et al., 2008).  
For the conversion of cholesterol into primary bile acids, different steps can be distinguished:  
a) Initiation 
b) ring structure modification 
c) side chain oxidation and 
d) amino acid conjugation.  
 
Initiation 
The initiation of the classic pathway includes conversion of cholesterol into 7α-
hydroxycholesterol by the enzyme cholesterol 7α-hydroxylase (CYP7A1), expressed 
exclusively in the liver (Figure 1.7, reaction 1). This reaction is considered as the rate-limiting 
step in this route. 
Cholesterol can be hydroxylated at three different positions on the side chain and this leads to 
formation of 24-hydroxycholesterol, 25-hydroxycholesterol and 27-hydroxycholesterol. These 
oxysterols serve as substrates for bile acid synthesis. Cholesterol 24-hydroxylase is the 
enzyme that synthesizes 24(S)-hydroxycholesterol (Figure 1.7, reaction 2) and is detectable in 
neurons of the brain. The enzyme contributes little to overall bile acid synthesis but is 
important in the turnover of cholesterol in the brain. Cholesterol 25-hydroxylase (Figure 1.7, 
reaction 3) that synthesizes 25-hydroxycholesterol does not contribute significantly to bile 
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acid synthesis, but may play a role in cholesterol catabolism in a tissue-specific fashion, as 
does the cholesterol 24-hydroxylase.  
Sterol 27-hydroxylase (CYP27A1) synthesizes 27-hydroxycholesterol from cholesterol, 
which is the most abundant oxysterol in the plasma of mice and human (Figure 1.7, reaction 
4). This reaction is the start of the alternative biosynthesis pathway.  
To be converted into bile acids, oxysterols must undergo 7α-hydroxylation. Two enzymes can 
catalyze this step, namely CYP39A1 oxysterol 7α-hydroxylase and CYP7B1 oxysterol 7α-
hydroxylase. CYP39A1 acts on 24(S)-hydroxycholesterol (Figure 1.7, reaction 5) and 
CYP7B1 acts on 25- and 27-hydroxycholesterol (Figure 1.7, reaction 6). CYP7B1 oxysterol 
7α-hydroxylase is expressed at high levels in the adult liver. 5-10% of the bile acid pool in 
humans derives from oxysterols. (Russell, 2003) 
 
Figure 1.7: Hydroxylation. Cholesterol can be hydroxylated at 4 different positions. (adapted from Russell, 
2003) 
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Ring structure modification 
Next, the 7α-hydroxylated intermediates derived from cholesterol and the oxysterols are 
converted into their 3-oxo, Δ4 forms (Figure 1.8, reaction 7) by 3β-hydroxy-Δ5-C27-steroid 
oxidoreductase (C27-3β-HSD). This enzyme will act only on sterols with a 7α-hydroxyl group, 
and thus this step lies downstream of the cholesterol and oxysterol 7α-hydroxylases. The 
reaction catalyzed by these enzymes is complex and involves isomerization of the double 
bond from 5 to 4 position and the oxidation of the 3β-hydroxyl to a 3-oxo group (Figure 1.8, 
reaction 7). Since the C27-3β-HSD enzyme is unique, loss of this enzyme blocks the synthesis 
of bile acids.  
In a subsequent step, the products of this reaction can take one of the two routes of bile acid 
synthesis. In the presence of sterol 12α-hydroxylase, the resulting product will be converted 
ultimately into cholic acid (Figure 1.8, reaction 8). In the absence of sterol 12α-hydroxylase, 
the intermediates are converted into chenodeoxycholic acid or another bile acid. The 
concentration of sterol 12α-hydroxylase in the liver determines the relative amounts of the 
two primary bile acids, cholic acid and chenodeoxycholic acid.  
Both, the 12α-hydroxylated intermediates and the C27-3β-HSD intermediates that escape the 
12α-hydroxylation, are subject to reduction of the double bond in the A-ring by the enzyme 
Δ4- 3-oxosteroid 5β reductase (Figure 1.8, reaction 9). 
The final step of ring modification is the reduction of the 3-oxo-group to an alcohol in the 
alpha stereochemical configuration and is catalyzed by 3α-hydroxysteroid dehydrogenase 
(Figure 1.8, reaction 10) (Russell, 2003) 
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Figure 1.8: Ring structure modifications . 7α-hydroxylated intermediates and oxysterols are converted into their 
3-oxo, Δ4 forms. In presence of sterol 12α-hydroxylase, the synthesis will result in cholic acid; in the absence, it 
will result in chenodeoxycholic acid or another bile acid.Then, the double bonds of the A-ring are reduced. In the 
final step, the 3-oxo-group is reduced to an alcohol. (adapted from Russell, 2003). 
 
Side chain oxidation 
After ring modifications, the bile acid precursors undergo progressive oxidation and 
shortening of the sterol side chain. The first few steps are performed by sterol 27-hydroxylase 
(Figure 1.9, reaction 11), the same mitochondrial cytochrome P450 (CYP27A1) that initates 
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bile acid synthesis through the formation of 27-hydroxylcholesterol (Figure 1.7, reaction 4). 
This enzyme introduces a hydroxyl group at carbon 27, oxidizes this group to an aldehyde and 
then to a carboxylic acid.  
The oxidized bile acid intermediates are then subject to shortening of the side chain. The 
terminal three carbon atoms are removed by a series of reactions. The first reaction is 
catalyzed by bile acid coenzyme A ligase (Figure 1.9, reaction 12), which activates the sterol 
intermediate by conjugation with coenzyme A. After activation, the 25(R) isomers must be 
converted into 25(S) isomers before subsequent steps in side chain shortening can take place. 
This reaction is catalyzed by 2-methylacyl-coenzyme A racemase (Figure 1.9, reaction 13).  
The sterol products are then subject to dehydrogenation catalyzed by the branched chain acyl 
coenzyme A oxidase enzyme (Figure 1.9, reaction 14). The next step involves hydration and 
oxidation at the Δ24 bond and is catalyzed by the D-bifunctional protein (Figure 1.9, reaction 
15).  
The last step in the side chain shortening process is cleaving of the C24-C25 bond to form 
propionyl-coenzyme A and a C24-coenzyme A bile acid intermediate (Figure 1.9, reaction 16). 
This reaction is catalyzed  by peroxisomal thiolase 2 (Russell et al., 2003). 
Coenzyme A esterase in the peroxisomes can catalyze the hydrolysis of bile acid thioesters in 
free bile acids and CoA, hereby generating cholic acid and chenodeoxycholic acid.  
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Figure 1.9: Oxidation and side chain shortening. First, a hydroxyl group is introduced at C27, hereby oxidizing 
this group to an aldehyde and then carboxylic acid. Then, side chain shortening occurs by a series of reactions. 
(adapted from Russell, 2003). 
 
Conjugation 
The final step in bile acid synthesis involves the addition of an amino acid, glycine or taurine, 
in amide linkage to carbon 24 (Figure 1.10, reaction 17). This reaction is catalyzed by the bile 
acid coenzyme A:amino acid N-acyltransferase enzyme.  
Chapter 1: General introduction 
17 
 
Figure 1.10: Conjugation (adapted from Russell, 2003). 
Conjugation of bile acids increases the amphipathicity and enhances the solubility of the 
molecules, which makes them impermeable to cell membranes. Sulphonic acid group of 
taurocholic acid and the carboxyl group of glycocholic acid are ionized at physiological pH, 
which renders the bile salt (the ionized form of the bile acid) very amphipathic, together with 
the planar structure of the bile acid and the hydroxyl groups on the ring. For example, 
conjugation of cholic acid with glycine reduces the pKa from 6.4 to 4.4 ensuring that the bile 
acid is completely ionized and highly soluble (Russell et al., 2003). 
Additionally, besides conjugation with amino acids, there are four more types of conjugation 
(Hofmann et al., 2008): 
1) Sulfation 
2) Ester glucoronidation at C24 
3) Ethereal conjugation at C3  
4) N-acetylglucosamination at C7 in bile acids with a β-hydroxyl group 
Because conjugated and free bile acids do not cross cell membranes, dedicated transport 
systems are required to move bile acids in and out of cells.  
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Secondary bile acids 
During the enterohepatic cycle, bile acids are exposed to bacterial enzymes. When primary 
bile acids are modified by these enzymes, the resulting bile acid is called a secondary bile 
acid. Figure 1.11 shows the chemical structure of the major bile acids present in human bile.  
 
Figure 1.11: Chemical structure of the major bile acids present in human bile (Hofmann et al., 2008). 
In the colon of animals with a cecum, anaerobic bacteria remove the hydroxyl group at C7 to 
form a new class of bile acids termed 7-deoxy bile acids. 
 
Bile acid transporters of the enterohepatic cycle 
To maintain bile acid homeostasis, transport proteins that make the enterohepatic cycle 
possible are needed (Figure 1.5). Approximately 95% of the bile acids that are excreted in the 
bile derive from the recirculating pool. Therefore, hepatocytes must transport bile acids 
efficiently from the portal blood into the bile. This vectorial trans-hepatocellular movement of 
bile acids is a concentrative transport process that is driven by a distinct set of transport 
systems at the sinusoidal and canalicular plasma membranes (Table 1.1). Three different 
groups can be distinguished (Dawson et al., 2009):  
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1) Primary (adenosine triphosphate (ATP)-dependent) transport systems  
2) Secondary (Na+ gradient dependent) transport systems 
3) Tertiary (OH- or HCO3- dependent anion exchange) transport systems 
Table 1.1: Overview of bile acid transporters. (adapted from Marin et al., 2016) 
 
Next, an overview of the transport proteins is given.  
 
Sinusoidal (basolateral) uptake 
Bile acids are 100- to 1000-fold concentrated in bile compared to plasma. Therefore, 
hepatocellular secretion of bile acids (and their precursors) occurs against a steep 
concentration gradient and necessitates active transport (Pellicoro et al., 2007). Uptake is 
initiated at the basolateral membrane that is in direct contact with portal blood plasma, via 
sodium-dependent and independent mechanisms. The uptake of conjugated bile acids is 
predominantly mediated (>75%) by Na+-dependent transport using NTCP. In contrast, 
Chapter 1: General introduction 
20 
unconjugated bile acids are taken up predominantly via Na+-independent transport using 
OATPs (Kullak-Ublick et al., 2000). 
NTCP 
The Na+/taurocholate cotransporting polypeptide (NTCP) is a member of the solute carrier 
(SLC) family 10 (SLC10) of sodium/bile salt cotransporters and the NTCP gene has been 
mapped to chromosome 14q24  (Hagenbuch et al., 2004). In man, the family includes two 
bile acid carriers (SLC10A1/NTCP; SLC10A2/ASBT, see later). NTCP was the first bile acid 
carrier identified at both the molecular and functional levels (Alrefai et al., 2007; Hagenbuch 
et al., 1994; Hallen et al., 2002). It is expressed exclusively in hepatocytes and is localized at 
the basolateral membrane (St-Pierre et al., 2001). The transporter is distributed 
homogeneously throughout the liver lobule (Trauner et al., 2003). NTCP consists of 349 
amino acids with a mass of 56 kDa (Dawson et al., 2009). The transporter has been cloned 
from rat, human, mouse and rabbit liver (Claro da Silva et al., 2013). 
NTCP is a secondary transport system. The transport is unidirectional and has two important 
driving forces for hepatic uptake: 1) an inwards chemical Na+ gradient that is a result of the 
Na efflux out of the cell by the Na/K ATPase pump, where 3 Na+ ions are exchanged for 2 K+ 
ions and 2) an intracellular negative electrical gradient of about -35 to -40 meV. The outward 
conductance of K+ via K+ channels in the basolateral membrane further contributes to the 
regulation of this negative membrane potential. Together, the chemical and electrical 
gradients produced by the sodium pump are able to move solutes into the hepatocytes against 
their concentration gradients, with a 2:1 stoichiometry (Na+:bile acids = 2:1) (Boyer, 2013; 
Meier et al., 2002). 
NTCP transport activity is highest for glycine and taurine conjugated dihydroxy and 
trihydroxy bile acids. Conjugated taurocholate is taken up for more than 80% via NTCP, 
unconjugated cholate for less than 50% (Trauner et al., 2003). However, most bile acids are 
conjugated and therefore, uptake of bile acids into the hepatocytes occurs predominantly by 
NTCP (Anwer et al., 2014). The high level of NTCP expression at the sinusoidal membrane 
of hepatocytes and the high affinity for conjugated bile acids promotes their efficient 
extraction from portal blood. Thus, NTCP functions to maintain the enterohepatic cycle of 
bile acids and keeps plasma concentrations at a minimum (Dawson et al., 2009). Although, 
bile acids are the major physiological substrate for NTCP, other compounds can be 
transported like estrogen conjugates, bromosulphothalein, thyroid hormones and 
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dehydroepiandrosteron (DHEA) (Kosters et al., 2008). In addition, NTCP also mediates 
uptake of drugs such as rosuvastatin and micafungin and drugs that are covalently bound to 
taurocholate such as chorambucil-taurocholate (Trauner et al., 2003). 
OATPs 
Uptake of bile acids into the hepatocytes occurs predominantly by NTCP, and to a lesser 
extent by organic anion-transporting polypeptides (OATPs). OATPs are members of the 
solute carrier organic anion transporter (SLCO) superfamily. This OATP superfamily consists 
of 6 different families, which can be further subdivided into subfamilies based on their amino 
acid sequence identity. Currently, 11 human OATPs have been identified (van de Steeg et al., 
2010; Iusuf et al., 2011). The OATP genes of the OATPs expressed in liver can be found on 
chromosome 12q12 (Alrefai et al., 2007). OATP1A2, OATP1B1 and OATP1B3 consist of 
670, 691 and 702 amino acids and a weight of 85, 84 and 120 kDa, respectively. 
OATPs are tertiary transport systems and function as electroneutral anion exchanges. They 
are thought to transport bile acids and other solutes in exchange for intracellular anions, such 
as glutathione and bicarbonate (Boyer et al., 2013). Four OATPs have been functionally 
identified in human liver (OATP1A2, OATP1B1, OATP1B3, OATP2B1) and many are also 
expressed in other tissues like the blood-brain barrier, kidney, choroid plexus, lung, heart, 
intestine, placenta and testis (Kullak-Ublick, 2001; Tamai et al., 2001). OATP1B1 and 1B3 
are hepatocyte specific and functionally most important. OATP1B1 is expressed on the 
basolateral membrane throughout the hepatic lobule in human liver, while OATP1B3 is most 
strongly expressed in pericentral regions of the hepatic lobule. The highest expression in liver 
is found for OATP1B1 and has 80% sequence homology with OATP1B3 (Hagenbuch et al., 
2004; Boyer et al., 2013; Pauli-Magnus et al., 2005). 
OATPs mediate the sodium-independent cellular uptake of a wide variety of organic 
endogenous and exogenous compounds, such as bile acids, bilirubin, steroid and thyroid 
hormones and their conjugates, and numerous drugs, xenobiotics and environmental toxins. 
Most OATP substrates are organic anions with molecular weights greater than 300 Da, but 
they can also transport cations and neutral compounds (Boyer et al., 2013). In contrast to 
NTCP, unconjugated bile acids can be efficiently taken up by the liver by OATPs. Because of 
this broad substrate specificity and due to their expression in pharmacokinetically important 
tissues (liver, small intestine, kidney), OATPs of the 1A/1B subfamilies are thought to play an 
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important role in drug disposition (van de Steeg et al., 2010; Tamai et al., 2001;Kullak-Ublick 
et al., 2001).  
 
Alternative basolateral bile acid efflux 
Under normal physiological conditions, bile acid uptake is the predominant transport across 
the basolateral membrane of hepatocytes and the basolateral efflux into the sinusoids is 
negligible. However, under cholestatic conditions (see later), basolateral bile acid efflux can 
be upregulated and can in part compensate for the disturbed canalicular bile acid secretory 
pathway (Meier et al., 2002) to protect the liver (Halilbasic et al., 2013). This alternative 
basolateral bile acid efflux is mediated by members of the ATP-binding cassette (ABC) 
superfamily of transporters, namely the multidrug resistance proteins (MRPs) family. This 
subfamily of transporters consists of at least six members (MRP1-6) with four of them 
expressed in the liver. MRP3 and MRP4 are expressed in the basolateral membrane of the 
hepatocyte, whereas MRP2 is localized on the canalicular membrane (see later) (Alrefai et al., 
2007). MRP1 is almost absent in the liver. In cholestatic conditions, an upregulation of MRP3 
and MRP4 can be observed. These transporters are expressed at extremely low levels in 
normal hepatocytes. Both are ATP-dependent pumps with a wide range of substrates (Alrefai 
et al., 2007; Sievänen, 2007). Additionally, the heterodimeric Organic Solute Transporters α 
and β (OSTα/β) participate in this basolateral efflux (Halilbasic et al., 2013). 
 
Canalicular excretion 
After uptake in the hepatocytes, bile acids and other organic solutes move across the cell to 
the canalicular membrane, where they can be excreted into bile. This can occur by rapid 
diffusion in association with cytosolic proteins, in association with intracellular membranes, 
or by transcytosis in membrane vesicles associated with microtubules. The hydrophobicity of 
the compounds influences which pathway the solute will take. The more hydrophobic the 
solute, the more it will associate with intracellular membranes rather than the cytosolic 
proteins (Boyer et al., 2012; Trauner et al., 2003).  
Canalicular bile acid transport is a critical component of their enterohepatic circulation and 
represents the rate-limiting step in hepatic excretion and bile formation. Additionally, it is the 
main generator of bile flow (Kosters et al., 2008). Secretion of bile acids into bile across the 
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canalicular membrane occurs against a steep concentration gradient that ranges between 100-
1000 fold. Therefore, the canalicular excretion of bile acids occurs via direct transporter 
systems whose function depends on ATP hydrolysis. The most important efflux transporters 
are BSEP, which is responsible for the transport of monovalent bile acids, and MRP2, which 
is the main transporter of divalent bile acids. (Alrefai et al., 2007; Trauner et al., 2003) 
BSEP 
The Bile Salt Export Pump (BSEP) is the predominant efflux transporter on the canalicular 
membrane. BSEP is a member of the multidrug resistance P-glycoprotein family that belongs 
to the ABC superfamily (ABCB11) (Noé et al., 2002). Human BSEP can be found on 
chromosomes 2q24. It has been cloned from pig, human, rabbit, rat and mouse (Alrefai et al., 
2007). BSEP is a direct transport system that requires ATP. It consists of 1321  amino acids 
and it has a mass of 150-170 kDa. BSEP was also found in human testis (Stieger et al., 2007). 
BSEP mediates the transport of mainly monovalent bile acids. BSEP has a poor affinity for 
unconjugated bile acids, and a high affinity for conjugated bile acids (Kosters et al., 2008). 
Whereas bile acids are the major physiological substrates, BSEP is also able to transport a 
limited number of drugs, such as pravastatin. Other drugs like cyclosporine, rifamycin, 
troglitazone and glibenclamide are no substrates but interact with BSEP and inhibit bile acid 
export (Dawson et al., 2009). 
MRP2 
The Multidrug Resistance Protein 2 (MRP2) is another transporter of the ABC transporter 
superfamily (Nies et al., 2007) and is a unidirectional ATP-dependent efflux pump. Human 
MRP2 gene (ABCC2)  is mapped on chromosome 10q24.  
The gene has been cloned from six mammalian species including human, rhesus monkey, rat, 
rabbit, mouse and dog and three other vertebrates. (Fardel et al., 2005).  
In the liver, it is predominantly localized in the canalicular membrane of the hepatocytes. 
Additionally, this protein can be found in the kidneys and enterocytes of the duodenum and 
jejunum. MRP2 mediates the transport of divalent bile acids and it does not have the capacity 
to transport monovalent bile acids. It has a wide range of organic substrates (mainly organic 
anions), such as glutathione, glucuronide and sulfate conjugates and also some unconjugated 
drugs (Alrefai et al., 2007).  
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Intestinal bile acid uptake 
Bile acids are reabsorbed in the intestines through a combination of passive absorption in the 
proximal small intestine, active transport in the distal ileum, and passive absorption in the 
colon. Bile acids are actively transported into the distal ileum by the Apical Sodium 
Dependent Bile Acid Transporter (ASBT). (Dawson et al., 2009)  
ASBT 
ASBT, the ileal counterpart of hepatic NTCP, is also a member of the SLC10 family of 
sodium/bile salt cotransporters. The ASBT gene is localized on chromosome 13q33 in human. 
NTCP and ASBT are phylogenetically related. 
ASBT is, just like NTCP, a secondary transporter system that is driven by sodium and a 
negative intracellular potential to move bile acids from the lumen of the small intestine across 
the apical brush border. The ASBT mediated transport is electrogenic with 2:1 Na+/bile acid 
coupling stoichiometry. It consists of 348 amino acids and has a mass of 48 kDa. It has been 
cloned from hamster, human, rat, rabbit and mouse ileum (Alrefai et al., 2007; Dawson et al., 
2009). 
ASBT is expressed in the apical membrane of ileal enterocytes, proximal renal convoluted 
tubule cells, epithelial cells lining the biliary tract (cholangiocytes) and gallbladder epithelial 
cells.  
Human ASBT transports both conjugated and unconjugated bile acids with preference for 
conjugated. ASBT has a higher affinity for dihydroxy bile acids that are more hydrophobic 
than trihydroxy bile acids.  
 
Intestinal bile acid efflux 
OSTα/β 
Organic solute transporter α/ β (OSTα/β) is a unique heteromeric sterol transporter. Both 
subunits are required for the functional expression of this transporter. It was cloned from 
human and mice. It is located on chromosome 16B13 (Alrefai et al., 2007; Boyer et al., 2013; 
Dawson et al., 2009; Kosters et al., 2008). 
OSTα/β is Na+-independent facilitated diffusion transporter. Therefore, in contrast with other 
bile acid transporters, substrates can be driven bidirectionally (uptake or efflux) across the 
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membrane of the cell depending on the electrical chemical gradient. The transporters can only 
function as heterodimers, secreting bile acids back into the circulation, both in the intestine 
and hepatocytes (Kosters et al., 2008). 
Human OSTα/β is expressed in a variety of tissues with the highest levels in liver, small 
intestine, colon, kidney, adrenal gland, testes and ovary (Kosters et al., 2008). It is also 
expressed at lower levels in other tissues like heart, lung, brain, … OSTα is built up of 340 
amino acids, while OSTβ is 128 amino acids in size.  
Substrates include conjugated bile acids. In addition, OSTα/β transports sterols conjugated 
with sulphate or glucuronic acid, including DHEAs, estrone-3-sulfate, digoxin, and 
prostaglandin E2 (Ballatori et al., 2013). 
 
Bile acid transporters in cholangiocytes and renal epithelial cells 
Besides the expression in cells of the enterohepatic cycle, bile acid transporters are also 
expressed in other epithelial cells, such as cholangiocytes and renal proximal tubule cells (Xia 
et al., 2006). Between the cholangiocytes and hepatocytes, there is a cholehepatic shunt 
(Figure 1.12) in which bile acids are actively absorbed by cholangiocytes lining bile ducts and 
then, these bile acids cycle back to the hepatocytes for resecretion (Alrefai et al., 2007). The 
exact physiological relevance of this shunt is not clear, but this pathway may play a role in the 
modification of bile in the bile ductules and may become important under cholestatic 
conditions, providing a mechanism to avoid high levels of intracellular bile acids, or help 
improve bile flow within the liver (Kosters et al., 2008). Transport of bile acids in and out the 
cholangiocytes is mediated by a similar set of transporters found in the terminal ileum. ASBT 
mediates the Na+-dependent uptake of bile acids across the apical membrane (de Lima 
Toccafonda Vieira et al., 2014), and OSTα/β, MRP3 or t-ASBT (truncated ASBT) are 
potentially responsible for efflux of bile acids through the basolateral membrane into the 
blood. The bile acids enter the peribiliary plexus adjacent to intrahepatic bile ducts, and are 
then forwarded to the hepatic sinusoids for reuptake in the hepatocytes (Xia et al., 2006).  
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Figure 1.12: Cholehepatic shunting. 
Active bile acid transport has also been reported in renal proximal tubule (Figure 1.13) 
(Trauner et al., 2003). Reabsorption of bile acids from the glomerular filtrate ensures the 
conservation of bile acids that escape hepatic clearance. Under normal conditions, urinary 
excretion of bile acids is smaller compared to the amount of bile acids in the glomerular 
filtrate due to almost complete renal reabsorption. ASBT, MRP4 and MRP2 were found to be 
localized on the apical membrane of renal epithelial cells. Additionally, OSTα/β is also 
expressed on the basolateral membrane of proximal tubule suggesting its involvement in bile 
acid efflux from renal epithelial cells (Alrefai et al., 2007). 
 
Figure 1.13: Bile acid transporters in the renal proximal tubular cell. (adapted from: Gai et al., 2013) 
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Drug-induced liver injury 
Drug-induced liver injury (DILI) is a leading cause for the withdrawal of drugs from the 
market. A variety of clinical presentations can be seen in patients, ranging from asymptomatic 
mild biochemical abnormalities to an acute illness with jaundice that resembles viral hepatitis 
(Pauli-Magnus et al., 2006). Drugs can cause liver injury via different and overlapping 
pathologic mechanisms (de Lima Toccafondo Vieira et al., 2014). 
DILI can be classified as hepatocellular, cholestatic and mixed type liver injury, depending on 
the serum biochemistry markers (Schadt et al., 2016). Hepatocellular injury is mainly 
characterized by the elevation of serum aminotransferases, while cholestatic liver damage is 
reflected in increased levels of alkaline phosphatase, γ-glutamyltranspeptidase and conjugated 
bilirubin in serum. On the one hand, in most hepatocellular forms, most cases are attributed to 
idiosyncratic reactions, where immunoallergic mechanisms resulting from hypersensitivity 
and unusual metabolism of the drug are the predominant pathophysiological pathways. On the 
other hand, cholestatic drug induced injury (also referred to as drug induced cholestasis) 
results from a drug- or metabolite-mediated inhibition of hepatobiliary transporters. 
Basolateral uptake transporters are important in controlling hepatic drug and toxin exposure, 
canalicular (apical) transporters are responsible for drug clearance from the liver as well as for 
the secretion of bile acids and other bile constituents. Among 784 DILI cases reported 
between 1970 and 2004, almost one-half of the cases had either cholestatic or mixed 
cholestatic hepatic toxicity (Yang et al., 2013). 
Cholestatic drugs may disturb bile acid homeostatis by direct inhibition of bile acid transport, 
or by indirect processes, such as regulation of transporter localization or expression (Yang et 
al., 2013). The interactions of drugs with transporters can lead to toxic concentrations of bile 
acids, bilirubin or substrate drugs in blood or liver (Figure 1.14) (Pauli Magnus et al., 2006; 
Padda et al., 2011), leading to drug-drug interactions, hypercholanemia, hyperbilirubinemia 
and cholestasis. (Vaz et al., 2014; Shneider et al., 1997; Keppler et al., 2014; Marin et al., 
2016; Perez et al., 2009). Several transport proteins have been identified as potential targets 
of drug-induced cholestasis. These include the basolateral uptake transporters (NTCP and 
OATPs), canalicular efflux transporters (BSEP, MRP2) and basolateral efflux transporters 
(MRP3 and MRP4). Since hepatic accumulation of compounds is regulated by both uptake 
and efflux processes, inhibition of uptake can also exert a protective effect by preventing the 
hepatic accumulation. 
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Many drugs can inhibit OATPs. Inhibition of OATPs can lead to drug induced benign isolated 
hyperbilirubinemia. This transient jaundice may arise due to inadequate bilirubin clearance 
from the body via OATP1B1 and OATP1B3. Drug interference with MRP2 may also be 
correlated to clinical hyperbilirubinemia, since MRP2 directly regulates bilirubin elimination 
via excretion of glucuronide metabolites into the bile (de Lima Toccafonda Vieira et al., 
2014). Although the inhibition of OATPs and MRP2 in itself possess a moderate risk, it can 
increase the concentration of substrate drugs to elevated and toxic levels (e.g. statins) 
(Maddrey et al., 2005). Consequently, it can cause drug-drug interactions that result in altered 
pharmacokinetics (Maddrey et al., 2005).  
Drugs may also inhibit the hepatic uptake and/or efflux of bile acids resulting in an increase in 
intracellular concentrations leading to hepatotoxicity. To predict the hepatic exposure to bile 
acids, inhibitory effects of drugs on each transport protein, as well as drug concentrations at 
the interaction site should be considered. Inhibition of NTCP or BSEP can lead to bile acid 
retention that may lead to hypercholanemia and severe cholestasis, resulting in liver failure 
(Alrefai et al., 2007; Stieger et al., 2011). Prior to their interference with bile secretion, drugs 
with intrahepatic cholestatic potential need to be taken up in the liver cells, which can be 
modulated by OATPs or NTCP (de Lima Toccafonda Vieira, 2014). During cholestasis, a 20- 
to 100-fold increase in systemic bile acid concentrations have been reported, which is 
associated with morbidity (Greupink et al., 2012). Drug-induced cholestasis may mimic other 
intrahepatic and extrahepatic cholestatic diseases. Not recognizing a drug as a triggering 
factor for cholestasis extends the exposure, which may lead to worse liver injury (Padda et 
al., 2011). Basolateral efflux transporters, like MRP3 and MRP4, play a minor role in bile 
acid transport in normal conditions. However, in cholestatic condititions, they can be 
upregulated to compensate for impaired biliary excretion. Impaired function of these 
transporters can thus lead to accumulation of toxic bile acids in hepatocytes and is therefore 
also a risk factor for the development of drug-induced cholestasis (Yang et al. 2013). 
Given the overlap in substrate specificity of uptake and efflux transporters involved in 
vectorial transport of bile acids, it is not unexpected that compounds may modulate multiple 
hepatobiliary transport mechanisms. The relative effect of compounds on several processes 
should be considered to predict the potential clinical consequences (de Lima Toccafonda 
Vieira, 2014).  
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Figure 1.14: Transporter-related mechanisms in the development of liver injury. Red and green rectangles 
designate potentially harmful (red) or protective (green) transporter related mechanisms, respectively (adapted 
from Pauli-Magnus et al., 2006). 
 
Rifampicin for example, is one of the most commonly used anti-tubercular drugs and is 
known to be hepatotoxic. Several studies showed that rifampicin caused a direct toxic injury 
to the hepatocytes and that it significantly increases the level of serum conjugated bilirubin 
and total bile acids in man (Chen et al., 2009). Rifampicin is known as an OATP1, BSEP and 
MRP2 inhibitor (Stieger et al., 2000; Mita et al., 2006; Lengyel et al., 2008; Van de Steeg et 
al., 2010).  
As previously mentioned, DILI is a major cause of attrition during drug development and is 
responsible for drug withdrawals from the market. Additionally, hepatotoxicity is the most 
common single adverse drug event leading to refusal for drug approval. DILI also poses a 
significant burden to patient safety and to the costs of health care systems. Therefore, it is 
important to improve the understanding and characterization, and to develop better prediction 
methods to identify possible interactions (de Lima Toccafonda Vieira et al., 2014). 
Currently, this possible inhibition of transport proteins by new candidate drugs is investigated 
by means of in vitro and invasive, time-consuming and expensive preclinical in vivo tests. In 
in vitro tests, mainly BSEP inhibition was investigated, since it can lead to severe cholestasis 
(Stieger et al., 2000; Kis et al., 2012). To study transporter activity, two different types of in 
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vitro assay systems can be distinguished: membrane-based and cell-based assays. The two 
most commonly used membrane-based assays, which are suitable to investigate hepatobiliary 
transporters are the vesicular transport and the ATPase assay (Stieger et al., 2000). 
Transfected cell lines can be used to assess the uptake and efflux transporters separately. In 
cell-based assays, sandwich-cultured hepatocytes are widely used to assess drug-induced 
cholestasis, as they reflect in vivo properties (Annaert et al., 2005; Wolf et al., 2010; 
Nakanishi et al., 2011; De Bruyn et al., 2014; Chaterjee et al., 2014; Oorts et al., 2016). In in 
vivo toxicity studies, increasing amounts of potential new drugs are administered to animals. 
Blood and bile samples are subsequently taken to measure bile acid and bilirubin 
concentrations in blood and bile (Bergman et al., 2010). Another approach to study 
transporter activity is by using fluorescein conjugated bile acid analogues and fluorescence 
microscopy for in vitro (Yamaguchi et al., 2006) and invasive in vivo studies (Milkiewicz et 
al., 2001). These in vivo experiments require liver tissue and bile samples and are therefore 
very invasive. In addition, these studies cannot distinguish between influx or efflux 
interactions. Besides in vitro and in vivo experiments, in silico modeling was used to predict 
drug interactions with bile acid transport proteins. These models rely on a series of 
experimentally measured interactions of small molecules with membrane transporters and 
employ statistical learning approaches, such as quantitative structure-activity relationship.  
However, the quantitative models are limited to small sets of compounds (Warner et al., 
2012: Saito et al., 2009; Greupink et al., 2012).  
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Part II: Molecular Imaging 
Medical Imaging 
Medical imaging began in 1895 when the German physicist Wilhelm Conrad Roentgen 
discovered X-rays, an achievement that earned him the first Nobel Prize in Physics in 1901. 
While working with a cathode ray tube, he noticed that invisible rays were able to penetrate 
some solids better than others. This difference in penetration can be explained by the 
difference in density between several materials or tissues. X-rays can be detected on a 
photographic plate, providing a two dimensional image that is in accordance with the density 
of the material or tissue. In medical imaging, X-ray detection on a photographic plate is 
especially useful for the detection of structural skeletal disorders due to the higher density of 
bone compared to surrounding soft tissues. (Bradley WG et al., 2008) Consequently, X-ray 
imaging can be classified as a structural imaging technique. Nowadays, different imaging 
techniques are available that can be divided into two main categories: structural (or 
anatomical) and functional imaging.  
Structural imaging modalities visualize non-invasively the anatomy of the patient. The best 
known modalities are X-ray radiography (Figure 1.15, A), computed tomography (CT) 
(Figure 1.15, B), magnetic resonance imaging (MRI) (Figure 1.15, C) and ultrasound imaging 
(US) (Figure 1.15, D). These techniques were developed to visualize nonspecific macroscopic 
physical and physiological changes in tissues. These techniques were not able to identify the 
specific molecular events responsible for disease, although image spatial resolution has been 
constantly improved (Tian, 2012). 
 
 
Figure 1.15: Medical X-ray of the pelvis (A), CT of the head (B), MRI of the brain (C) and ultrasound image of 
a fetus (D) (Image obtained from http://commons.wikimedia.org, used under a Creative Commons Attribution-
ShareAlike license: http://creativecommons.org/licenses/by-sa/3.0/) 
Functional imaging modalities, such as planar scintigraphy, single photon emission computed 
tomography (SPECT), positron emission tomography (PET) and optical imaging (OI) focus 
on the study of molecular events in living subjects and are regarded as functional metabolic or 
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molecular imaging. The targets in functional imaging can include transporters, cell surface 
receptors, intracellular enzymes, etc. 
Nowadays, the traditional distinction between structural and functional imaging has become a 
little blurred with the introduction of functional MRI that can provide functional information 
as well. Moreover, the introduction of micro-bubbles enables functional imaging in US. 
Peptides, antibodies, etc. can be attached to the surface of microbubbles to target specific 
biochemical processes. 
An overview of the most commonly used preclinical imaging modalities with their main 
characteristics is shown in Table 1.2. 
 
Multi-modality 
Since none of the imaging modalities is perfect (Table 1.2), these imaging modalities are 
often combined into a single imaging device, called multi-modality imaging. For example, 
because the molecular imaging modalities SPECT and PET do not provide detailed 
anatomical information, they are often combined with CT or MRI. CT and MRI have a high 
spatial resolution and serve to identify morphological changes in small structures, however, 
they have lower sensitivity compared to SPECT and PET. So when these imaging modalities 
are combined into one imaging device, we combine ‘the best of both worlds’ (Khalil et al., 
2011). 
 
Molecular imaging 
Molecular imaging (MI) has its roots in functional imaging and is defined by Weissleder and 
Mahmood (Weissleder and Mahmood, 2001) as: 
 “Molecular imaging is the in vivo characterization and measurement of biologic processes on 
the cellular and molecular level. In contradistinction to ‘classical’ diagnostic imaging, it sets 
forth to probe such molecular abnormalities that are the basis of disease rather than to image 
the end results of these molecular alterations”  
In other words, it is a non-invasive, real-time visualization of biochemical events at the 
cellular and molecular level within living cells, tissues, and/or intact subjects (James et al., 
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2012). These events can be as simple as location(s) of a specific population of cells or levels 
of a given protein receptor on the surface of cells. In addition, it is possible to study more 
complex events, such as interaction of two intracellular proteins, cellular metabolic flux, etc. 
(Weissleder et al., 2010; Massoud et al., 2003). 
The reason for monitoring/imaging/quantifying various molecular targets are related to 
characterizing a disease process that may correlate with concentrations of one or more of 
these molecular targets. MI allows detection of functional alterations even before anatomical 
changes can be observed. Additionally, molecular imaging helps to dissect complex biology. 
Another important application is in the process of drug discovery and validation, as well as in 
predicting and monitoring response to various types of therapy. 
MI modalities include optical imaging that mainly records bioluminescent and fluorescent 
light, SPECT and PET that detect γ- and β+ radiation, functional MRI that detects differences 
in relaxation time, and US that detects sound waves reflected back from ligand-targeted 
acoustic particles (micro-bubbles) (Tian et al., 2012).   
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Table 1.2: Characteristics of preclinical imaging modalities (adapted from Massoud et al., 2003). 
 PET SPECT OI MRI CT US 
Radiation type high-energy γ rays  lower-energy γ rays  visible light or near 
infrared  
radiowaves X-rays high-frequency 
sound 
Spatial resolution 1-2 mm < 1 mm 2-5 mm 25-100 µm 50-200 µm 50-500 µm 
Depth no limit no limit 1-2 cm no limit no limit millimeters to 
centimeters 
Temporal resolution seconds to minutes seconds to minutes seconds to minutes minutes to hours minutes seconds to minutes 
Contrast agent 
administration 
10-11-10-12 M 10-10-10-11 M not well-
characterized 
10-3-10-5 M not well 
characterized 
not well 
characterized 
Amount of probe used nanograms nanograms micrograms to 
milligrams 
micrograms to 
milligrams 
not applicable micrograms to 
milligrams 
Quantitative degree +++ ++ + to ++ ++ ++ + 
Principle use metabolic, 
reporter/gene 
expression, enzyme 
targeting 
reporter/gene 
expression, 
receptor/ligand 
reporter/gene 
expression, cell 
trafficking 
morphological 
reporter/gene 
expression, 
receptor/ligand if 
many receptors 
morphological morphological 
Advantages high sensitivity, 
Isotopes can 
substitute naturally 
occurring atoms, 
quantitative 
translational research 
many molecular 
probes available, can 
image multiple 
probes 
simultaneously 
quick, easy, low 
cost, relative high-
throughput 
highest spatial 
resolution, combines 
morphological and 
functional imaging 
bone, tumor and 
anatomical imaging 
real-time, low cost 
Disadvantages cyclotron needed, 
relatively low spatial 
resolution, radiation  
relatively low spatial 
resolution, 
collimation, 
radiation 
low spatial 
resolution, 2D 
imaging only, 
relatively surface-
weighted 
relatively low 
sensitivity, long scan 
and postprocessing 
time, mass quantity 
of probe may be 
needed 
limited “molecular” 
applications, limited 
soft tissue resolution, 
radiation 
limited spatial 
resolution, mostly 
morphological 
Cost $$$$ $$$ $-$$ $$$$ $$ $$ 
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MI uses specific molecules as the source of image contrast. To obtain successful images of 
specific molecules in vivo at the molecular level, the following criteria should be met 
(Massoud et al., 2003): 
(1) availability of high affinity probes with reasonable pharmacodynamics;  
(2) the ability of these probes to overcome biological delivery barriers;  
(3) use of chemical or biological amplification strategies;  
(4) availability of sensitive, fast, high resolution imaging techniques  
Consequently, one of the key prerequisites for molecular imaging is the ability to design the 
perfect cell or tissue-specific probe. The MI research chain, i.e. the process of developing new 
probes/strategies/assays for MI is shown in Figure 1.16. However, not all research in the field 
is intended for clinical translation and then, the chain stops at step 10. It is an iterative 
process, based on lessons learned in a given application.  
 
Figure 1.16: Molecular imaging research chain. (adapted from James et al., 2012) 
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Molecular imaging and nuclear medicine 
Nuclear medicine, in the field of molecular imaging, offers important advantages over other 
MI modalities (Zanzonico, 2012):  
(1) The specific activity (i.e., activity per unit mass) of radiopharmaceuticals and the 
detection sensitivity of the imaging instruments are generally high. In contrast to CT 
and MRI, far lower mass doses are administered during nuclear medicine imaging. 
These sub-nmol doses correspond to nonpharmacological, non-perturbing mass doses 
of the radiopharmaceutical.  
(2) Nuclear medicine imaging is non-invasive, hereby allowing serial imaging to 
characterize the longitudinal time course of some processes.  
(3) Nuclear medicine images are (semi)-quantitative and may be parameterized.  
(4) A large number of targeted radiopharmaceuticals have been developed and will be 
developed in the future.  
However, there are also several drawbacks: 
(1) Nuclear imaging techniques have a poorer spatial resolution compared to CT and MRI 
(Table 1.2).  
(2) Nuclear imaging modalities deliver radiation doses for patients, with effective doses 
and maximal organ-absorbed doses per study in the order of ten mSv and up to several 
cGy, respectively (Stabin MG et al., 2008).  
(3) Only limited anatomical information can be obtained. This drawback is largely 
overcome with the introduction of multi-modality devices (e.g. PET-CT, SPECT-CT, 
PET-MRI). Here, functional information, obtained from PET or SPECT, is inherently 
co-registered with anatomical images.  
 
PET 
The principles of PET imaging are summarized in Figure 1.17. PET imaging requires the use 
of a cyclotron to generate short-living radionuclides such as 18F, 11C, 13N, 15O. PET uses the 
unique properties of these radioisotopes that decay via positron emission, also called β+ 
decay. An overview of the most common PET isotopes is listed in Table 1.3. Positron emitters 
are neutron-deficient isotopes that achieve stability through the nuclear transmutation of a 
proton into a neutron. As shown in the right part of Figure 1.17, this process involves the 
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emission of a positive electron (positron) and an electron neutrino. The energy spectrum of 
the emitted positron depends on the specific isotope. After emission, the positron will travel a 
certain distance that is dependent on the energy of the positron, called the positron range, in 
the surrounding tissue and will lose its energy through interactions with the surrounding tissue 
until it annihilates with an electron in the tissue. Annihilation is a process in which the 
combined energy of the positron and electron will result in the emission of two gamma 
photons with an energy of 511 keV that are emitted in opposite directions (180°) and since 
they are highly energetic, they are able to leave the subject’s body and can be detected 
externally by detectors (Tian et al., 2012). PET detectors take the form of a closed ring, or set 
of rings, surrounding the subject to be imaged. This circular configuration of the PET scanner 
and its scintillation detectors and photo multiplier tubes (amplifiers) allows simultaneous 
detection of these two photons. This detection of a coincidence event allows localization of an 
annihilation event somewhere along the line between the two detectors, which received a 
signal. A large number of such coincidence lines form the data set. Then, this raw data is 
reconstructed in 3D images that allow accurate positioning of the radioisotope in the body. 
(James and Gambhir, 2012) 
 
Figure 1.17: Basic principle of PET imaging (adapted from Nguyen et al., 2010). 
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In practice, a specific probe to visualize a specific molecular process is labeled with a 
positron-emitting radionuclide that is administered (mostly intravenously) to the subject that 
is then positioned into the PET scanner.  
 
Table 1.3: Commonly used radionuclides in PET and SPECT. EC= electron capture; IT= internal transition 
(adapted from Lee et al., 2010; Rowland and Cherry, 2008 ). 
Radionuclide Decay Mode Half-Life Modality 
11C β+ (100%) 20.39 min PET 
18F β+ (96.7%) 109.77 min PET 
 EC (3%)   
15O β+ (100%) 2.04 min PET 
13N β+ (100%) 9.97 min PET 
64Cu β+ (17.6%) 12.70 h PET/therapy 
 EC (43.4%)   
 β- (39.0%)   
124I β+ (23%) 4.20 days PET 
 EC (77%)   
68Ga β+ (89%) 67.71 min PET 
 EC (11%)   
89Zr β+ (23%) 3.30 days PET 
 EC (77%)   
99mTc IT (100%) 6.02 h SPECT 
111In EC (100%) 2.80 days SPECT 
123I EC (100%) 13.22 h SPECT 
125I EC (100%) 60 days SPECT 
131I β- (100%) 8.03 days SPECT/therapy 
201Tl EC 3.04 days SPECT 
 
SPECT 
SPECT imaging is based on the detection of nuclides that decay via the emission of gamma 
photons, called single-photon emitters. The most commonly used radioisotopes for SPECT 
imaging are displayed in Table 1.3. The unstable nucleus decays by isomeric transition (IT), 
β- decay, or electron capture (EC) into a stable nucleus, hereby emitting photons. A typical 
clinical SPECT camera is composed of one or more rotating gamma cameras to obtain 
multiple projections around the patient and to eventually obtain a tomographic reconstruction. 
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Since position detection of these photons in SPECT does not provide adequate information 
about the origin of the photon, it is not possible to determine a “line of response”, as done 
with PET. Therefore, to allow origin determination of the detected signal, a lead or tungsten 
collimator is added to the modality, where only photons that travel into a certain direction can 
pass through the holes of the collimator. The disadvantage of this is the fact that the 
collimator rejects most of the photons that are not traveling at right angles to the detector. 
Consequently, the sensitivity is typically two orders of magnitude lower than PET. In clinical 
cameras, mostly parallel-hole collimators are used (Figure 1.18), whereas in small-animal 
imaging systems, (multi)pinhole collimators are most often used (see later). The photons are 
converted into visible light by the NaI(Tl) crystal, and then the light is converted into an 
electrical signal by the photomultiplier tubes.  
 
Figure 1.18: Basic principles SPECT imaging. 
 
The gamma photons of SPECT radioisotopes have different energies, in contrast to PET 
isotopes where two gamma photons of 511 keV originate after annihilation. During SPECT 
image reconstruction, an energy window is determined that is typically 10-20% around the 
photon energy peak. A narrow window is chosen to avoid reconstruction of Compton scatter 
and to improve energy resolution to allow simultaneous imaging of multiple radionuclides 
(Zanzonico et al., 2012). For 99mTc, the energy window is displayed in Figure 1.19. When the 
energy window is carefully chosen, multi-radionuclide studies can be performed, in contrast 
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to PET imaging. After reconstruction, 2D and 3D images can be obtained. (James and 
Gambhir, 2012; Khalil et al., 2011; Zanzonico, 2012) 
 
Figure 1.19: Energy window of 99mTc. (adapted from Zanzonico., 2012) 
In practice, similar to PET, a specific probe to visualize a specific molecular process is 
labeled with a single-photon emitter that is administered to the subject that is then positioned 
into the SPECT scanner for imaging. 
 
Small animal imaging 
Small animal imaging has become an integral part of molecular medicine. Translation of ideas 
from bench to the clinic needs a verification and validation step where molecular diagnostic 
modalities are important tools in developing new tracers, drug design and therapeutics (Khalil 
et al., 2011) (see Figure 1.16). Small-animal imaging investigates biological function and 
structure in vivo in a non-invasive manner, to obtain quantitative, spatial and temporal 
information about a specific normal or diseased animal or tissue. Because of its non-invasive 
nature, it allows serial investigation of the same animal hereby obtaining information from the 
inception to progression of a certain disease state. It also allows monitoring of the 
effectiveness of treatment, with each animal serving as its own control and thereby reducing 
biological variability. Imaging also reduces the number of animals required for a study. 
Additionally, the same imaging modalities are used in the clinic and therefore, the findings of 
small-animal imaging can be translated into patients. Summarized, small animal imaging is 
clinically translatable, non-invasive and has a quantitative nature. Therefore, it is an important 
component of modern biomedical research (Zanzonico, 2012).  
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Since more than 75% of animals used for preclinical research are rodents (mostly rats and 
mice), the spatial resolution of preclinical imaging devices has to be improved because these 
rodents are typically 100 to 1000 times smaller than humans. Table 1.4 gives an overview of 
the characteristics of both clinical and preclinical SPECT (µSPECT) and PET (µPET) 
cameras. The improvement of spatial resolution is achieved at a substantial cost in terms of 
longer data acquisition times and/or higher administered activities and radiation dose. 
(Vanhove et al., 2015) 
Table 1.4: Characteristics of clinical and preclinical cameras (adapted from Khalil et al., 2011; Rowland and 
Cherry, 2008). 
 Clinical SPECT Clinical PET Preclinical PET Preclinical SPECT 
Spatial resolution 8-12 mm 4-6 mm 1-2 mm ≤ 1 mm 
Sensitivity 0.01-0.03% 1-3% 2-4% 0.3% 
Field of view 50 cm 50 cm 7 cm 8 cm 
 
µPET 
In case of µPET, this superior resolution is achieved by the application of smaller detector 
elements. Sensitivity can be improved by using a smaller detector ring diameter, by increasing 
the length of the detector ring, by using novel detector geometries that improve the photon 
absorption efficiency and by using detectors with better timing resolution and faster decay (de 
Kemp et al., 2010).  
µSPECT 
In case of µSPECT, better spatial resolutions can be achieved by the use of pinhole 
collimation, which magnifies the acquired projection images. Pinhole imaging with gamma 
rays is based on the same geometric principle as the optical pinhole camera (Figure 1.20). A 
scintillation detector is used instead of a film. Figure 1.21 shows a mouse that is projected 
through a parallel-hole collimator (left side) and a pinhole collimator (right side). In the case 
of an “ideal” parallel-hole collimator, the projection of the object is blurred only by the 
intrinsic gamma camera resolution, Ri. The value of Ri, which is typically 3-4 mm, is a 
measure for the width of the blob that appears when a pencil gamma beam is used to irradiate 
the crystal.  
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Figure 1.20: Early pinhole imaging. 
 
 
Figure 1.21: Parallel-hole versus pinhole collimator in small-animal imaging. Through magnification of a small 
object at short distance onto a large detector area, pinhole collimation geometry offers substantial increase in 
detection efficiency over that of parallel hole collimation geometry. Spatial resolution is determined by size of 
pinhole aperture (adapted from de Kemp et al., 2010). 
 
The spatial resolution Rs of a pinhole camera is approximated by the following formula:  
𝑅𝑠 =  
√[𝑑𝑒 (1 +
1
𝑀
)]
2
+  [
𝑅𝑖
𝑀
]
2
 
with 𝑀 =
𝑡
𝑏
 
de is the effective diameter of the pinhole, Ri is the intrinsic spatial resolution of the gamma 
detector, M is the pinhole magnification, t is the distance between the pinhole opening and the 
detector and b is the distance between the object and the pinhole (Figure 1.22). So when the 
distance between the mouse and the pinhole is 7 cm and the distance between the pinhole and 
the detector is 35 cm, the magnification of the mouse amounts 5. Therefore, when the size of 
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the projection of the mouse is reduced to its original size, it is not smoothed with an amount 
corresponding to Ri, but is smoothed only with Ri/5, thus improving spatial resolution. The 
smaller the object, the closer it can be placed to the pinhole and the higher the magnification 
can be.  
A consequent challenge is to acquire a sufficient number of counts in each individual voxel to 
support the high spatial resolution and to obtain a sufficient signal-to-noise ratio. The 
sensitivity of a pinhole system is approximated by: 
𝑆 = (
𝑑𝑒
2
16𝑏2
) 𝑁 
Where N represents the number of gamma detectors. The sensitivity can be improved by 
increasing the diameter of the pinhole opening to allow more gamma photons to pass. 
However, this will be at the cost of a poorer spatial resolution. The sensitivity can also be 
improved by bringing the object closer to the pinhole opening, however, this will be at the 
cost of the size of the field of view. 
In conclusion, the choices between spatial resolution, sensitivity and size of the field of view 
need to be carefully examined before performing a preclinical animal SPECT experiment. 
(Vanhove et al., 2015; Beekman and van der Have, 2006; Nuyts et al., 2009; Franc et al., 
2008; de Kemp et al., 2010) 
 
Figure 1.22: Principle of pinhole collimation. b represents the distance between the object and the pinhole and t 
represents the distance between the pinhole opening and the gamma detector. d e= effective diameter of the 
pinhole opening (adapted from Vanhove et al., 2016).  
When carefully designed, the use of multiple detectors in combination with multi-pinhole 
collimators can improve the spatial resolution and sensitivity with one order of magnitude, 
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compared to clinical systems (Figure 1.23). The use of multipinhole collimators and detectors 
(and resulting higher sensitivity) also allows dynamic imaging, in contrast to clinical systems. 
Today, all commercial µSPECT systems are equipped with multi-detector and multi-pinhole 
geometry. In this thesis, an USPECT-II/CT device (MILabs, The Netherlands) was used 
(Figure 1.24). The detectors are stationary and the animal bed is moving (van der Have F, 
2009). 
  
 
Figure 1.23: Early small-animal SPECT systems were developed using single scintillation camera with single-
pinhole collimator (A). Modern small-animal SPECT systems use multiple detectors, each with multipinhole 
collimators (B). (adapted from Franc et al., 2008) 
 
 
Figure 1.24: USPECT-II/CT. 
After imaging, the acquired projection data need to be reconstructed. In multi-detector multi-
pinhole µSPECT imaging, iterative reconstruction algorithms are routinely used that can take 
into account the complex system geometry .  
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Dynamic imaging and kinetic modeling 
After injection into the blood stream, the radiotracer is transported to several organs and is 
taken up by these organs. Dynamic imaging is an imaging procedure that follows the 
distribution of the radiotracer in function of time in different organs of interest: clearance 
from the blood, uptake in several tissues, secretion, possible trapping, etc. Both, PET and 
SPECT, have the potential to perform dynamic imaging studies.  
The uptake of the radiotracer depends on the affinity for the particular compound in the organ. 
Additionally, the uptake also depends on delivery of the tracer, which is reflected in the time 
course of activity in the blood. Therefore, it is very important to measure the arterial blood 
curve during the acquisition. Blood sampling is the gold standard to obtain arterial input 
functions. This can be achieved by manual sampling or continuous blood withdrawal and 
detection. However, for small animal imaging, this is a problem since the maximal sampling 
volume in a mouse of 25g is 0.015 mL (1%) for repeated measures within 24 hours. 
Therefore, image derived methods were introduced, where a region of interest (ROI) is drawn 
around the heart or an artery (Lammertsma, 2002; Gullberg et al., 2010; Vanhove et al., 
2015). To determine the ROI around the heart, radiotracers can be used that can visualize the 
left ventricular cavity. This was demonstrated in a PET study of Moerman et al. (2011), where 
[18F] fluoro-2-deoxy-D-glucose ([18F]FDG) was used to visualize the myocardium of the left 
ventricle. After the dynamic scan with the tracer of interest, [18F]FDG was administered to the 
mice and an additional static scan was done. A ROI around the left ventricle could be drawn 
based on the static FDG scan, and this ROI could be easily pasted on the dynamic tracer data, 
since the animal was not moved between the dynamic tracer acquisition and the static FDG 
scan.  
Besides the determination of the arterial input curve, the time course of the tracer in the 
organs of interest have to be determined. ROIs are drawn around the organs of interest and the 
tracer distributions in function of time are obtained as time activity curves (TACs).  
Tracer kinetic or compartmental modeling of these dynamic PET or SPECT measurements 
allow calculation of physiological parameters by fitting a mathematical compartmental model 
of tracer distribution and metabolism to the data. An example of a general two-tissue 
compartment model is given in Figure 1.25. 
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Figure 1.25: General two tissue compartment model. This model consist of a blood compartment, two tissue 
compartments and 4 rate constants. GB+I: gallbladder + intestines. 
 
A compartmental model is divided in physiologically separate entities in which the tracer is 
distributed. These entities are also called compartments that represent different organs or 
different states of the tracer within an organ, for example the bound and unbound fraction of 
the tracer. Between these compartments, there can be movements of the tracer, influx and 
efflux, which are expressed by means of rate constants, denoted with lower case k. For 
example, in Figure 1.25, the first compartment is the arterial blood. From the arterial blood, 
the tracer passes into a second compartment, namely the first tissue compartment C1, for 
example the liver. Then, the radiotracer can be transported into a second tissue compartment, 
C2, for example the gallbladder and intestines. This transport can be an indication of, for 
example, functioning hepatobiliary transport proteins. The influx in tissue compartment C1 
(liver) is represented by k1 and is an indicator of the blood clearance of the tracer, in this case 
from the liver sinusoids into the hepatocytes. k2 then represents the transport of the tracer 
from the liver back into the blood. k3 then represents efflux from the liver to the gallbladder 
and intestines. No transport from gallbladder and intestines to the liver is observed and 
therefore, k4 equals 0 in this specific example. All rate constants (k-values) are expressed as 
1/sec or 1/min.  
The kinetics of compartmental models can be described by a set of first-order linear 
differential equations. We are dealing with first order processes under the assumptions. Tracer 
kinetic modeling requires several assumptions: the physiological process of interest is not 
influenced by administration of the radiotracer, the physiological process has to remain 
constant during the acquisition and each compartment is homogeneous and the tracer is 
immediately mixed in the compartment (Watabe et al., 2006; Acton et al., 2004; Innis et al., 
2007; Kutner, 2014). 
Chapter 1: General introduction 
47 
When the first order kinetics are applied to the model depicted in Figure 1.25, the 
concentration of the tracer in compartments C1 and C2 in function of time can be described by 
two differential equations:  
𝑑𝐶1(𝑡)
𝑑𝑡
= 𝑘1𝐶𝑎(𝑡) − (𝑘2 + 𝑘3)𝐶1(𝑡) + 𝑘4𝐶2(𝑡) 
𝑑𝐶2(𝑡)
𝑑𝑡
= 𝑘3𝐶1(𝑡) − 𝑘4𝐶2(𝑡) 
Ca is the time course of the tracer in the arterial plasma, also referred as the arterial input 
curve. When the TACs, the arterial input function and a proposed model configuration are 
given, the underlying rate constants (k1-k4) can be calculated by solving the differential 
equations using for example least square methods. 
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Introduction 
Functional liver assessment is of great importance and the determination of clearance of 
hepatobiliary transport proteins substrates could be used as a measure for liver function. There 
are three factors that can modify the transport of hepatobiliary imaging agents through 
hepatocytes:  
1) Interindividual variability of transporters in the normal liver 
2) Modifications of transporter expression in diseased liver tissue and focal lesions 
3) Drug interactions.  
Prognostic tools are also important for the management of patients with severe chronic liver 
disease or liver failure, which is the major cause of mortality and morbidity after partial liver 
resection and is a result of insufficient functional remnant liver mass. Additionally, the 
investigation of liver function is important in the development of new drug candidates, the 
inhibition of hepatobiliary transporters, for example, can lead to drug induced liver injury (see 
Chapter 1). Several liver function tests have been developed. In this chapter, we will focus on 
molecular imaging techniques as useful tool to investigate hepatobiliary function in which 
measurement of hepatobiliary compounds in the liver may serve as biomarkers. An overview 
on the molecular imaging techniques and specific hepatobiliary contrast agents for the 
assessment of hepatobiliary function will be given (Hoekstra et al., 2013; Sakka, 2007; 
Stieger et al., 2012). 
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Hepatobiliary contrast agents in magnetic resonance 
imaging 
Magnetic resonance imaging (MRI) is a technique that uses a powerful magnet to aligh the 
nuclei of atoms (mainly H) inside the body, and a variable magnetic field that causes the 
atoms to resonate. Two relaxation times, the longitudinal relaxation T1 and spin-spin 
relaxation T2 (caused by interactions between neighbouring protons), can be used for image 
reconstruction.  
MRI of the liver is used for the characterization of masses, detection of primary and 
metastatic lesions, assessment of vascular structures, investigation of lesion vascularity and 
evaluation of the biliary tree. In MRI of the liver, several classes of contrast agents can be 
distinguished:  
1) Extracellular or nonspecific contrast agents 
2) Reticuloendothelial contrast agents 
3) Blood pool agents 
4) Hepatobiliary contrast agents 
A short description of the first three groups will be given, but the focus will be on the last 
group, since this group allows functional imaging of hepatobiliary transport because these 
agents are taken up by the hepatocytes. 
Most contrast agents are composed of gadolinium bound within an organic chelate, which 
makes them paramagnetic substances that can induce changes in the local magnetic field. The 
T1 shortening property of gadolinium based contrast agents (GBCAs) is the most useful and 
the contrast enhancement is used to detect the presence of the GBCAs. Other types of contrast 
agents are manganese and iron based (Bashir, 2014; Gandhi et al., 2006). 
 
Extracellular contrast agents 
Extracellular contrast agents, for example gadobutrol, are GBCAs that are distributed within 
the extracellular interstitial space. After intravenous injection, these contrast agents reach the 
liver via the hepatic arteries, which results in mild enhancement of the hepatic parenchyma. 
Solid liver lesions with an arterial-dominant vascular supply will have an arterial 
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hyperenhancement which is important for lesion detection and characterization. Additionally, 
the arterial hyperenhancement is important for the delineation of normal and variant hepatic 
arterial anatomy. After the arterial phase, further hepatic enhancement can be observed due to 
additional contrast medium that arrives in the liver via the portal vein, called the portal venous 
phase which occurs 60 to 70 seconds after intravenous injection of the contrast agent. In this 
phase, a washout appearance can be observed in liver lesions, since there is a weak additional 
enhancement of these lesions from the portal venous supply. After the portal venous phase, 
the equilibrium phase can be observed after 90 seconds, in which the contrast agent 
equilibrates between the arterial and venous distributions, as well as the extravascular and 
extracellular interstitium. 
 
Reticuloendothelial contrast agents 
These contrast agents target the reticuloendothelial system, particularly the liver and spleen. 
The uptake is a measure for the number of functioning macrophages. Examples of 
reticuloendothelial contrast agents are superparamagnetic iron oxide (SPIO) particles, which 
are phagocytosed by macrophages, and preferentially by Kupfer cells, which line the liver 
sinusoids. The reason for this affinity is unclear, but it may be related to particle size. SPIOs 
are negative contrast agents that reduce signal intensity, particularly on T2 and T2*. Most 
liver tumors (benign and malignant, primary or metastatic) are deficient in Kupffer cells and 
do not exhibit SPIO uptake, so tumors appear relatively hyperintense compared to normal 
tissue (Gandhi et al., 2006). 
 
Blood pool contrast agents 
The blood pool agents, for example gadofosveset trisodium, remain longer in the intravascular 
space than extracellular agents. Because of strong binding to serum albumin, they are cleared 
slowly and there is little leakage into the interstitial compartment. Due to the long serum half-
lives, there is only little parenchymal enhancement and therefore, they can be used for 
imaging vascular abnormalities in the equilibrium phase. There are three main categories: 
ultrasmall SPIO particles, agents that reversibly bind to plasma proteins and macromolecules 
(Gandhi et al., 2006; Bashir, 2014). 
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Hepatobiliary contrast agents 
Hepatobiliary contrast agents used in the clinic – transporter substrates 
There are two hepatobiliary contrast agents available in the clinic: Gadobenate dimeglumine 
(Gd-BOPTA, MultiHance, Bracco Diagnostics), which shows 5% uptake in a normal human 
liver, and Gadoxetate disodium (Gd-EOB-DTPA, Eovist, Bayer Healthcare), which shows 
50% uptake in normal liver, via OATPs and MRP2 (Ulloa et al., 2013; Nassif et al., 2012; 
Leonhardt et al., 2010; de Haën et al., 1995).  
Figure 2.1 displays representative images of the different phases from a liver MRI 
examination with gadoxetate disodium as contrast agent. Initially, these contrast agents 
distribute in a similar manner compared to extracellular contrast agents. There is both an 
arterial phase with enhancement (Figure 2.1, A), followed by a portal venous phase (Figure 
2.1, B) with washout features of liver lesions. Additionally, after the dynamic phase, 
hepatocyte uptake and biliary excretion can be observed (Figure 2.1, C). The contrast agents 
are taken up by the hepatocytes and are excreted to the gallbladder and intestines, reaching  
the hepatobiliary phase (Figure 2.1, D). In this phase, the liver and bile ducts are enhanced on 
T1-weighted images, due to accumulation of the contrast agents, and the blood vessels are 
dark. The hepatobiliary phase is typically reached between 20 and 120 minutes for gadoxetate 
disodium, and between 45 and 120 minutes for gadobenate dimeglumine and has an optimal 
uptake into hepatocytes and excretion into bile to allow visualization of both the biliary 
system and liver.  
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Figure 2.1: MRI images of the different phases from a liver MRI examination with gadoxetate disodium as 
contrast agent. A: late hepatic arterial phase with enhancement of the hepatic artery and early enhancement of 
the portal vein. B: portal venous phase with enhancement of the portal and hepatic veins, and also a strong 
enhancement of the hepatic parenchyma, due to early hepatocyte uptake of the contrast agent.  C: late dynamic 
phase with strong enhancement of the liver with relative washout in the vessels. The liver enhancement is caused 
by a combination of residual intravascular enhancement, leakage to the extravascular extracellular interstitial 
space and active hepatocyte uptake by OATPs. D: Hepatobiliary phase with strong enhancement of liver, 
washout of the blood vessels and excretion into the bile ducts  (adapted from Bashir, 2014).  
 
Additionally, hepatocyte-containing lesions will also be enhanced. This contrast enhancement 
pattern depends on: 
1) the presence of functioning hepatocytes 
2) vascular supply of the lesion 
3) characteristics of the biliary structures within the lesions.  
These hepatobiliary imaging agents can be used as biomarker of hepatobiliary transporter 
function in a noninvasive manner. The majority of the liver function tests measures the global 
function of the liver, with no consideration for segmental variations in function or 
dysfunction. Liver-specific MR contrast agents can assess liver function at segmental level, 
with an excellent anatomical resolution. This can be important in the treatment planning 
before liver resection for example in liver cirrhosis and hepatocellular carcinomas (HCC), 
which do not have a normal liver parenchyma. However, further technical development and 
clinical validation of this method is needed (Serlin et al., 2014; Pastor et al., 2014). 
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In the clinic, hepatobiliary imaging agents are mostly used for the characterization of liver 
lesions of hepatocellular origin (HCC, focal nodular hyperplasia (FNH), hepatocellular 
adenoma (HCA)) and of nonhepatocellular origin (cavernous hemangioma, cysts, metastases). 
FNH and HCA are often difficult to differentiate by conventional MRI. However, the 
distinction is important since FNH needs no therapeutic intervention but HCA does, due to its 
potential for malignant transformation and bleeding. Hepatobiliary contrast agents accumulate 
differently in these lesions: in FNHs, there is an accumulation of the contrast agents, since the 
bile ducts are not connected to the biliary tree.  
Additionally, biliary tree imaging can be performed in the hepatobiliary phase to give both 
anatomical and functional information, which can be useful for identifying sites of bile duct 
injury and bile leakage. For example, cholestasis can be detected by a decrease, delay or total 
lack of contrast excretion into the biliary track (Frydrychowicz et al., 2012; Gandhi et al., 
2006; Bashir et al., 2014; Pascolo et al., 1999; Zech et al., 2007; Choi et al., 2014). 
 
Bile acid analogues 
In addition to the two hepatobiliary contrast agents used in the clinic, several experimental 
liver-specific MR contrast agents were developed. In the scope of this thesis, the focus will be 
on bile acid analogues. 
In 2004, Anelli et al. (Anelli et al., 2004) published 12 bile acid analogues (Figure 2.2) that 
formed a complex with gadolinium in order to become contrast agents that were actively 
taken up by the hepatocytes at higher rates compared to Gd-EOB-DTPA and Gd-BOPTA. All 
agents showed biliary and renal excretion in different ratios. Different configurations were 
investigated and the extent of biliary excretion depends on several structural features such as 
the nature of the bile acid, the site of conjugation of the gadolinium complex and the global 
charge of the conjugate. One conjugate, compound 1j (Figure 2.2), was identified as possible 
NTCP substrate.  
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Figure 2.2: Bile acid analogues synthesized by Anelli et al. Bile acid analogues are indicated by the numbers 1a-
1j (adapted from Anelli et al., 2004). 
Gadocoletic acid trisodium salt (B22956/1; compound 1g in Figure 2.2), used as blood pool 
agent, was investigated by Libra et al. (Libra et al., 2006) as hepatobiliary imaging agent. The 
aim of the incorporation of a bile acid in the structure of B22956/1 was to increase plasma 
protein binding and so increasing the blood half-life. Biliary excretion is the primary 
elimination route of this compound, in contrast to Gd-BOPTA and Gd-EOB-DTPA. Libra et 
al. revealed that OATPs and MRP2 are involved in the uptake and efflux of B22956/1. 
Vivian et al. published trifluorinated bile acid analogues for 19F magnetic resonance imaging 
in the context of diagnosing bile acid malabsorption (Figure 2.3). First, cholic acid-
trifluoroacetyl lysine (CA-lys-TFA) was synthesized and NTCP and ASBT were identified as 
the involved transport proteins (Vivian et al., 2013). A limitation of this imaging probe is that 
the molecule is deconjugated by gut bacterial enzymes (Vivian et al., 2014). Therefore, an 
additional bile acid analogue was synthesized to diminish the potential for differences in 
intestinal microbiota to alter probe concentrations and also increase the probe half-life (Vivian 
et al., 2014). In this context, CA-sar-TFMA was synthesized, a compound that is structurally 
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similar to cholylsarcosine. NTCP and ASBT were also identified as the involved transporters 
and no bacterial metabolization was observed in vitro. 
 
 
Figure 2.3: Structures of CA-lys-TFA (A) and CA-sar-TFMA(B) (adapted from Vivan et al., 2013; Vivian et al., 
2014). 
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Fluorescent hepatobiliary contrast agents 
Fluorescent indocyanine green (ICG) imaging is used in the operating room to assess the 
function of liver segments. ICG is transported via OATPs, NTCP and MRP2. The vascular 
clearance of ICG over time is a measure for hepatic function. ICG clearance was mostly 
measured by blood sampling after intravenous injection. Today, ICG plasma clearance can be 
measured noninvasively at the bedside. It is for example used in the operating room to 
visualize the resection limits of HCCs by using a fluorescence camera. However, ICG is of 
concern for patients with iodine allergy (Sakka et al., 2007). 
Besides ICG, mainly bile acid analogues were developed as fluorescent hepatobiliary agents. 
Plasma clearance of bile acids is a quantitative measure of liver function and is based on the 
principle that bile acid uptake and metabolism is a liver specific function. Two main classes 
can be distinguished: 1) (amino)fluorescein coupled to the carboxylic group of a bile acid and 
2) nitrobenzoaxdiazolyl (NBD) coupled to the ε-amino group of a conjugated bile acid 
(Holzinger et al., 1997). 
A first group, fluorescein conjugated bile acid analogues (Figure 2.4), express several 
physicochemical and biological properties similar to endogenous bile acids, including rapid 
secretion into bile. These imaging agents have been used in several studies to investigate the 
(patho)physiology of bile acid transport both in vitro and in vivo. Milkiewicz et al. 
(Milkiewicz et al., 2000), for example, performed a pilot study that revealed that there was a 
reduced clearance of cholyl-lysyl-fluorescein (CLF) in patients with liver cirrhosis. CLF is an 
OATP1B1, weak OATP1B3, MRP2 and MRP3 substrate (de Waart et al., 2010). Therefore, 
CLF was suggested as imaging agent for the assessment of liver function. Additionally, 
aminofluorescein (amF) bile acid analogues are used to assess liver function. Holzinger et al. 
(Holzinger et al., 1997) proposed amF conjugated cholylglycine, 
cholylglycylamidofluorescein (CGamF) as characterizing agent for hepatocyte transport 
function in health and disease. This contrast agent is mainly used in in vitro studies.  
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Figure 2.4: Structure of CLF and CGamF (adapted from de Waart et al., 2010). 
Secondly, an NBD amino-group was used as fluorophore and was introduced in different 
positions of the steroid nucleus. 3-, 7-, and 12-α and -β NBD analogues of cholic acid and its 
tauro conjugates (Figure 2.5) have been synthesized and were evaluated in vitro and in 
invasive in vivo studies (Schramm et al., 1991; Schneider et al., 1991; Schramm et al., 1993).  
 
Figure 2.5: Structures of taurine-conjugated bile salt derivatives 3β-NBD-NCT (A), 7β-NBD-NCT and 12β-
NBD-NCT (adapted from Schneider et al., 1991). 
 
NBD labeled 24-lysyl conjugates have been studied as substrates for hepatic and intestinal 
transport proteins (Holzinger et al., 1996; Maglova et al., 1995) (Figure 2.6). Yamaguchi et 
al. (Yamaguchi et al., 2006) identified OATP1B1 and OATP1B3 as the involved uptake 
transporters of chenodeoxycholyl-NBD-lysine (CDC-NBD-L).  
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Figure 2.6: Structures of chenodeoxycholyl-NBD-lysine (CDC-NBD-L) and cholyl-NBD-lysice (C-NBD-L) 
(adapted from Maglova et al., 1995). 
In 2012, Májer et al. (Májer et al., 2012) reported two new isomeric 3-deoxy 3-NBD-amino 
derivatives of UDCA and DCA (Figure 2.7).  
 
Figure 2.7: Structures of 3-deoxy 3-NBD-amino deoxycholic (left) and ursodeoxycholic acid (right) (adapted 
from Májer et al., 2012).  
Additionally, Tauro-nor-THCA-24-DBD, a synthetic fluorescent bile acid analogue with a 
fluorophore at the side chain of the taurine conjugated bile acid (Figure 2.8), was synthetized 
by Yamaguchi et al. (Yamaguchi et al., 2010) and was used by De Bruyn et al. (De Bruyn et 
al., 2014) to study interference of drugs with NTCP and BSEP in a fluorescence-based in 
vitro assay. However, to the best of our knowledge, none of these agents were used in 
humans.  
 
Figure 2.8: Structure of tauro-nor-THCA-24-NBD (adapted from Yamaguchi et al., 2010).  
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PET tracers  
Several PET tracers were developed to study hepatic bile acid transporters (Testa et al., 2015). 
Table 2.1 displays an overview of these tracers. The bile acid analogues are indicated in 
underlined italic font.  
Table 2.1: Hepatobiliary PET tracers (adapted from Testa et al., 2015). 
PET tracer Bile acid 
transporters studied 
Preclinically/clinically References 
[11C]dehydropravastatin OATPs, MRP2 Preclinical Shingaki et 
al., 2013 
[11C]rosuvastatin OATPs, NTCP, 
MRP2 
Preclinical 
 
He et al., 2014 
[11C]TIC-Me OATP1B1, 
OATP1B3, MRP2 
Preclinical 
Clinical 
Takashima et 
al., 2010 
Takashima et 
al., 2014 
[11C]glyburide OATPs Preclinical Tournier et 
al., 2013 
[11C]telmisartan OATP1B3 Preclinical 
Clinical 
Shimizu et al., 
2012; Iimori 
et al., 2011 
[11C]cholylsarcosine Bile acid transporters Preclinical 
Clinical 
Frisch et al., 
2012 
[18F]CDCA Bile acid transporters Preclinical Jia et al., 2014 
[11C]MTCA 
[11C]MTCDCA 
[11C]MTDCA 
[11C]MTUDCA 
[11C]MTLCA 
Bile acid transporters Preclinical Schacht et al., 
2016 
 
Transporter substrates 
[11C]dehydropravastatin is a pravastatin analogue and is taken up into the hepatocytes by 
OATPs and excreted into the biliary system via MRP2. This compound was investigated in 
vitro, in cryopreservated rat and human hepatocytes and also in control, rifampicin-treated 
and MRP2 knock-out rats (Shingaki et al., 2013).  
Rosuvastatin is a known OATPs, NTCP and MRP2 substrate. Therefore, its [11C]-analogue 
was synthesized as imaging agent of hepatobiliary rosuvastatin transport. In rats, 
[11C]rosuvastatin was transported by Oatps, but not by Ntcp. It is then metabolized in the liver 
and/or excreted by Mrp2 and Bcrp. The inhibitory effect of rifampicin was also demonstrated. 
It was suggested as a useful PET probe for human hepatic transporters (He et al., 2014).  
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[11C]tetranoisocarbacyclin methyl ester ([11C]TIC-Me) is a prostaglandin E2 analogue and is 
taken up in the liver via OATP1B1 and OATP1B3 and excreted via MRP2. The metabolite 
profile and biliary clearance of this tracer was determined in vitro and in vivo in normal rats, 
Mrp2 knock-out rats and in humans. Additionally, the effects of rifampicin on hepatobiliary 
functionality were assessed in humans (Takashima et al., 2010; Takashima et al., 2012; Testa 
et al., 2015).  
Glyburide is a antidiabetic agent, used in the treatment of type 2 diabetes. It is a substrate of 
several ABC transporters but it is also a substrate of OATP1B1, OATP2B1 and OATP1A2. 
Its [11C]-labeled form (Tournier et al., 2013) demonstrated the pharmacological consequences 
of the interaction between glyburide and inhibitors of OATP and ABC transporters in vivo.  
[11C]telmisartan is a radiolabeled angiotensin receptor antagonist. It is transported into the 
liver mainly by OATP1B3. Its transport was investigated in normal and rifampicin-treated rats 
and then in healthy volunteers. Uptake in the liver was observed with gradual elimination to 
the gallbladder and intestine and the tracer was found to be safe and promising in order to 
study OATP1B3 in humans (Shimizu et al., 2012; Iimori et al., 2011).  
 
Bile acid analogues 
Cholylsarcosine is an analogue of the conjugated bile acid cholyl-glycine and is formed by 
cholic acid and the amino acid N-methylglycine (sarcosine). Frisch et al. (Frisch et al., 2012) 
introduced [11C]cholylsarcosine (Figure 2.9) as an imaging agent for the visualization and 
quantification of normal and pathologic hepatic excretory functions. NTCP and BSEP are the 
expected transporters, because of the high similarity between cholylsarcosine and 
cholylglycine. However, no in vitro transporter characterization was performed. This 
radiotracer was investigated in pigs and hepatic uptake and biliary excretion was observed. 
After administration of cholyltaurine, both hepatic uptake and biliary excretion were inhibited 
in vivo.  
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Figure 2.9: Structure of [11C]-cholylsarcosine (adapted from Frisch et al., 2012). 
An 18F labeled chenodeoxycholic acid analogue was proposed by Jia et al. (Jia et al., 2014). 
No characterization of the involved uptake and efflux transporters was done, but in vivo 
evaluation in mice showed that this tracer had a similar uptake and efflux pattern as 
[11C]cholylsarcosine. This tracer was proposed as PET tracer FXR in related disease.  
 
Figure 2.10: Structure of [18F]CDCA (adapted from Jia et al., 2014). 
 
Recently, Schacht et al. (Schacht et al., 2016), inspired by the research of Frisch et al. (Frisch 
et al., 2012), proposed five methyl-taurine-conjugated bile acids. In vivo studies in pigs 
revealed that these tracers behave in a similar manner as endogenous taurine-conjugated bile 
acids, and therefore, they identified these agents as promising tracers for functional PET 
imaging of patients with cholestatic liver disease. However, no in vitro experiments were 
performed to identify the involved uptake and efflux transporters.  
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Figure 2.11: Structures of [18F] bile acid analogues (adapted from Schacht et al., 2014). 
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SPECT tracers 
[99mTc]mebrofenin 
[99mTc]mebrofenin ([99mTc]MEB) is a second-generation hepatic imino diacetic acid (HIDA) 
derivative and lidocaine analogue (Figure 2.12).  
 
Figure 2.12: Structure of [99mTc]mebrofenin. 
 
After intravenous injection, this ionic tracer binds to plasma proteins (mainly albumin) and 
circulates to the liver, where it dissociates in the space of Disse and is taken up by the 
hepatocytes via OATP1 (Morandi et al., 2005; Ghibellini et al., 2008). Subsequently, 
[99mTc]MEB is transported through the hepatocytes, and is then secreted in the gallbladder 
through MRP2 (Nies et al., 2007). Finally, [99mTc]MEB is eliminated into the small intestine. 
In the clinic, it is used to assess many clinical indications, for example acute cholecystitis, 
biliary leak, complications after liver transplantation, prediction of remnant liver function, 
differential diagnosis of hepatic tumors, … (Ziessman, 2014; Lambie et al., 2011). Because of 
the high hepatic clearance rate via the biliary system, mainly dynamic assessment of 
[99mTc]MEB is performed using planar scintigraphy. To measure global liver function, 
regions of interest are drawn around the heart, liver and total field of view. Out of these 
measures, the total uptake rate corrected for the patient’s body surface area (%/min/m²) can be 
calculated. Remnant liver function can also be calculated by dividing the summed counts 
within the delineated functional remnant liver by the total liver counts within the same time 
frame and multiplying this factor with total liver uptake rate (Erdogan et al., 2004).  
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Figure 2.13 shows an example of  [99mTc]MEB hepatobiliary dynamic scintigraphy. Figure 
2.13 A depicts [99mTc]MEB uptake in a superimposed image of the dynamic scintigraphy. A 
region of interest can be drawn around the entire liver (dark grey line), the heart (white line), 
the future remnant liver (light grey line) and the total field of view (not shown). The 
corresponding time activity curves are shown in Figure 2.13 B. The region of interest around 
the heart can be obtained from the first time frames after injection of the radiotracer (Figure 
2.13 C). The uptake of [99mTc]-MEB by the liver (slope, D) is calculated as an increase in 
[99mTc]MEB uptake (y), over a predefined time interval (x), usually 200 seconds.  
 
Figure 2.13: [99mTc]MEB hepatobiliary scintigraphy (adapted from Hoekstra et al., 2013). 
  
[99mTc]Galactosyl serum albumin  
[99mTc]diethylenetriamine-pentaacetic acid-galactosyl human serum albumin ([99mTc]GSA) is 
an asialoglycoprotein analogue that binds to the asialoglycoprotein receptors on the 
hepatocyte and is then exclusively taken up in the hepatocytes via receptor-mediated 
endocytosis. This tracer is used for functional liver scintigraphy, however, it is not suitable for 
the evaluation of the biliary tract, since there is no biliary excretion. Evaluation of liver 
function via [99mTc]GSA shows a good relationship with conventional liver function tests (e.g. 
total and direct bilirubin, antithrombin, prothrombin time, etc.). After dynamic [99mTc]GSA 
scintigraphy with the gamma camera positioned over the heart and liver region, regions of 
interest are drawn around the heart and liver and blood clearance ratio (ratio of the heart 
uptake after 15 minutes and heart uptake after 3 minutes; HH15=H15/H3) and hepatic uptake 
ratio (LHL15= L15/(L15+H15); liver uptake after 15 min divided by the sum of the liver and 
heart uptake after 15 minutes) values are calculated, which are the two most commonly used 
parameters in planar [99mTc]GSA scintigraphy. In the clinic, the preoperative hepatic uptake 
ratio is used as reliable indicator for predicting postoperative complications in patients with 
Chapter 2: Functional hepatobiliary imaging 
74 
HCC and chronic liver disease that have a significantly lower LHL15. However, 
postoperative liver failure was also observed in patients with normal LHL15 values. This can 
be explained by the fact that LHL15 only measures total liver function and not the function of 
the functional remnant liver.  
To overcome this shortcoming, static and dynamic SPECT imaging can be performed to 
measure segmental liver function and functional liver volume. Planar scintigraphy images are 
two dimensional reconstructions of the tracer distribution in a field of view leading to 
superposition of tissue or tissue segments. SPECT imaging, in contrast, offers three 
dimensional tomographic images that allow measurements of radioactivity in volumes of 
interest, for example liver segments. Therefore, [99mTc]GSA SPECT can be used to assess 
specifically the functional remnant liver. In cirrhotic patients for example, advanced fibrosis 
is accompanied by a reduction in functional hepatocytes (Hoekstra et al., 2013). 
 
Bile acid analogues 
Huang et al. (Huang et al., 2009) synthesized rhenium and technetium labeled bile acid 
tricarbonyl complexes (Figure 2.14). However, no in vitro or in vivo evaluation of these 
compounds was done. To the best of our knowledge, these were the only technetium labeled 
bile acids reported to date.  
 
Figure 2.14: Structures of technetium labeled bile acid analogues (adapted from Huang et al., 2009).  
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Drug induced liver injury (DILI) is responsible for up to 15% of cases of acute liver failure in 
Europe and US, and is a one of the leading causes of drug withdrawal from the market and 
attrition in the development process of new drug candidates. Therefore, it is important to 
understand, characterize, and develop prediction methods to identify possible interactions. 
One of the involved causes of DILI is drug induced cholestasis and many cases are caused by 
inhibition of hepatic transporters by drugs. Clinically relevant hepatic transport systems 
include the Organic Anion Transporting Polypeptides (OATPs), sodium Taurocholate 
Cotransporting Protein (NTCP), Multidrug Resistance-associated Protein-2 (MRP2) and bile 
salt export pump (BSEP). Cholestatic drugs may disturb bile acid homeostatis by direct 
inhibition of bile acid transport, or by indirect processes, such as regulation of transporter 
localization or expression Inhibition of these transporters for example, can lead to toxic 
concentrations of bile acids, bilirubin or substrate drugs in blood or liver, which can lead to 
hypercholanemia, hyperbilirubinemia, cholestatic liver injury and drug-drug interactions.  
Currently, these interactions are investigated by in vitro and invasive, time consuming, and 
expensive preclinical in vivo experiments. Therefore, the overall aim of this thesis is the 
development of non-invasive predictive methods to visualize and quantify disturbed 
hepatobiliary transport by drugs in preclinical animal species as an alternative to the invasive 
methods. An additional advantage is that the number of sacrificed animals can be reduced. 
This overall aim can be subdivided in  four research questions. 
 
Question 1: Is it possible to visualize and quantify altered hepatobiliary transport in 
mice? (Chapter 5) 
[99mTc]mebrofenin ([99mTc]MEB) is a second-generation hepatic imino diacetic acid (HIDA) 
derivative, which is commonly used in hepatobiliary scintigraphy to investigate the function 
and dysfunction of the liver. After intravenous injection, this ionic tracer binds to plasma 
proteins (mainly albumin) and circulates to the liver, where it dissociates and is taken up by 
the hepatocytes, through a carrier-mediated, sodium-independent transport mechanism, the 
organic anion transport protein 1 (OATP1/Oatp1). Subsequently, [99mTc]MEB  is transported 
through the hepatocytes, and is then secreted in the gallbladder through MRP2/Mrp2. Finally, 
[99mTc]MEB is eliminated into the small intestine. Therefore, this radiotracer was chosen as 
biomarker to study hepatobiliary transporter function in vivo and will be evaluated in a non-
invasive manner by dynamic SPECT imaging in mice. Wild type mice will be evaluated to 
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determine the coefficient of variation of the measurements. As proof-of-principle, a bile duct 
ligated animal (mechanical inhibition of hepatobiliary efflux) will be investigated. In addition, 
transporter knock-out (KO) mice models will be used to study altered uptake and efflux 
transporter function. Slco1a/1b and Abcc2 KO mice will be evaluated. These mice lack the 
Oatp1a/1b and Mrp2 transporters, respectively. Lastly, rifampicin will be used as model drug 
to visualize and quantify pharmacological inhibition of transporters. It has been shown that 
rifampicin mediates the inhibition of OATP1B1 in vitro, mouse Oatp1a/1b in vivo and Mrp2 
in vitro. 
 
Question 2: Can this quantification be further refined by kinetic modeling of 
[99mTc]MEB? (Chapter 6) 
Tracer kinetic or compartmental modeling of dynamic SPECT measurements allows 
calculation of physiological parameters by fitting a mathematical compartmental model of 
tracer distribution and metabolism to the data. We will investigate if tracer kinetic modeling 
can be used to absolutely quantify altered hepatobiliary transport in Mrp2 KO and rifampicin 
treated mice. A two-tissue compartmental model will be proposed. Additionally, a non-
invasive method to obtain the blood input function will be evaluated.  
 
Question 3: Is a humanized mouse model useful for the prediction of disturbed human-
type hepatobiliary transport? (Chapter 7) 
Due to species differences, many hepatotoxicants remain undetected in preclinical safety 
studies. Therefore, a chimeric mouse model with a humanized liver will be evaluated to study 
human-type hepatobiliary transport. [99mTc]MEB transport will be assessed to characterize the 
chimeric “humanized” model.  
 
Question 4: Can bile acid analogues serve as biomarkers for DILI? (Chapter 8) 
To investigate non-invasively the effect of inhibition of hepatobiliary transporters on the 
transport of bile acids, there is a need for labeled bile acid analogues since [99mTc]MEB has 
no chemical similarities with endogenous bile acids. Therefore, radiolabeled primary bile acid 
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analogues will be synthesized. We will investigate a technetium labeled chenodeoxycholic 
and cholic acid analogue: technetium labeled diethylene triamine pentaacetic acid 
chenodeoxycholic acid ([99mTc]DTPA-CDCA) and technetium labeled diethylene triamine 
pentaacetic acid cholic acid, ([99mTc]DTPA-CA), respectively. Technetium will be used as 
radioisotope since it is easily produced (it can be eluted from a generator), its suitable half-life 
(6 hours) and its limitless depth of penetration. Additionally, in vitro assays will be performed 
to identify the involved uptake and efflux transporters. Lastly, in vivo SPECT evaluation of 
normal and disturbed hepatobiliary transport will be performed to illustrate the ability of these 
agents to visualize and quantify (altered) hepatobiliary transport in vivo. 
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NaI(Tl) scintillation detector  
10 samples with 100 µL [99mTc]TcO4- ranging from 0.37 to 45 kBq and determined with a 
conventional CRC-15R dose calibrator (Capintec, Ramsay, NJ) are measured with the NaI(Tl) 
scintillation detector (in cps) (Perkin Elmer, Waltham, USA) to obtain a calibration curve 
from cps to MBq/mL with the following equation:   
Radioactivity in kBq= 0.00013*(counts/30sec)  R²= 0.9983 
This calibration curve will be used in Chapter 5 to measure the exact amount of radioactivity 
in the manual blood samples.  
 
µSPECT 
To obtain quantitative measurements from the µSPECT camera (USPECT-II, MILabs, 
Utrecht, The Netherlands), 8 samples with predetermined amounts of [99mTc]TcO4- ranging 
from 0.37 MBq to 74 MBq, measured with a CRC-15R dose calibrator were acquired during 
10 minutes. The field of view was determined by means of a 30 seconds CT acquisition. ROIs 
were manually drawn around the content of the syringe (approximately 1 mL), to determine 
the total amount of radioactivity and in the middle of the syringe, to determine the activity 
concentration (Figure 4.1). The resulting output, measured in counts or counts/mL, was 
expressed as a function of the true activity (MBq or MBq/mL) as measured by the dose 
calibrator. The resulting calibration curve was used to quantify the amount of radioactivity in 
MBq  or concentration of radioactivity in MBq/mL in specific organs (Chapter 5, 6, 7 and 8).  
 
The calibration curves were obtained with the following equations:  
Total amount of radioactivity (MBq)= 1095*counts     R²= 0.9986 
Concentration of radioactivity (MBq/mL)= 2.646*106*counts/mL     R²= 0.9987 
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Figure 4.1: ROIs around syringe which is used for the calibration curve of the USPECT-II imaging system. Red: 
ROI that is used for determination of total amount of radioactivity (in MBq). Blue: ROI that is used for the 
determination of the radioactivity concentration (in MBq/mL).  
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Introduction 
As outlined in Chapter 1, the liver is an important organ for homeostasis. Hepatobiliary 
transport processes are essential for these key functions and therefore, hepatocytes express 
several transport systems (Kullak-Ublick et al., 2000; Wolkoff et al., 2003).  
Clinically relevant hepatic transport systems include the organic anion transport pumps 
(OATPs), sodium taurocholate cotransporting protein (NTCP), multidrug resistance protein 2 
(MRP2) and bile salt export pump (BSEP) (Kosters et al., 2008; Kullak-Ublick et al.,2000; 
Meier et al., 2002; Trauner et al., 2003). Numerous drugs are substrates or inhibitors of these 
hepatic transporters and therefore, unexpected and unwanted interactions are frequently 
observed as stated in Chapter 1 (Shitara et al., 2005; Maddrey, 2005). Therefore, in drug 
research, it is important to assess the inhibition of hepatic transporters at an early 
developmental phase. Currently, this possible inhibition is investigated by means of in vitro 
and invasive, time-consuming and expensive preclinical in vivo tests (Chapter 1).  
The current study, in contrast, describes a non-invasive in vivo method to assess the effect of 
drugs on the hepatobiliary transport mechanisms in mice as an alternative for invasive 
methods. Consequently, the number of sacrificed animals and costs can be reduced. In 
addition, the proposed method can be used in both preclinical and clinical settings. We aim to 
introduce a radioactive labeled substrate for the hepatic transporters, which can be used to 
visualize the hepatic uptake, efflux and possible inhibition of these processes with molecular 
imaging techniques, such as Single Photon Emission Computed Tomography (SPECT). In 
this context, we propose the second-generation hepatic imino diacetic acid (HIDA) derivative 
mebrofenin (MEB), which is commonly used in hepatobiliary scintigraphy to investigate the 
function and dysfunction of the liver as outlined in Chapter 2 (Bujanover et al., 1983; Newell 
et al., 2000; Morandi et al., 2005; Ghibellini et al., 2008). Normal transport of [99mTc]MEB is 
shown in Figure 5.1, A.  
First, we will evaluate the possibility of visualizing and quantifying normal hepatobiliary 
transport in mice. The interanimal and intra-animal variability of the dynamic imaging 
procedure will be evaluated.  
Following the study of [99mTc]MEB as a suitable SPECT tracer for the evaluation of 
hepatobiliary transport, the effect of altered hepatobiliary transport on [99mTc]MEB kinetics 
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will be investigated in mice. Based on the results, a non-invasive in vivo method is proposed 
to assess disturbances in the transport of [99mTc]MEB in mice. 
As proof-of-principle, mechanical inhibition will be obtained by placing a ligation around the 
bile duct. Pharmacological inhibition will be achieved by administration of rifampicin, an 
antibiotic that is often used to treat tuberculosis and other bactericidal infections. Rifampicin 
is known to mediate the inhibition of OATP1B1, OATP1B3 in vitro (de Graaf et al., 2011; 
Ghibellini et al., 2008), mouse Oatp1a/1b in vivo (Van de Steeg et al., 2010) and Mrp2 in 
sandwich-cultured rat hepatocytes (Lengyel et al., 2008). However, less is known about the 
effects of rifampicin on the function of hepatic MRP2 in humans, as these may be hard to 
detect in circulating blood, since inhibition of MRP2 leads to an accumulation of substrates in 
the liver. Thus, rifampicin provided an ideal test compound for this study. We hypothesized 
that rifampicin inhibits Oatp1a/1b as well as Mrp2, with inhibition reflected in altered time–
activity curves (TACs) for the blood, liver, and gallbladder+intestines (Figure 5.1 D) (Kosters 
et al., 2008; Kullak-Ublick et al., 2000). As a reference, and to investigate in vivo the relative 
contributions of uptake and efflux transporters in [99mTc]MEB handling, dynamic µSPECT 
imaging was used to characterize the behavior of [99mTc]MEB in mice unable to express the 
uptake transporters Oatp1a/1b (Slc1a/1b-/-/-/-, Oatp1a/1b knock-out (KO)) (Van de Steeg et al., 
2010) or the efflux transporter Mrp2 (Abcc2-/-, Mrp2 KO) (Vlaming et al., 2006). It was 
further hypothesized that elevated concentrations of [99mTc]MEB would be detected in the 
blood of Oatp1a/1b KO mice and in the liver of Mrp2 KO mice (Figure 5.1 B and C, 
respectively).  
Critical for the interpretation and translation of the data in such experiments is a 
comprehensive mechanistic understanding of the hepatic handling of [99mTc]MEB. 
[99mTc]MEB is an in vitro substrate of OATP1B1, OATP1B3, MRP2, and MRP3, but not of 
OATP2B1 and NTCP (Ghibellini et al., 2008, de Graaf et al., 2011). Although unlikely, it is 
not yet known whether [99mTc]MEB (an anion) is a substrate for OCT1 (organic cation 
transporter 1). Considering the high-level expression of OCT1 in the sinusoidal membrane, in 
the present work it was also important to formally exclude OCT1-mediated [99mTc]MEB 
transport. 
In summary, the possibility of non-invasive visualizing and quantifying transporter activity in 
a reproducible manner will be examined. Furthermore, we will examine whether we can 
quantify altered hepatobiliary transport and whether we can distinct the effect on the 
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sinusoidal uptake into the liver and efflux into the bile. If these aims will be fulfilled, one will 
have a possible model to predict the effects of drugs in a (pre-)clinical setting. Since this 
method could be used in preclinical and clinical research, the translation from animal to 
human could be made more easily.  
 
 
Figure 5.1: Study hypothesis for [99mTc]MEB transport in wild-type (A), Oatp1a/1b KO (B), BDL and Mrp2 KO 
(C) and rifampicin-treated (D) mice. In wild-type mice, rapid uptake in the liver and efflux to the gallbladder and 
intestines are expected, in contrast to Oatp1a/1b KO mice, in which no noteworthy uptake is anticipated. In 
Mrp2 KO mice, normal uptake in the liver and the absence of efflux to the gallbladder and intestines is 
hypothesized whereas in rifampicin-treated mice, decreased uptake and efflux are assumed. 
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Materials and methods 
In vitro assays  
Chinese hamster ovary (CHO) cells, CHO-OCT, Human Embryonic Kidney (HEK), 
HEK293-OATP1B3 cells were purchased from Solvo Biotechnologies (Hungary); CHO-
NTCP and HEK293-OATP1B1 cells were a kind gift from the same company. The cells were 
stably transfected with genes encoding human NTCP (SLC10A1), OATP1B1 (SLCO1B1), 
OATP1B3 (SLCO1B3) and OCT1 (SLC22A1). The cell lines were cultured in a humidified 
atmosphere at 37°C in the presence of 5% CO2. The culture medium of the CHO cells 
consisted of Dulbecco’s modified Eagle’s medium (DMEM)/F12, supplemented with 10% 
fetal calf serum, 2 mM L-glutamine, 0.3 mM L-proline, and antibiotics 
(Penicillin/Streptomycin; 50 U/mL; 50 µg/mL). The culture medium of the HEK293 cells 
consisted of DMEM glutamax; high glucose; pyruvate supplemented with 10% fetal calf 
serum, 5 mL MEM-non essential amino acid solution, and antibiotics 
(Penicillin/Streptomycin; 50 U/mL; 50 µg/mL). 
For transport experiments, all CHO and HEK cells were seeded in 24-well plates (6.0×105 
cells/well) in 1 mL of culture medium. After 18–24 h, the medium was removed and the cells 
were washed twice with washing buffer (1.25 mL sterile HBSS+/+ (HBSS with Ca2+ and 
Mg2+), 10 mM HEPES, pH=7.4, 37°C). Incubation buffers (500 µL/well) were obtained by 
adding the (radiolabeled) compounds to the washing buffer. Final concentrations were 1 µM 
3H-estradiol-17β-glucuronide (E17βG, for OATP1B1), 1 µM 3H-taurocholic acid (TCA, for 
NTCP), 1 µM 14C-tetra-ethyl-ammonium (TEA, for OCT1), and 100 µM [99mTc]MEB (for all 
cell lines). The plates were incubated at 37°C and 5% CO2. The incubation was stopped by 
adding 1.5 mL of ice-cold HBSS+/+ (1% BSA) after which the wells, containing the cells, 
were washed twice more with HBSS+/+. Next, the cells were lysed with 200 µL mammalian 
protein extraction reagent (MPer, Invitrogen, Belgium) and the plates were shaken for 10 min 
at 120 rpm. A 150 µL aliquot of this solution was used for NaI(Tl) scintillation counting and 
liquid scintillation counting. 
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Murine models 
FVB wild-type (WT) mice (♀, 5 weeks, 20–25 g) were from Janvier (France) and Slco1a/1b-
/-/-/- (♂, 5 weeks, 25–30 g; Oatp1a/1b KO mice) and Abcc2-/- (♀, 5 weeks, 20–25 g; Mrp2 
KO mice) animals were from Taconic Farms (USA). The mice were housed and handled 
according to guidelines approved by the European Ethics Committee and acclimatized for at 
least one week before the experiments. All of the animals were kept under environmentally 
controlled conditions (12 h normal light/dark cycles, 20–22°C and 60% relative humidity) 
with food and water ad libitum. The study protocol was approved by the Animal 
Experimental Ethical Committee of Ghent University (ECD10/39).  
 
Radionuclides, radiopharmaceuticals and chemicals 
Mebrofenin (N-(3-bromo-2,4,6 trimethylphenylcarbamoylmethyl)-iminodiacetic acid) was 
obtained as a commercial kit from GE Healthcare (Bridatec®, Belgium) in a preparation 
containing 40 mg of mebrofenin and 0.3 mg of tin(II)chloride-dihydrate. [99mTc]TcO4- was 
eluted from a sterile 99mTc-generator (DrytecTM, GE Healthcare). The Bridatec kit was 
reconstituted according to the manufacturer’s recommendations with 1480 MBq [99mTc]TcO4- 
in 4 mL saline. Radiochemical purity was determined according to Billinghurst et al. 
(Billinghurst et al., 2004). The formulations employed had a radiochemical purity of ≥ 95%. 
Rifampicin and polyethyleneglycol 400 (PEG400) were obtained from Sigma Aldrich 
(Belgium), and dimethyl sulfoxide (DMSO) from Acros Organics (Belgium). 
 
Molecular imaging 
Dynamic µSPECT/CT acquisitions were acquired on a USPECT-II/CT device (MILabs, 
Utrecht, The Netherlands) (van der Have et al., 2009) equipped with a cylindrical collimator 
containing 75 pinholes of 1 mm diameter (rat whole-body collimator; spatial resolution, 0.8 
mm). All acquisitions were acquired in list mode.  
After an overnight fast (minimum 6 h), the WT, Oatp1a/1b KO and Mrp2 KO mice were 
anesthetized with a mixture of  isoflurane (1.5%) and medical O2 to allow placement of an 
intravenous needle (30G) and polyethylene (PE10) tubing (Becton Dickinson, Belgium) in a 
lateral tail vein. The mice were placed in a prone position on the mouse scan bed. 200 µL (37-
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74 MBq; 2 mg MEB)  [99mTc]MEB was injected via the intravenous PE10 tubing, directly 
after scan initiation (IV, intraveneous).  
One hour before tracer injection, rifampicin-treated mice were pre-treated with five different 
rifampicin doses (100, 50, 37.5, 25, or 12.5 mg/kg in 100 µL DMSO, intraperitoneal (IP)) and 
the vehicle-control mice with vehicle (100 µL DMSO, IP). Then, the mice were anesthetized 
and a PE10 tubing was placed intravenously. 200 µL (37-74 MBq; 2 mg MEB) [99mTc]MEB 
was injected directly after scan initation. During tracer injection, a second dose of rifampicin 
(25, 12.5, 9.37, 6.25, or 3.12 mg/kg in 100 µL PEG400:saline, 30:70, v:v) or vehicle (100 µL 
PEG400:saline, 30:70, v:v) was intravenously co-administered. 
In one WT animal, after anesthesia, bile duct ligatures (BDL) were placed posterior and 
anterior to the gallbladder to obstruct bile flow completely (Figure 5.2). Immediately after 
surgery, a PE10 tubing was placed in a lateral tail vein and the bile duct-ligated mouse was 
placed in a supine position on the mouse scan bed. [99mTc]MEB was injected via the 
intravenous PE10 tubing, directly after scan initiation. 
 
Figure 5.2: Placement of a bile duct ligature in a mouse. The ligature is placed around the bile duct. 
 
Chapter 5: In vivo visualization and quantification of normal and disturbed hepatobiliary 
transport by means of [99mTc]mebrofenin 
97 
All the mice were imaged while anesthetized, with their body temperature was maintained 
during imaging using a heated bed. The axial field of view required for the SPECT scan was 
chosen based on 3 planar X-ray images (Figure 5.3). Subsequently, a 15 min dynamic SPECT 
acquisition using 60 time frames of 15 s was initiated 5 s before the injection of [99mTc]MEB. 
Lastly, a CT acquisition (5 min; tube current, 612 µA; tube voltage, 50 kV) was performed for 
anatomical correlation. The resultant CT scan is inherently co-registered with the 
corresponding µSPECT acquisition. 
 
Figure 5.3: Field of view determination by means of 3 planar X-ray images (~ 30 seconds acquisition time). 
The dynamic SPECT scans were iteratively reconstructed using an ordered subsets 
expectation maximization algorithm (3 iterations; 16 subsets; 0.75 mm voxel size; decay 
correction), including only those photons from the acquired list-mode data with an energy 
range of 140 ± 20 %. After reconstruction, three regions of interest (ROIs) were manually 
drawn over the liver, the gallbladder+intestines and the urinary bladder using PMod software 
(PMod Technologies, Zürich, Switserland) to obtain a time activity curve (TAC) for each 
ROI. ROI volumes varied between 67 and 1578 mm³ (Figure 5.4). Additionally, 
reconstructions of different phases (frame 1-4, frame 5-12, frame 13-20 and frame 21-60) 
were performed to visualize the distribution of [99mTc]MEB as function of time. Three-
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dimensional projection images of the co-registered CT and µSPECT images were performed 
using ImageJ software.  
 
Figure 5.4: ROI determination using the PMOD software. Coronal views of the sum of the 10 first frames (2.5 
minutes; A) and all 60 frames (0-15minutes; B). The sum of the first 10 frames can be used to draw the ROI 
around the liver (blue), the sum of all the frames can be used to draw the ROI around the gallbladder and 
intestines (red). 
For WT mice, the interanimal and intra-animal variation was investigated, to determine the 
reproducibility of the imaging experiments. 
The total activity in each organ, expressed in MBq (normalized to an injection of 37 MBq and 
a mouse weight of 20 g), was expressed as a function of time (in seconds).  
 
Determination of the [99mTc]mebrofenin blood curve  
After an overnight fast, the mice were injected with 200 µL of [99mTc]MEB (2.7 mg, 74 MBq) 
through a lateral tail vein. Blood samples (30 µL) were taken by intravenous puncture in the 
contralateral tail vein at 1, 2, 5, 7, 10, and 15 min post-injection. The radioactivity in these 
samples was counted in a calibrated NaI(Tl) scintillation counter (Perkin Elmer, Belgium). A 
calibration curve was used to determine the activity in MBq.  
To determine the blood curve of rifampicin-treated mice, the animals were pre-treated with 
the drug (100, 50, 37.5, 25, or 12.5 mg/kg in 100 µL DMSO, IP) or with vehicle (100 µL 
DMSO). Rifampicin (25, 12.5, 9.37, 6.25, or 3.12 mg/kg in 100 µL PEG400:saline, 30:70, 
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v:v) or vehicle was also co-injected with the tracer. Blood samples were then taken as 
described above and used to determine the % injected dose per gram blood (%ID/g) in 
function of time, to calculate the area under the blood curve (AUCblood curve)  and the T1/2 values 
of the distribution and elimination× phases, T1/2,α and T1/2,β, respectively.  
Statistical and kinetic analysis 
Statistical analysis was performed using Prism, version 3.00 (GraphPad), and SPSS, version 
19, for Windows (Microsoft). The TACs were described by calculating the maximal activity 
in liver and gallbladder, time-to-peak of the liver (i.e. the time point at which the maximal 
tracer amount or plateau was reached), and AUC liver and AUCgallbladder+intestines. Additionally, as 
a measure of Mrp2 transport, the tracer emergence time in the gallbladder was determined, 
defined as the time point when radioactivity in the gallbladder appeared in the dynamic 
SPECT data. AUCs were calculated using the trapezoidal method. To obtain rifampicin dose–
response curves, time-to-peak of the liver  and AUCgallbladder+intestines were expressed as a 
function of the administered doses. Time-to-peak of the liver was a measure of [99mTc]MEB 
uptake and AUCgallbladder+intestines a measure of [99mTc]MEB efflux. Bi-exponential curve fitting 
was applied to generate the blood curves. T1/2 values were computed using the method of least 
squares.  
𝐶𝑝 = 𝐶1𝑒
−𝛼𝑡 + 𝐶2𝑒
−𝛽𝑡 
Clearance values were calculated according to Ghibellini et al. (Ghibellini et al., 2004; 
Ghibellini et al., 2008).  
𝑇𝑜𝑡𝑎𝑙 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =
𝐷𝑜𝑠𝑒
𝐴𝑈𝐶𝑏𝑙𝑜𝑜𝑑 ,0→∞
 
𝐻𝑒𝑝𝑎𝑡𝑖𝑐 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =  
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝑙𝑖𝑣𝑒𝑟
𝐴𝑈𝐶𝑏𝑙𝑜𝑜𝑑,0→180
 
𝐵𝑖𝑙𝑖𝑎𝑟𝑦 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =  
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝐺𝐵 + 𝐼
𝐴𝑈𝐶𝑏𝑙𝑜𝑜𝑑 ,0→180
 
Differences between two groups were tested for significance using the nonparametric Mann–
Whitney test for two groups. All experiments were performed at n=3 (unless stated 
otherwise); P ≤ 0.05 was considered significant.   
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Results 
In vitro assessment of the potential role of OCT1 
Small-scale in vitro experiments using stably transfected cells and parental or mock-
transfected controls confirmed the OATP1B1- and OATP1B3-mediated transport of 
[99mTc]MEB and a lack of detectable transport by NTCP (Figure 5.6) (Ghibellini et al., 2008; 
Lengyel et al., 2008). Not unexpectedly, in the transfected cells OCT1-mediated transport of 
[99mTc]MEB could not be demonstrated, whereas 14C-TEA uptake was 33 ± 6.0-fold higher 
than in the parental controls (Figure 5.5). 
 
Figure 5.5: Positive controls: (A) 3H-taurocholate uptake (A), 14C-tetra-ethyl-ammonium uptake (B) and 3H-
estradiol-17β-glucuronide uptake (C, D) (n=3). 
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Figure 5.6: [99mTc]MEB uptake in function of time. The tracer is only transported through OATP1B1 and 
OATP1B3. Data are mean±SD (n=3). 
 
Interanimal and intra-animal variation of the dynamic µSPECT 
acquisitions 
Interanimal variation 
In order to investigate the variation between several animals; we imaged 3 WT animals on the 
same day. The time activity curves are displayed in Figure 5.7, and the corresponding metrics 
with their mean, standard deviation (SD) and coefficient of variation (% CV) are shown in 
Table 5.1. The coefficient of variation was maximally 11.5%. 
 
 
Figure 5.7: TACs of [99mTc]MEB in the liver (A) and gallbladder and intestines (B) of 3 wild type FVB mice. 
Mice were imaged on the same day. 
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Table 5.1: Metrics of the time activity curves of [99mTc]MEB of 3 wild type mice 
 Mouse 1 Mouse 2 Mouse 3 Mean SD % CV 
Maximal activity liver (MBq) 22.61 21.14 23.26 22.34 1.09 4.87 
Time to peak liver (seconds) 143 128 157 143 15 10.5 
AUC liver (MBq*sec) 7786 6718 6920 7141 821 11.5 
Maximal activity 
gallbladder+intestines (MBq) 
30.59 31.16 30.91 30.90 0.30 1.00 
AUC gallbladder+intestines 
(MBq*sec) 
17290 18900 17810 18000 821 4.56 
 
Intra-animal variation of the dynamic µSPECT acquisitions 
In order to investigate the variation within one animal; we imaged one animal on 3 different 
days. The time activity curves and corresponding metrics are shown in Figure 5.8 and Table 
5.2, respectively. The coefficient of variance was maximally 12.6%. 
 
 
Figure 5.8: TACs of [99mTc]MEB in the liver (A) and gallbladder and intestines (B) of one mouse (Mouse 3) on 
three different days. 
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Table 5.2: Metrics of the time activity curves of [99mTc]MEB of one WT mouse (Mouse 3) on three different 
days  
 Day 1 Day 2 Day 3 Mean SD % CV 
Maximal activity liver (MBq) 18.96 23.17 23.26 21.80 2.46 11.28 
Time to peak liver (seconds) 158 158 158 158 0 0 
AUC liver (MBq × sec) 6344 8128 6920 7130 910 12.6 
Maximal activity 
gallbladder+intestines (MBq) 
31.37 32.46 30.91 31.58 0.80 2.5 
AUC gallbladder+intestines 
(MBq × sec) 
19960 19480 17810 19083 1128 5.9 
 
Wild-type FVB mice 
Figure 5.9 shows the projection images of the co-registered CT and SPECT images of the first 
four time frames (Figure 5.9 A, 0-1 minutes), frame 5-12 (Figure 5.9 B, 1-3 minutes), frame 
13-20 (Figure 5.9 C, 3-5 minutes) and frame 21-60 (Figure 5.9 D, 5-15 minutes). In the first 
minute, after injection, mainly the blood pool is visible, including the abdominal aorta and the 
heart. In the next phase (1-3 minutes), mainly the liver is visible, which can be explained by 
the fact that [99mTc]MEB is taken up from the blood into the hepatocytes. Additionally, the 
gallbladder can be observed, indicating that the efflux is already initiated. Then (3-5 minutes), 
the liver, gallbladder and intestines are visible, indicating efflux. In the last phase (5-15 
minutes), only the intestines are visible, indicating that all the radioactivity is transported to 
the intestines. 
Figure 5.10 depicts the mean TACs of [99mTc]MEB of 3 WT FVB mice. Corresponding 
metrics are shown in Table 5.3. The maximal activity in the liver (19.2 ± 2.4 MBq) was 
reached after 134 ± 41 s (time-to-peak liver) and was followed by a rapid exponential decrease 
to the background level within 15 min (900 s). According to the dynamic SPECT data, the 
mean appearance time of [99mTc]MEB in the gallbladder was 147 ± 26 s (Table 5.3). At the 
end of the acquisition, the majority of [99mTc]MEB was found in the intestines.   
The venous blood curve was consistent with a two-phase model, characterized by an initial 
rapid decline of the radiopharmaceutical from the blood (distribution phase), with a T1/2,α of 
17 ± 2 s, due to its distribution within the vascular space and the high extraction rate of 
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[99mTc]MEB by the liver. This initial decline was followed by a slower decline (elimination 
phase) with a T1/2,β of 332 ± 121 s (Table 5.3). 
 
 
Figure 5.9: Projection images of co-registered CT and µSPECT images of [99mTc]MEB of WT mouse of the first 
minute (A, frame 1-4); 1-3 minutes (B, frame 5-12), 3-5 minutes (C, frame 13-20); and the last 10 minutes (D, 
frame 21-60). 1= heart; 2= abdominal aorta; 3= liver; 4= gallbladder; 5= intestines.  
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Figure 5.10: Mean TACs ±SD (n=3) of [99mTc]MEB in wild type mice. TACliver and TACgallbladder+intestines are 
expressed in MBq. Blood curves are expressed in %ID/g. 
Bile duct ligature: proof-of-principle 
Next, we investigated the effect of complete obstructive cholestasis, induced by BDL in a WT 
animal, on [99mTc]MEB transport (Figure 5.11, Figure 5.12).  
The effect of BDL, i.e., obstructive cholestasis and thus a higher concentration of 
[99mTc]MEB in the liver, is clearly seen by comparing Figure 5.10 with Figure 5.12. While in 
the TAC of WT mice a peak in the liver was followed by a rapid decrease to background 
levels, in the TAC of the BDL animal there was a continuous increase of [99mTc]MEB uptake 
in the liver, with a maximum of 28.39 MBq. The tracer was not subsequently cleared but 
instead remained in the liver until the end of the SPECT scan. Expressed as AUC liver (MBq ×
 s), the activity in the liver of the BDL animal was 3.5-fold higher than that in non-treated 
animals (non-BDL and BDL: 6417 MBq × s and 22202 MBq × s, respectively). The 
AUCgallbladder+intestines was 17808 MBq × s in the non-treated animal and undetectable in the 
BDL animal. Taken together, the total activity in the liver and gallbladder+intestines was 
nearly identical in the two treatment groups (non-BDL 24225 MBq × s versus BDL 22202 
MBq × s).  
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Figure 5.11: Projection images of co-registered CT and µSPECT images of [99mTc]MEB of a mouse with a bile 
duct ligature of the first minute (A, frame 1-4); 1-3 minutes (B, frame 5-12), 3-5 minutes (C, frame 13-20); and 
the last 10 minutes (D, frame 21-60). 1= heart; 2= abdominal aorta; 3= liver; 4= gallbladder; 5= intestines.  
 
Figure 5.12: Proof of principle: TAC (n=1) of [99mTc]MEB in 1 bile duct ligated mouse. TACliver is expressed in 
MBq.  
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Role of Oatp1a/1b transporters in the hepatic transport of 
[99mTc]mebrofenin  
Subsequently, the relative role of the uptake transporter family Slc01a/1b on the hepatic 
handling of [99mTc]MEB was determined. The projection images of the different phases are 
shown in Figure 5.13. The majority of the tracers remains in the blood pool. The mean TACs 
of the Oatp1a/1b KO animals are shown in Figure 5.14. 
The majority of [99mTc]MEB activity was located in the blood and urinary bladder, with only 
a small amount of activity detected in the liver. [99mTc]MEB levels in the 
gallbladder+intestines did not exceed the limit of quantification. This was in contrast to the 
WT mice, in which the majority of the [99mTc]MEB was found in the gallbladder+intestines. 
Specifically, the mean TACliver of the Oatp1a/1b KO mice did not exceed baseline levels. The 
AUCliver was 3.4-fold lower in Oatp1a/1b KO mice than in WT animals (p= 0.014) (Table 
5.3). At the final time point, 3.6±1.5% of the injected dose was present in the urinary bladder. 
In the blood, the mean AUC in the Oatp1a/1b KO mice was 5.1-fold larger than in their WT 
counterparts (p≤0.05) (Figure 5.14, Table 5.3). Hepatic clearance was lower compared to WT 
mice.  
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Figure 5.13: Projection images of co-registered CT and µSPECT images of  [99mTc]MEB of an Oatp1a/1b KO 
mouse of the first minute (A, frame 1-4); 1-3 minutes (B, frame 5-12), 3-5 minutes (C, frame 13-20); and the last 
10 minutes (D, frame 21-60). 1= heart; 2= abdominal aorta.  
 
Figure 5.14: Mean TACs ±  SD (n=3) of [99mTc]MEB in Oatp1a/1b KO mice. TACliver and TACurinary bladder are 
expressed in MBq. Blood curves are expressed in %ID/g. 
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Role of the Mrp2 transporter in the hepatic transport of [ 99mTc]-
mebrofenin 
The distribution of [99mTc]MEB to the livers of Mrp2 KO mice was similar to that observed in 
WT mice (Figure 5.15, Figure 5.16, Table 5.3). This observation was supported by similar 
maximal activity in the liver (p>0.05) values between the two genotypes. Overall, the AUC liver 
of Mrp2 KO mice was 2.3-fold higher than that of WT mice (p≤0.05) (Table 5.3), mainly due 
to the impaired hepatic clearance. In line with the observations from WT animals, the activity 
in the urinary bladder was too low to be quantified.  
 
Figure 5.15: Projection images of co-registered CT and µSPECT images  of [99mTc]MEB of Mrp2 KO mouse of 
the first minute (A, frame 1-4); 1-3 minutes (B, frame 5-12), 3-5 minutes (C, frame 13-20); and the last 10 
minutes (D, frame 21-60). 1= heart; 2= abdominal aorta; 3= liver; 5= intestines. 
 
As shown in Table 5.3, activity in the gallbladder was observed after 375 ± 63 s in Mrp2 KO 
mice compared to 147 ± 26 s in their WT counterparts (p≤0.05). The AUCgallbladder+intestines in 
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the Mrp2 KO mice was 4.7-fold lower than in the WT mice (p≤0.05). Total clearance and 
hepatic clearance was similar compared to WT mice. However, biliary clearance was lower.  
The blood curve and corresponding metrics of the Mrp2 KO mice were comparable to those 
of the WT mice (p>0.05).  
 
Figure 5.16: Mean TACs ± SD (n=3) of [99mTc]-MEB in Mrp2 KO mice. TACliver, TACgallbladder+intestines and 
TACurinary bladder are expressed in MBq. Blood curves are expressed in %ID/g.  
 
The effect of d ifferent r ifampicin d oses o n the hepatic t ransport o f 
[99mTc]mebrofenin 
The data generated thus far allowed us to investigate mechanistically the role of uptake and 
efflux transporters in the in vivo disposition of [99mTc]MEB. With this framework established, 
we aimed to determine whether it was possible to discriminate dose-dependently between the 
inhibition of hepatic uptake transporters and that of efflux transporters. Since rifampicin is 
both a substrate and an inhibitor of OATPs/Oatps and MRP2/Mrp2, it was selected as the test 
agent. 
In Figure 5.17, the projection images of the co-registered CT and µSPECT acquisitions are 
shown. Again, divided in different phases.  
The mean TACs of the vehicle-control and rifampicin-treated (highest dose, 100 mg/kg IP, 25 
mg/kg IV) mice are shown in Figure 5.18A and Figure 5.18B, respectively. In the control 
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mice, the TACs were similar to those of the untreated WT mice. The metrics of the different 
rifampicin doses are shown in Table 5.3.  
 
Figure 5.17: Projection images of co-registered CT and µSPECT image of [99mTc]MEB of a rifampicin treated 
mouse of the first minute (A, frame 1-4); 1-3 minutes (B, frame 5-12), 3-5 minutes (C, frame 13-20); and the last 
10 minutes (D, frame 21-60). 1= heart; 2= abdominal aorta; 3= liver; 5= intestines. 
 
Figure 5.18: Mean TACs ±SD in the vehicle-control mice (n=3) (A) and in rifampicin-treated mice (n=3) (B). 
TACliver, TACgallbladder+intestines, and TACurinary bladder are expressed in MBq. Blood curves are expressed in %ID/g.  
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The time-to-peak in the liver of mice treated with the highest dose of rifampicin was 5.1-fold 
higher than that of vehicle-control mice (p≤0.05) while the AUCliver was 1.6-fold higher 
(p=0.034). Moreover, the mean emergence time of tracer activity in the gallbladder was 
prolonged 4.0-fold in rifampicin-treated mice (p≤0.05) whereas the AUCgallbladder+intestines 
decreased by a factor of 10 (p≤0.05). A TACurinary bladder could be determined in the rifampicin-
treated mice but not in the vehicle-control mice.  
The mean AUCblood in mice treated with the highest dose of rifampicin was 4.3-fold greater 
than that of their WT counterparts (p≤0.05). Additionally, T1/2 values were 2.8-fold higher 
(p≤0.05). All clearance values were lower compared to vehicle controlled mice.  
In order to investigate if mild alterations can be detected with the proposed method, we 
administered 5 different rifampicin doses (100 mg/kg IP + 25 mg/kg IV; 50 mg/kg IP + 12.5 
mg/kg IV; 37.5 mg/kg IP + 9.37 mg/kg IV; 25 mg/kg IP + 6.25 mg/kg IV; 12.5 mg/kg IP + 
3.12 mg/kg IV), or vehicle in wild type mice (n=3 for each dose), to obtain a dose response 
curve (Figure 5.19, Table 5.3). The time-to-peak in the liver and the area under the 
gallbladder+intestines curve are expressed in function of the administered dose in Figure 
5.19A and Figure 5.19B, respectively (only the i.p. dose is displayed. Note that 1h after each 
i.p. dose, a second i.v. dose was given, co-injected with [99mTc]MEB). The curves 
demonstrate a dose-dependent effect on the uptake and efflux of [99mTc]MEB. Higher doses 
of rifampicin delayed the time-to-peak and caused a smaller AUCgallbladder+intestines, representing 
decreases in hepatic uptake and in efflux to the gallbladder and intestines, respectively. 
 
Figure 5.19: Mean dose response curves of rifampicin ±SD (n=3). Time to peak liver was expressed in seconds, 
AUC gallbladder+intestines was expressed as MBq*s. Note that only the i.p. dose is displayed. However, 1h after each 
i.p. dose, a second i.v. dose was given (co-injected with [99mTc]-MEB).  
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Table 5.3 Metrics of the time-activity curves of [99mTc]MEB in wild type, Slco1a/1b-/-/-/-, Abcc2-/- and rifampicin treated mice. 
 
 
 
Maximal 
activity liver 
(MBq) 
T ime to 
peak liver 
(s) 
AUC liver 
(MBq × s) 
Maximal 
activity 
gallbladder + 
intestines 
(MBq) 
Emergence 
time 
gallbladder 
(s) 
AUC 
gallbladder + 
intestines 
(MBq × s) 
AUC blood 
curve 
(MBq/ml × s) T 1/2,α (s) T 1/2,β (s) 
 
Total 
clearance 
(mL/min) 
 
Hepatic 
clearance 
(mL/min) 
 
Biliary 
clearance 
(mL/min) 
Wild type mice  19.17±2.39 134±41 6507±820 28.9 ± 1.00 147 ± 26 18269±4349 1411 ± 157 17±2 332±121 1.82±0.12 0.82 1.22 
Oatp1a/1b KO mice 3.44±0.51 77.5±23 1926±264 * * * 6771 ± 839 29±7 * * 0.03 n/a 
Mrp2 KO mice 22.12±1.71 212±23 15010±1382 ‡ 375 ±  63 3916±475 1769 ± 212 18 ± 3 375 ± 63 1.63±0.61 0.75 0.33 
 Dose 
(mg/kg)          
   
R
if
am
p
ic
in
 t
re
at
ed
 
w
il
d
 t
y
p
e 
m
ic
e
 
IP IV             
100 25 12.7 ±3.00 747±37 10048±2355 ‡ 555 ± 65 1639±776 6411 ± 544 40±4 853±273 0.19±0.064 0.12 0.14 
50 
12.
5 
16.32±0.76 442±65 11297±436 ‡ 385 ± 31 3736±858 † † † † † † 
37.5 
9.3
7 
14.50±0.71 300±47 9700±1655 ‡ 457 ± 53 6742±3201 † † † † † † 
25 
6.2
5 
17.13±0.40 235±26 9686±606 ‡ 240 ± 15 937 ±411 † † † † † † 
12.5 
3.1
2 
16.40±0.42 157±12 6282±846 ‡ 240 ± 42 13300±2149 † † † † † † 
Vehicle controlled mice 18.69±3.82 145±31 6120±124 29.16±0.51 140 ± 20 17752±688 1514 ± 140 15 ± 2 300±21 1.90±0.29 0.74 1.16 
 
 Data are mean (n=3) ± standard deviation 
*  could not be observed 
†  not investigated 
‡  linear increase, no maximal activity 
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Discussion 
Drug-induced liver injury is one of the leading causes for the withdrawal of approved drugs 
from the market (Maddrey et al., 2005), highlighting the importance of assessing this effect 
early on in drug research. One of the underlying causes of drug-induced liver injury is an 
altered functional activity of hepatic uptake or efflux transporters. In this study, we 
investigated [99mTc]MEB transport through Oatp and Mrp2. Based on the results, we were 
able to propose a non-invasive method to visualize and quantify altered hepatobiliary 
transporter activity. Moreover, the proposed method enables the differentiation between 
altered influx and efflux. By using dynamic SPECT measurements to calculate TACs of 
[99mTc]MEB that quantify transport via the liver to the gallbladder and intestines, our method 
offers a novel approach, as thus far it has not been possible either to visualize or quantify in 
vivo hepatic drug interactions and the differentiation between uptake and efflux alterations. 
First, the specificity for [99mTc]MEB for the human transport proteins was investigated by 
means of CHO cell lines expressing these human transporters. Our data confirmed the results 
of Ghibellini et al. that identified OATP1B1 and OATP1B3 as uptake transporters of 
[99mTc]MEB  (Ghibellini et al.; 2008). Additionally, the current study was able to exclude 
OCT1 as a [99mTc]MEB transporter. 
Then, we clearly demonstrated the possibility to non-invasively visualize and quantify the in 
vivo hepatobiliary transport in a reproducible manner. Repeated measurements were 
performed in different animals and on different days. Out of these measurements, TACs were 
calculated to quantify the transport over the liver or in the gallbladder and intestines. The 
ROIs of the gallbladder and intestines were considered together as one ROI. The rationale 
behind this is the common bile duct, forming a direct connection between the liver and 
intestines. As a consequence, not all the bile flow to the gallbladder for temporary storage, but 
some bile flow directly to the intestines. The interanimal and the intra-animal measurements 
of the maximal activity in the liver and areas under the curve were not significantly different. 
Furthermore, the coefficient of variation did not exceed 13%. Consequently, these results 
indicate that it is possible to visualize and quantify the activity of hepatic transporters with 
[99mTc]MEB in a reproducible manner. Secondly, we set out a mean TAC of the liver and 
gallbladder+intestines in wild type FVB mice. Significant differences in the following 
experiments will be due to altered hepatobiliary transport.  
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The primary aim of our study was the visualization of disturbed hepatobiliary transporter 
function. As proof-of-principle, a BDL was placed so as to simulate extrahepatic cholestasis. 
This mechanical inhibition caused the complete obstruction of bile flow and subsequently the 
accumulation of [99mTc]MEB in the liver, thus demonstrating the ability of the proposed 
method to visualize and quantify disturbances in hepatobiliary transport.  
To examine the possibility of distinguishing between uptake and efflux transporter alterations, 
Oatp1a/1b KO and Mrp2 KO mice were investigated. Experiments in the Oatp1a/1b KO mice 
confirmed the critical role played by transporters of the Oatp1a/1b family in the hepatic 
uptake of [99mTc]MEB, consistent with the findings of Van de Steeg et al. (Van de Steeg et al., 
2010). The liver TACs of Oatp1a/1b KO mice did not exceed baseline levels, due to the 
impaired hepatic uptake of [99mTc]MEB. Consequently, blood concentrations remained 
elevated in comparison with WT mice, due to absence of Oatp1a/1b. 
We were also able to demonstrate in vivo that the biliary efflux transporter Mrp2 is involved 
in [99mTc]MEB transport. Specifically, in Mrp2 KO mice the absence of the efflux transporter 
led to the hepatic accumulation of [99mTc]MEB, reflected in a higher AUCliver. Consequently, 
less [99mTc]MEB reached the gallbladder and intestines, resulting in a lower 
AUCgallbladder+intestines and a delayed tracer emergence time. The corresponding blood 
concentrations were comparable to those of the WT animals, since hepatic uptake was not 
disturbed.  
To assess the effect of pharmacological inhibition on transporter activity, rifampicin was 
administered to WT mice, by both the IP and the IV routes. This double administration led to 
the impaired uptake and efflux of [99mTc]MEB. Inhibition of [99mTc]MEB uptake occurs at the 
level of the basolateral (sinusoidal) Oatps, with rifampicin acting as a competitive inhibitor of 
the transporters (Vavricka et al., 2002). Since hepatic uptake was impaired, the time-to-peak 
in the liver of [99mTc]MEB was delayed and blood concentrations of the tracer were elevated. 
Additionally, urinary elimination of [99mTc]MEB was increased in rifampicin-treated mice. 
This increase in renal excretion reflected the decreased uptake of [99mTc]MEB through 
Oatp1a/1b and the increased blood concentrations (higher AUCblood). Rifampicin is both a 
substrate and an inhibitor of Oatps. Therefore, a certain amount of rifampicin is able to enter 
the hepatocytes, where it inhibits the Mrp2 transporter at the level of the canalicular 
membrane. Consequently, an accumulation of [99mTc]MEB in the liver (higher AUCliver) can 
be detected whereas the decreased amounts of [99mTc]MEB in the intestines are due to a 
Chapter 5: In vivo visualization and quantification of normal and disturbed hepatobiliary 
transport by means of [99mTc]mebrofenin 
116 
combination of Oatp and Mrp2 inhibition (lower AUCgallbladder+intestines). These observations 
suggest that the impaired liver uptake and efflux is caused by a combination of rifampicin-
mediated Oatp1a/1b and Mrp2 inhibition (Lengyel et al., 2008; Mita et al., 2006). To the best 
of our knowledge, Mrp2 inhibition has not been previously shown in vivo. Our study 
demonstrates the feasibility of visualizing and quantifying the effect of Oatp1a/1b and Mrp2 
modulation by various drugs in vivo, with rifampicin as a model drug, and confirms the 
findings of Van de Steeg et al. (Van de Steeg et al., 2010) with methotrexate and tritium-
labeled fexofenadine.  
Additionally, we were able to show that slight alterations in transporter activity can be 
detected with the proposed imaging method. Using five different rifampicin doses, a dose-
response curve of the rifampicin-mediated inhibition of [99mTc]MEB transport was obtained. 
The data demonstrated a dose-dependent effect on the uptake and efflux of [99mTc]MEB. 
Higher doses of rifampicin delayed time-to-peak in the liver and caused a smaller 
AUCgallbladder+intestines, representing decreases in hepatic uptake and in efflux to the gallbladder 
and intestines, respectively. While Mrp2 inhibition occurred at low rifampicin concentrations 
(12.5 mg/kg IP, 6.25 mg/kg IV), Oatp inhibition was seen at higher concentrations of the drug 
(37.5 mg/kg IP, 9.37 mg/kg IV).  
In summary, this study shows that it is possible to quantitatively discriminate between the 
lack of functional activity of sinusoidal uptake and that of biliary efflux transporters. 
Therefore, the method described in this chapter offers a promising approach to investigate the 
interaction between new chemical entities and hepatobiliary transporters.  
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Introduction 
As outlined in Chapter 5, identification of possible interactions of new candidate drugs with 
hepatobiliary transport mechanisms is important early during drug development (Cuperus et 
al., 2014; de Lima Toccafondo Vieira et al., 2014; Ho et al., 2005; Schuetz et al., 2014). In 
Chapter 5, a non-invasive in vivo method to visualize and semi-quantify (disturbed) hepatic 
transport by means of dynamic µSPECT imaging of [99mTc]-mebrofenin ([99mTc]MEB) was 
proposed (Neyt et al., 2013). Quantification was done using a calibration curve based on a 
known standard. Impaired uptake was reflected in elevated blood concentrations, a lower 
maximal liver uptake and a decreased AUCgallbladder+intestines. Impaired efflux was shown in a 
higher AUCliver value and a decreased AUCgallbladder+intestines.  
In this chapter, we will further optimize the quantification of the (disturbed) hepatobiliary 
transport by using tracer kinetic modeling. As outlined in Chapter 1, these models describe 
the tracer kinetics mathematically by using a number of compartments, representing distinct 
anatomical, physiological, or biochemical stages in the behavior of the tracer. The tracer 
kinetics are described by a set of differential equations that provide the link between activity 
levels measured on, for example, dynamic µSPECT images and physiologic parameters 
associated with the hepatobiliary transport. The goal is the implementation of a two-tissue 
compartment kinetic model of [99mTc]MEB to describe impaired hepatobiliary uptake and/or 
efflux caused by drugs or genetic disorders.  
Previously, Ghibellini et al. (Ghibellini et al., 2008) reported a pharmacokinetic model, based 
on human data, to simulate the effect of changes in hepatic uptake and/or secretion associated 
with disease states on [99mTc]MEB disposition. Using a three-tissue compartment model 
including liver, gallbladder and urinary bladder, they concluded that [99mTc]MEB could be a 
useful biomarker to assess the impact of altered hepatic function at the transport level, caused 
by drugs or genetic disorders. In the current study, we used a simplified version of the model 
proposed by Ghibellini et al. (two-tissue compartment model) in mice, since we observed 
almost no radioactivity in the urinary bladder and kidneys in mice (Neyt et al., 2013). In 
contrast to Ghibellini et al., who used the model to simulate the effect of altered hepatobiliary 
transport, we validated and implemented the model in vivo, before and after administration of 
the Oatp and Mrp2 inhibitor rifampicin, and in Mrp2 knock-out (KO) mice.  
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Kinetic parameters of wild type (WT), Mrp2 KO and rifampicin treated mice are compared. 
The kinetic parameters can offer a detailed quantitative description of altered hepatobiliary 
transport, in addition to the metrics of the time activity curves (TACs) as performed before 
(Neyt et al., 2013).  
Moreover, a novel non-invasive method was used to obtain an image derived input function of 
[99mTc]MEB. As outlined in Chapter 1, the biggest challenge in preclinical kinetic modeling is 
the determination of the arterial input function. The “gold standard” in the clinic is arterial 
blood sampling. However, in rodents, invasive blood sampling is restricted to a small fraction 
of the total blood (Parasuraman, 2010). According to Diehl et al. (Diehl et al., 2001), it is 
limited to 7.5% of the circulatory blood volume corresponding to 100 µL for a 25g mouse. 
Apart from manual sampling, automated on-line blood sampling can be used during 
preclinical imaging. However, this technique only exists for tracers using positron emitters. 
To generate the arterial input function in a non-invasive way, image-derived methods were 
introduced that obtain the blood TACs from a region of interest (ROI) in the blood pool, such 
as the left ventricular cavity. However, the definition of the heart is sometimes challenging 
when no detailed anatomical information is present. Therefore, in the current study, 
[99mTc]tetrofosmin was introduced as imaging agent to visualize the perfusion of the 
myocardium. On the static [99mTc]tetrofosmin scan, a ROI can be drawn into the left ventricle 
and this ROI can be easily copy-pasted on the dynamic [99mTc]MEB data, when 
[99mTc]tetrofosmin and [99mTc]MEB are acquired sequentially without changing the position 
of the animal between the two acquisitions.  
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Materials and Methods 
Animal Model 
FVB wild-type (WT) mice (♀, 5 weeks, 20–25 g) were from Janvier (France) and Abcc2-/- 
(♀, 5 weeks, 20–25 g; Mrp2 KO mice) mice were from Taconic Farms (USA). The mice were 
housed and handled according to guidelines approved by the European Ethics Committee and 
acclimatized for at least one week before the experiments. All of the animals were kept under 
environmentally controlled conditions (12 h normal light/dark cycles, 20–22°C and 60% 
relative humidity) with food and water ad libitum. The study protocol was approved by the 
Animal Experimental Ethical Committee of Ghent University (ECD10/39). n=5 per group. 
 
Molecular Imaging 
Dynamic µSPECT/CT acquisitions were acquired on a USPECT-II/CT device (MILabs, 
Utrecht, The Netherlands) (van der Have et al., 2009) equipped with a cylindrical collimator 
containing 75 pinholes of 1 mm diameter (rat whole-body collimator; spatial resolution, 0.8 
mm). All acquisitions were acquired in list mode.  
After an overnight fast (minimum 6 h), the WT and Mrp2 KO mice were anesthetized with a 
mixture of isoflurane (1.5%) and medical O2 to allow placement of an intravenous needle 
(30G) and polyethylene (PE10) tubing (Becton Dickinson, Belgium) in a lateral tail vein. The 
mice were placed in a prone position on the mouse scan bed. 200 µL (37-74 MBq; 2 mg 
MEB)  [99mTc]MEB was injected via the intravenous PE10 tubing, directly after scan 
initiation.  
One hour before tracer injection, rifampicin-treated mice were pre-treated with rifampicin 
(100 mg/kg in 100 µL DMSO, IP). Then, the mice were anesthetized and a PE10 tubing was 
placed intravenously. 200 µL (37-74 MBq; 2 mg MEB) [99mTc]MEB was injected directly 
after scan initation. During tracer injection, a second dose of rifampicin (25 mg/kg in 100 µL 
PEG400:saline, 30:70, v:v) was intravenously co-administered. 
All the mice were imaged while anesthetized, with their body temperature maintained during 
imaging using a heated bed. The axial field of view required for the SPECT scan was chosen 
based on 3 planar X-ray images. Subsequently, a 15 min dynamic SPECT acquisition using 
60 time frames of 15 s was initiated 5 s before the injection of [99mTc]MEB.  
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Immediately after dynamic scan termination and without repositioning the animal, 185 MBq 
of [99mTc]tetrofosmin was injected. 20 minutes post-injection, with the animal still in the same 
position, a static SPECT scan of 30 minutes was performed. Lastly, a CT acquisition (5 min; 
tube current, 612 µA; tube voltage, 50 kV) was performed for anatomical correlation. The 
resultant CT scan is inherently co-registered with the corresponding µSPECT acquisition. 
On the dynamic [99mTc]MEB data, ROIs were manually drawn over the liver and 
gallbladder+intestines using PMOD software (PMOD technologies, Switserland). On the 
static [99mTc]tetrofosmin data, a ROI was manually drawn over the left ventricle of the heart. 
Since the position of the mice was unaffected between the two acquisitions, the ROI drawn 
around the left ventricle (Figure 6.1), was copied to the dynamic [99mTc]MEB images to 
obtain an image derived input function (IDIF) (Figure 6.2). Using the changing activity levels 
measured in liver, gallbladder+intestines and blood pool, TACs were obtained. 
The U-SPECT-II calibration curves (Chapter 4) were used to determine the total amount or 
concentration of the radiotracer. The total activity in each organ, expressed in MBq 
(normalized to an injection of 37 MBq), was expressed as a function of time (in seconds). The 
image derived blood function was expressed as MBq/mL as a function of time (in seconds).  
 
 
Figure 6.1: Slice through the heart on the [99mTc]tetrofosmin SPECT scan. ROI drawn around the left ventricle. 
1: left ventricle; 2: right ventricle.  
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Figure 6.2: An overview of the processing used to obtain all the time activity curves that are needed to obtain a 
pharmacokinetic model of [99mTc]MEB. 
 
Correlation of image derived blood function with manual blood samples  
The image derived input functions were correlated with the blood curve obtained from manual 
samples (both expressed as MBq/mL).  
 
Kinetic modeling 
A two-tissue compartment kinetic model of [99mTc]MEB is used, based on the model 
presented by Ghibellini et al., (Ghibellini et al., 2008) to describe impaired hepatobiliary 
uptake and/or efflux caused by drugs or genetic disorders (Figure 6.3).  
The differential equations of the model are shown below (Eq. 1-3). X0 represents the activity 
of the bolus injection of [99mTc]MEB in MBq, Vc the volume of the central blood pool 
compartment in mL and Cc the activity concentration of [99mTc]MEB (in MBq/mL) in the 
blood at a certain time point t. The activity level in the liver and gallbladder+intestines (in 
MBq), at a certain time point t, is represented by Xliver and Xbile, respectively. 𝐶𝑐
0, 𝑋𝑙𝑖𝑣𝑒𝑟
0  and 
𝑋𝑏𝑖𝑙𝑒
0 represent activity concentration and level directly after tracer injection (time point 0) for 
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the blood, liver and gallbladder+intestines, respectively. All rate constants were assumed to 
be first order: k12 represents hepatic basolateral uptake; k21 hepatic basolateral excretion and 
k20 hepatic canalicular efflux. 
𝑑𝐶𝑐
𝑑𝑡
=  −𝑘12 ×𝐶𝑐 + 𝑘21  × 
𝑋𝑙𝑖𝑣𝑒𝑟
𝑉𝑐
                                         𝐶𝑐
0 =  
𝑋0
𝑉𝑐
  [𝐸𝑞.1] 
𝑑𝑋𝑙𝑖𝑣𝑒𝑟
𝑑𝑡
= 𝑘12 ×𝑉𝑐×𝐶𝑐 − 𝑘20 ×𝑋𝑙𝑖𝑣𝑒𝑟 − 𝑘21 ×𝑋𝑙𝑖𝑣𝑒𝑟         𝑋𝑙𝑖𝑣𝑒𝑟
0 = 0 [𝐸𝑞. 2]   
𝑑𝑋𝑏𝑖𝑙𝑒
𝑑𝑡
= 𝑘20×𝑋𝑙𝑖𝑣𝑒𝑟                                                                  𝑋𝑏𝑖𝑙𝑒
0 = 0   [𝐸𝑞.3] 
The rate constants were obtained by solving the differential equations that were fit 
simultaneously to blood, liver and gallbladder+intestines TACs using nonlinear least-squares 
regression. Kinetic parameters of WT, rifampicin treated and Mrp2 KO mice are compared. 
Additionally, the model fit is investigated by fitting the measurements in blood pool and 
gallbladder+intestines to the calculated model curves. The model curves are calculated from 
the measurements in the liver.  
Besides the kinetic rate constants, total clearance rates were calculated as described by 
Ghibellini et al. (Ghibellini et al., 2008).  
 
Figure 6.3: Scheme of the pharmacokinetic model describing the disposition and elimination of [99mTc]MEB in 
mice. X0 represents the IV bolus of [99mTc]MEB; Cc is the concentration of [99mTc]MEB in the blood (MBq/mL) 
and Vc is the central compartment volume (mL). The activity levels in the liver and the gallbladder+intestines, 
expressed in MBq, is represented by Xliver and Xbile, respectively. All rate constants were assumed to be first 
order: k12 represents hepatic basolateral uptake; k21 represents hepatic basolateral excretion and k20 represents 
hepatic canalicular efflux. 
 
Statistical Analysis 
Statistical analysis was performed using SPSS, version 22, for Windows (Microsoft). 
Differences between two groups were tested for significance using the nonparametric Mann–
Whitney test for two groups. All experiments were performed at n=5 (unless stated 
otherwise); a p-value of 0.05 or smaller was considered significant.  
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Results 
Correlation of image derived blood function with manual blood samples 
A comparison between the image derived input function and sampling blood curves (gold 
standard) showed acceptable agreement by graphical inspection (Figure 6.4). Additionally, 
AUC analysis showed similar AUCs (p>0.05). The AUC of WT mice was 1355±158 and 
1492±308 MBq/mL x s for manual sampling and IDIF, respectively. The mean AUC of Mrp2 
KO mice was 1639±93 and 1478±258 MBq/mL x s for manual sampling and IDIF, 
respectively. Lastly, the mean AUC of rifampicin treated mice was 6340±535 and 6216±794 
MBq/mL x s for manual sampling and IDIF, respectively. 
 
Figure 6.4: Visual inspection of the sampling blood curve (red, with standard deviations) and the image derived 
blood curve (blue, with standard deviations) clearly showed overlapping curves in WT (A; n=5), rifampicin 
treated (B; n=5) and Mrp2 knock-out (C; n=5) mice.  
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Kinetic Modeling 
The model depicted in Figure 6.3 was suitable for describing [99mTc]MEB disposition in all 
groups. The corresponding mean kinetic parameters, k12, k21 and k20 and standard deviations 
that were obtained per group are shown in Table 6.1.  
k12, and k20 values were 3- and 9-fold smaller in rifampicin treated mice compared to vehicle 
controlled mice (p≤0.05), respectively. k21 values were larger in rifampicin treated mice 
(p≤0.05). In Mrp2 KO mice, k12 and k21 values were similar to those of WT mice. In contrast, 
k20 values were 8- fold lower compared to WT mice (p≤0.05) (Table 6.1). 
The goodness of fit of the model to three data sets is shown in Figure 6.5. Measurements are 
shown as symbols, the model is shown as solid lines. The cumulative amounts of [99mTc]MEB 
in the liver are also depicted on the graph. 
 
 
Figure 6.5: Goodness of fit. The kinetic model was fitted to the measured values in a WT (A), Mrp2 KO and 
rifampicin treated (C) mouse (n=1).  
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Table 6.1: Mean kinetic parameters and standard deviations of WT, Mrp2 KO and rifampicin treated 
mice.*:significantly different compared to WT (p≤0.05) (n=5 per group). 
 k12 (1/min) k21 (1/min) k20 (1/min) Total clearance 
(mL/min) 
WT (n=5) 0.984±0.356 0.000±0.000 0.351±0.021 1.67±0.61 
Mrp2 KO (n=5) 0.782±0.347 0.000±0.000 0.042±0.005* 1.32±0.55 
RIF treated 
(n=5) 
0.363±0.161* 0.119±0.086* 0.038±0.006* 0.17±0.039* 
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Discussion 
As stated in Chapter 5, numerous drugs can interact with hepatobiliary transport mechanisms 
and can lead to toxic concentrations of bile acids or substrate drugs in blood or liver (Cuperus 
et al., 2014; Ho et al., 2005; Schuetz et al., 2014). Therefore, it is important to detect these 
interactions from early on in drug research (de Lima Toccafondo Vieira et al., 2014). In 
Chapter 5, these interactions were visualized and quantified by means of metrics of the time 
activity curves. Impaired uptake was reflected in elevated blood concentrations, a lower 
maximal tracer uptake in the liver and decreased AUCgallbladder+intestines. Impaired efflux was 
shown in a higher AUCliver value and a decreased AUCgallbladder+intestines. In addition to these 
metrics, the aim of the current study was to evaluate altered hepatobiliary transport by means 
of kinetic modeling of [99mTc]MEB, based on the kinetic model of [99mTc]MEB that was 
developed by Ghibellini et al. (Ghibellini et al., 2008). 
A kinetic modeling approach requires bolus administration of a radiotracer immediately 
followed by dynamic recordings of the time activity curves of the radiotracer in tissues and 
blood pool. The gold standard to obtain dynamic recordings of the activity level in the blood 
pool is arterial blood sampling, however, this is very challenging in mice. Therefore, an 
image-derived method has been applied in the current study. [99mTc]tetrofosmin was used as 
imaging agent to visualize the myocardium. After intravenous injection, [99mTc]tetrofosmin is 
rapidly cleared from the blood and accumulates in the myocardium, skeletal muscle, spleen, 
liver and kidneys. Uptake in the myocardium is approximately 1% of the injected dose after 2 
hours and is a consequence of passive diffusion of [99mTc]tetrofosmin in the myocardial cells, 
followed by mitochondrial uptake and is proportional to the flow.  
Application of this approach to the liver is very challenging, due to the dual input of the tracer 
from the portal vein and hepatic artery, compromising 75% and 25%, respectively (Keiding et 
al., 2012; Winterdahl et al., 2011). However, in the current study, our goal is not to obtain 
exact kinetic parameters of [99mTc]MEB in mice, but to detect differences in kinetic 
parameters between wild type and rifampicin treated or Mrp2 KO mice. In this context, it is 
important to use the same input source in all subjects, i.e. blood pool in the heart, which is in 
line with the kinetic model of Ghibellini et al., where they performed blood sampling in the 
arm to obtain the input function (Ghibellini et al., 2008). 
After generation of the TACs, physiological parameters can be calculated by fitting a 
mathematical model of tracer distribution and metabolism to the data. Previously, Ghibellini 
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et al. (Ghibellini et al., 2008) reported a pharmacokinetic model to simulate the effect of 
changes in hepatic uptake and/or secretion of [99mTc]MEB associated with disease states in 
humans. In the current study, we used a simplified version of this model in mice by excluding 
the urine compartment, since no radioactivity was observed in the urinary bladder and kidneys 
in previous experiments. Additionally, an adjustment was done by evaluating the gallbladder 
and intestines as one compartment, in comparison with Ghibellini et al., who only used the 
gallbladder as second tissue compartment. The rationale behind this is outlined in Chapter 5. 
Disturbed hepatobiliary transport was investigated by means of pharmacological inhibition 
with rifampicin, a known Oatp and Mrp2 inhibitor and in Mrp2 KO mice, which lack the 
Mrp2 transporter. 
In rifampicin treated mice, significantly decreased k12 and k20 values were observed, as 
expected, since rifampicin is an Oatp and Mrp2 inhibitor (Neyt et al., 2013). Additionally, 
k21values were increased, which can be explained by a shortcoming of the proposed model. 
During the acquisition time used in this study, no urinary excretion was observed. However, 
due to inhibition of Oatp, urinary excretion will probably occur, but we were not able to 
detect this in the current study, due to the short acquisition time. Since we were not able to 
include the urinary bladder in the model, there is an overestimation of k21. 
Mrp2 KO mice show a similar uptake in comparison with WT mice, which is reflected in 
similar k12 en k21 values. In contrast, the efflux is as expected significantly decreased (lower 
k20 values. 
In conclusion, kinetic parameters obtained using a two-tissue compartment model of 
[99mTc]MEB can be used to quantify (altered) hepatobiliary transport, which can be suitable 
during drug development.  
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Introduction 
One of the underlying causes of drug-induced liver cholestasis is an altered functional activity 
of hepatic uptake or efflux transporters. In chapter 5, we demonstrated that dynamic µSPECT 
imaging of [99mTc]MEB is a useful method to discriminate quantitatively between the lack of 
functional activity of sinusoidal uptake and biliary efflux transporters. Therefore, this method 
can be used to investigate the interaction between new chemical entities and hepatobiliary 
transporters (Neyt et al., 2013).  
During drug development, the FDA requires in vivo toxicity studies conducted in at least two 
different animal species before human studies can be performed. In these preclinical 
toxicology studies, many hepatotoxicants remain undetected due to species differences, also 
known as the “preclinical species specificity issue”. There can be a difference in transporter 
expression, substrate affinity, physiological function, compensatory mechanisms and 
metabolic pathways, and this can lead to a difference in hepatotoxicant tolerance. Therefore, 
in the context of interpreting hepatotoxicity data from animal models, it is important to assess 
and understand the potential interspecies differences in mechanisms of drug toxicity. One of 
these mechanisms is hepatobiliary transport of drugs. Interspecies differences in transporter 
expression and substrate affinity can lead to interspecies differences in hepatic concentration 
of the drugs. For example, Wang et al. (Wang et al., 2015) compared and quantified 
interspecies differences in expression of the hepatobiliary transporters in liver tissue and 
hepatocytes of beagle dogs, cynomolgus monkeys, Sprague-Dawley rats and Wistar rats. 
They found that there were notable interspecies differences in the relative abundance of 
hepatic transporters. Li et al. (Li et al., 2008) also reported a 10-fold higher hepatic Mrp2 
expression in rats compared to humans. Therefore, species differences should be considered 
carefully during the interpretation of preclinical data and in translating the preclinical findings 
to the clinic. 
In Chapter 5 and 8, the effect on human transporters was tested by means of CHO- and HEK- 
cell lines that were transfected with the human transport proteins. However, there is a need for 
in vivo human-specific identification tools. Investigations of new drug candidates in human 
subjects is expensive, time-consuming and regulatory complex and therefore, there is a need 
for the development of preclinical methodologies and models that provide more predictive 
information about human drug metabolism or pharmacodynamic responses (de Lima 
Toccafondo Vieira and Tagliati, 2014; Xu et al., 2014; Peltz et al., 2013). 
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Consequently, chimeric mice models with a humanized liver were introduced to overcome 
this issue. In this chapter, we investigate human-type hepatobiliary transport of 
[99mTc]mebrofenin ([99mTc]MEB) in vivo in chimeric urokinase-type Plasminogen Activator 
SCID mice, since this model could offer a better understanding of interactions of drugs on  
[99mTc]MEB transport via mainly human transporters in vivo.   
The mice that were used in the current study were transplanted with human hepatocytes at the 
Center of Vaccinology at Ghent University. To allow successful repopulation of human 
primary hepatocytes into mice, rejection of the graft by the host’s immune system must be 
avoided and an environment that promotes engraftment and expansion of liver cells must be 
created. (Meuleman et al., 2005; Meuleman and Leroux-Roels, 2008) Therefore, urokinase-
type plasminogen activator (uPA)-transgenic mice were created. The liver-specific (albumin-
promoter) overexpression of the uPA-transgene causes a severe chronic liver disease, hereby 
creating an environment that favors hepatocyte engraftment. These mice were backcrossed 
with immunodeficient SCID mice, thereby avoiding rejection of the transplanted xenogeneic 
human hepatocytes (Yoshizato et al., 2013). The success of human liver cell engraftment and 
expansion in the transplanted uPA+/+ transgenic SCID mice can be evaluated by quantifying 
human albumin levels in mouse plasma (HuAlb, in mg/mL) at regular intervals. Several 
weeks after transplantation, a high proportion of diseased liver tissue, sometimes exceeding 
90%, is replaced by human hepatocytes (Meuleman and Leroux-Roels, 2009).  
 
Figure 7.1: Generation of a humanized mouse model. (a) Human hepatocytes are obtained and isolated via the 
collagenase perfusion method. (b) intrasplenic transplant of the human hepatocytes in 10-14 day old mice (d) 
After transplantation, chimerism is evaluated by determination of human albumin in mouse serum samples 
(adapted from Moreno et al., 2007).  
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In these humanized mice, normal [99mTc]MEB transport was investigated to characterize the 
chimeric model. To study the effect of liver disease in itself, heterozygous mice of 5 and 8 
weeks, which experience spontaneous somatic deletion of the transgene, thereby generating 
healthy mouse hepatocytes that can quickly repopulate the diseased liver, were used as 
controls.  
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Materials and Methods 
Animal Model 
Chimeric uPA+/+ SCID (“humanized mice”, n= 11) and uPA+/- SCID (heterozygous) mice of 5 
and 8 weeks (n=3 per group) were obtained from the Center of Vaccinology at Ghent 
University. The chimeric mice were produced as described previously (Meuleman et al., 
2005). Briefly, uPA+/+ SCID mice were transplanted with primary human hepatocytes within 
2 weeks after birth. uPA+/- SCID mice were not transplanted and served as control animals. 
WT mice were obtained from Janvier (France). The mice were housed and handled according 
to guidelines approved by the European Ethics Committee and acclimatized for at least one 
week before the experiments. All the animals were kept under environmentally controlled 
conditions (12 h normal light/dark cycles, 20–22°C and 60% relative humidity) with food and 
water ad libitum. The study was approved by the Animal Experimental Ethical Committee of 
Ghent University (ECD13/01). 
 
Molecular Imaging 
Dynamic µSPECT/CT acquisitions were acquired on a USPECT-II/CT device (MILabs, 
Utrecht, The Netherlands) equipped with a cylindrical collimator containing 75 pinholes of 1 
mm diameter (rat whole-body collimator; spatial resolution, 0.8 mm). All acquisitions were 
acquired in list mode.  
After an overnight fast (minimum 6 h), the mice were anesthetized with a mixture of 
isoflurane (1.5%) and medical O2 to allow placement of an intravenous needle (30G) and 
polyethylene (PE10) tubing (Becton Dickinson, Belgium) in a lateral tail vein. The mice were 
placed in a prone position on the mouse scan bed. 200 µL (37-74 MBq; 2 mg MEB)  
[99mTc]MEB was injected via the intravenous PE10 tubing, directly after scan initiation. 
Mice were imaged while anesthetized, with their body temperature maintained during 
imaging using a heated bed. The axial field of view required for the SPECT scan was chosen 
based on 3 planar X-ray images. Subsequently, a 15 min dynamic SPECT acquisition using 
60 time frames of 15 s was initiated 5 s before the injection of [99mTc]MEB. Lastly, a CT 
acquisition (5 min; tube current, 612 µA; tube voltage, 50 kV) was performed for anatomical 
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correlation. The resultant CT scan is inherently co-registered with the corresponding µSPECT 
acquisition. 
The dynamic SPECT scans were iteratively reconstructed using an ordered subsets 
expectation maximization algorithm (3 iterations; 16 subsets; 0.75 mm voxel size; decay 
correction), including only those photons from the acquired list-mode data with an energy 
range of 140 keV ± 20 %. After reconstruction, three regions of interest (ROIs) were 
manually drawn over the liver, the gallbladder+intestines and the urinary bladder using PMod 
software (PMod Technologies, Zürich, Switserland) to obtain a time activity curve (TAC) for 
each ROI. The total activity in each organ, expressed in MBq (normalized to an injection of 
37 MBq and a mouse weight of 20 g), was expressed as a function of time (in seconds). 
 
Statistical analysis 
Statistical analysis was performed using Prism, version 3.00 (GraphPad, USA), and SPSS, 
version 22, for Windows (IBM, USA). The TACs were described by calculating the maximal 
activity in the liver and time-to-peak of the liver (i.e. the time point at which the maximal 
tracer amount or plateau was reached) as indicators of the uptake, and maximal activity in the 
gallbladder+intestines and area under the gallbladder and intestines curve 
(AUCgallbladder+intestines) as indicators of the efflux. AUCs were calculated using the trapezoidal 
method.  The humanized mice were divided in 4 groups:  
1) Human albumin level > 5 mg/mL, weight ≤ 11g (n=1) 
2) Human albumin level > 5 mg/mL, weight > 11g (n=2) 
3) Human albumin level < 5 mg/mL, weight ≤ 11g (n=4) 
4) Human albumin level < 5 mg/mL, weight > 11g (n=4) 
Differences between the groups were tested for significance using the nonparametric Mann-
Whitney U or Kruskal-Wallis test. A p-value of 0.05 was considered as significant. Due to the 
small sample size in certain groups (n=2) in combination with the nonparametric test, a p-
value between 0.05 and 0.1 was considered as marginally significant. 
  
Chapter 7: [99mTc]mebrofenin transport in a humanized mouse model 
140 
Results 
[99mTc]MEB disposition in mice with liver disease (heterozygous mice) 
Figure 7.2 displays the time activity curves of [99mTc]MEB of the liver (Figure 7.2, A) and 
gallbladder+intestines (Figure 7.2, B) in heterozygous mice (uPA+/- SCID) of 5 and 8 weeks, 
compared to that in WT mice. The corresponding metrics are shown in Table 7.1. A 
significant difference was found between the time-to-peak in the liver, maximal activity in the 
gallbladder and the AUCgallbladder+intestines between WT and heterozygous mice of 5 weeks 
(Mann Whitney U test, p≤0.05), and between WT and heterozygous mice of 8 weeks (Mann 
Whitney U test, p≤0.05). The boxplots are shown in Figure 7.3. 
 
Figure 7.2 Mean time activity curves + SD (n=3) of liver (A) and gallbladder + intestines (B) of wild type, 8-
week-old heterozygous and 5-week-old heterozygous mice. 
 
Table 7.1: Metrics of the TACs of heterozygous mice. Data are mean ± SD (n=3). 
 Maximal activity 
liver (MBq) 
Time-to-peak 
liver (s) 
Maximal activity 
gallbladder+intestines (MBq) 
AUCgallbladder+intestines 
(MBq x s) 
uPA+/- 8 weeks 20.19 ± 1.86 233 ± 15 24.74 ± 1.25 11957 ± 2053 
uPA+/- 5 weeks 17.90 ± 4.22 413 ± 79 14.03 ± 3.95 5634 ± 2669 
WT 21.88 ± 2.95 168 ± 17 35 ± 1.76 20100 ± 1028 
 
In heterozygous mice of 5 weeks, the time-to-peak was 2.5 times later, the maximal activity in 
the gallbladder and intestines 2.5 times lower, and the AUCgallbladder+intestines 3.6 times smaller 
compared to WT mice (all p-values ≤ 0.05). In heterozygous mice of 8 weeks, the time to 
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peak was 1.4 times later, the maximal activity in the gallbladder and intestines 1.5 times 
lower, and the AUCgallbadder+intestines 1.7 times smaller compared to WT mice (all p-values ≤ 
0.05). 
 
Figure 7.3: Boxplots of the maximal liver activity (A), time-to-peak in the liver (B), the maximal activity in 
gallbladder+intestines (C) and the AUC of gallbladder+intestines (D) in heterozygous mice (n=3 per group). 
 
[99mTc]MEB disposition in chimeric (humanized) mice  
Figure 7.4 displays the time activity curves of [99mTc]MEB of the liver and 
gallbladder+intestines in chimeric “humanized” mice. The corresponding metrics are shown 
in Table 7.2. A significant difference was found in efflux metrics, namely the maximal 
activity in gallbladder+intestines, and the AUCgallbladder+intestines (Kruskal-Wallis test; p≤0.05). 
Boxplots are shown in Figure 7.5. 
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Figure 7.4: Time activity curves of liver (A) and gallbladder + intestines (B) of humanized mice. 
 
 
Figure 7.5: Boxplot of the maximal liver activity (A), time-to-peak in the liver (B), the maximal activity in 
gallbladder+intestines (C) and the AUC of the gallbladder+intestines (D) in humanized mice. Significant 
differences are indicated. *: p≤0.05; Δ: 0.05<p<0.1.  
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Table 7.2: Metrics of TACs of humanized mice.  
 Maximal activity 
liver (MBq) 
Time-to-
peak liver (s) 
Maximal activity 
gallbladder+intestines (MBq) 
AUCgallbladder+intestines 
(MBq x s) 
HuAlb>5 mg/mL, 
weight≤11g  
(n=1) 
22.76* 278* 14.08* 6068* 
HuAlb<5 mg/mL, 
weight≤11g (n=4) 
18.36 ± 1.39 180 ± 40 21.13 ± 2.25 9799 ± 1234 
HuAlb>5 mg/mL, 
weight>11g 
(n=2) 
22.15 ± 3.30 218 ± 85 17.64 ± 5.59 7888 ± 2534 
HuAlb<5 mg/mL, 
weight>11g 
(n=4) 
19.70 ± 1.70 169 ± 31 27.20 ± 2.07 14642 ± 1704 
WT (n=3) 21.88 ± 2.95 168 ± 17 35 ± 1.76 20100 ± 1028 
 
After pairwise comparison of the significant different parameters (the efflux metrics: maximal 
activity in gallbladder+intestines, and AUCgallbladder+intestines), a significant lower maximal 
activity in gallbladder+intestines, and a significant lower AUCgallbladder+intestines was found for 
both parameters in  1) all the humanized mice (≤ 11g and > 11g) with human albumin levels 
larger than 5 mg/mL compared to WT mice and 2) mice with human albumin levels below 5 
mg/mL and weight lower or equal than 11g, compared to WT mice (p≤0.05).  
Additionally, a marginally significantly lower maximal activity in the gallbladder and 
intestines, and smaller AUCgallbladder+intestines (0.05<p<0.1) was found in mice with a weight 
larger than 11g and a high human albumin level, compared to mice with a weight larger than 
11g and a low human albumin level. Lastly, a marginally significantly lower maximal uptake 
in liver and gallbladder+intestines, and smaller AUCgallbladder+intestines was found in mice with 
high human albumin level and low weight, compared to mice with a low human albumin level 
and high weight.    
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Discussion 
In the current study, the aim was to investigate human-type [99mTc]MEB transport by means 
of SPECT imaging in mice with a humanized liver, expressing human OATPs and MRP2. 
Consequently, this model could offer a better understanding of interactions of drugs with 
human transporters, since species differences are avoided. Heterozygous mice were used as 
controls, to assess the effect of the liver disease in itself (Wang et al., 2015; Yoshizato et al., 
2013; Peltz et al., 2013; Xu et al., 2015).  
First, we demonstrated that the heterozygous mice have impaired liver function, which is 
reflected in decreased maximal uptake value in the liver, decreased AUCliver and decreased 
AUCgallbladder+intestines. Additionally, we demonstrated that the liver function improved in time. 
This can be explained by the fact that the heterozygous mice experience a spontaneous 
somatic deletion of the transgene, thereby generating healthy mouse hepatocytes that can 
quickly repopulate the diseased liver and that can restore liver function. Liver function can 
thus be followed in time by means of repeated SPECT imaging of [99mTc]MEB. 
Molecular SPECT imaging of the chimeric “humanized” mice demonstrated that the liver 
function, and more in particular liver efflux of [99mTc]MEB, is dependent on the weight of the 
animal and the human albumin level in mouse plasma, since these mice exhibit different 
amounts of human and murine hepatocytes. uPA+/+ SCID mice have high uPA activity, which 
leads to a lower weight. The lower the weight, the higher the uPA activity and the higher the 
effect of the liver disease in itself (cf. heterozygous mice) (Tateno et al., 2015). Additionally, 
it has been demonstrated that mice with a high human serum albumin level have more 
functional human hepatocytes compared to mice with low human serum albumin levels. The 
repopulation indexed (RI%) is higher in mice with high human albumin levels (Tateno et al., 
2004; Okumura et al., 2007; Tateno et al., 2015). Normal hepatic uptake of [99mTc]MEB was 
observed in all groups, and this was reflected in similar uptake metrics in all the “humanized” 
mice compared to WT mice. This indicates that there is a normal hepatic blood flow and 
functioning of the human hepatic uptake transporters, OATP1B1 and OATP1B3. However, 
efflux parameters are significantly decreased in “humanized” mice compared to WT mice. 
Additionally, marginally significant differences are found in the efflux parameters between 
several groups. This can be explained by differences in efflux between rodents and humans.  
Arguments for this hypothesis can be found in the literature. In 2008, Li et al. (Li et al., 2008) 
reported a fourfold higher elimination rate of Mrp substrates in rats compared to humans. 
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They used hepatocyte fluorescent dye efflux assays and demonstrated marked species 
differences on MRP/Mrp function between rat and human, with a higher elimination rate 
observed in rat hepatocytes. In 2009, Li et al. (Li et al., 2009) reported and even quantified the 
absolute species difference in Mrp2 expression. They found a 10-fold higher Mrp2 amount in 
the liver of rats compared to humans.  
Wang et al. (Wang et al., 2015) also reported a lower MRP2 abundance in human hepatocytes 
compared to rat hepatocytes. They studied and quantified transporter abundances of 
hepatobiliary transporters in human, beagle dogs, cynomolgus monkeys, Sprague-Dawley rats 
and Wistar rats. They found interspecies differences in the transporter abundances. The 
findings of Li et al. and Wang et al. are in accordance with our findings: decreased efflux in 
mice with a humanized liver.  
Ohtsuki et al. (Ohtsuki et al., 2014) determined the protein expression levels of transporters in 
the uPA/SCID “humanized” mouse model in order to validate the model. They found that 
protein expression levels in plasma membrane fractions of humanized mice were similar 
compared to protein expression levels in plasma membrane fraction of the corresponding 
human liver. However, they found a difference in expression level between several subjects 
and also found these differences in the corresponding transplanted mice. Consequently, 
differences between several humanized mice could be explained by inter-donor differences on 
the protein expression level. However, the humanized mice in the current study received 
hepatocytes from the same donor, so the inter-subject difference cannot be the cause of altered 
efflux.  
Additionally, differences in Mrp2/MRP2 transporter affinities for numerous substrates were 
previously reported (Takekuma et al., 2007; Ishizuka et al., 1999; Ninomiya et al., 2005; 
Shilling et al., 2006). For example, Ishizuka et al. (Ishizuka et al., 1999) reported a 12.9-fold 
lower Km value of 2,4-dinitrophenyl-S-glutathione into canalicular membrane vesicles of 
mice compared to humans, which is a measure for a higher affinity. Takekuma et al. 
(Takekuma et al., 2007) reported a 3.6-fold higher affinity for glucuronized mycophenolic 
acid of rat Mrp2 compared to humans.  
The pronounced interspecies difference in the biliary excretion of Mrp2/MRP2 substrates can 
thus result from a combination of the protein expression level (Vmax) and the intrinsic 
transporter affinity (Km) for its substrates.  
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We can conclude that functional liver imaging in the current study revealed differences in 
liver functionality between WT and humanized uPA+/+ SCID mice, and between the different 
groups of humanized mice. Consequently, the selection of mice for the mechanistic evaluation 
of new drug candidates or metabolism studies must be handled with care. Molecular SPECT 
imaging can thus be a useful screening method to carefully select a homogenous group of 
chimeric mice with similar liver function.   
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Introduction 
As outlined in Chapter 1, bile acids play an essential role in the absorption of lipids, 
cholesterol and lipid-soluble vitamins in the intestinal lumen. The majority of the bile acids 
undergo efficient enterohepatic cycling, whereas only 5% of the bile acids enter the colon and 
are excreted from the body. Hepatobiliary transport proteins are essential for this 
enterohepatic cycling of bile acids. The most important bile acid transporters in the liver are 
OATPs, NTCP, BSEP and MRP2. A detailed discussion is given in Chapter 1.  
Additionally, these hepatobiliary transport mechanisms are crucial for the overall excretion 
process of substrate toxic compounds, such as drugs, xenobiotics and toxins. This essential 
function makes the liver vulnerable to drug toxicity, since numerous drugs are substrates or 
inhibitors of hepatic transporters and hence, unexpected and unwanted interactions are 
frequently observed (Maddrey, 2005; Shitara et al., 2005). As stated in Chapter 1 and 5, it is 
important to assess the inhibition of hepatic transporters early in the development of new drug 
candidates. In Chapter 5, dynamic µSPECT scanning of [99mTc]mebrofenin ([99mTc]MEB) 
was proposed as non-invasive method to visualize and quantify normal and disturbed 
hepatobiliary transport in a non-invasive manner (Neyt et al., 2013). However, [99mTc]MEB 
has no chemical similarities with endogenous bile acids. To assess non-invasively the effect 
of inhibition of hepatobiliary transporters on endogenous bile acids, there is a need for labeled 
bile acid analogues. 
Previously, Gadolinium (Gd)(III), fluorescent, 18F and 11C labeled bile acid analogues were 
synthetized, as discussed in Chapter 2. Typically, these tracers have some shortcomings: 
Gd(III) labeled contrast agents do not allow dynamic imaging and larger amounts have to be 
administered. The fluorescently labeled bile acid analogues have a lower tissue depth, the 
radioactive tracers labeled with 18F and 11C are difficult to synthetize (e.g. need for cyclotron) 
and 11C tracers have a short half-life.  
The aim of the current study is the (radio)synthesis of a technetium labeled chenodeoxycholic 
and cholic acid analogue: technetium labeled diethylene triamine pentaacetic acid 
chenodeoxycholic acid ([99mTc]DTPA-CDCA) and technetium labeled diethylene triamine 
pentaacetic acid cholic acid, ([99mTc]DTPA-CA), respectively. Technetium was used as 
radioisotope since it is easily produced (it can be eluted from a generator), its suitable half-life 
(6 hours) and its limitless depth of penetration. Additionally, in vitro assays have been 
performed to identify the involved uptake and efflux transporters. Lastly, in vivo µSPECT 
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evaluation of normal and disturbed hepatobiliary transport have been performed to illustrate 
the ability of these agents to visualize and quantify (altered) hepatobiliary transport in vivo. 
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Materials and methods 
General procedures and materials 
Unless stated otherwise, all chemical reagents were obtained from commercial sources and 
used without further purification. Mebrofenin (N-(3-bromo-2,4,6 
trimethylphenylcarbamoylmethyl)-iminodiacetic acid) was obtained as a commercial kit from 
GE Healthcare (Bridatec®) in a preparation containing 40 mg of mebrofenin and 0.3 mg of 
tin(II)chloride-dihydrate.  [99mTc]TcO4- was eluted from a sterile [99mTc]-generator (Drytec; 
GE Healthcare). Exact mass measurements were performed on a Waters LCT Premier XETM 
Time of Flight (ToF) mass spectrometer equipped with a standard electrospray (ESI) and 
modular Lockspray TM interface. Samples were infused in a acetonitrile (MeCN) / water 
(1:1) + 0.1 % formic acid mixture at 100 µL/min. Where reversed phase flash purification was 
performed, Reveleris C18 RP 12g cartridges were used on a Reveleris X2 device (Grace) with 
a flow rate of 20 mL/min and a water:acetonitrile gradient (from 10 to 95% acetonitrile in 20 
minutes; with 0.1% formic acid added to the solvents). Radiochemical yield/purity was 
determined by means of RP-HPLC (Econosphere C18 10 µm, length 250 mm, ID 10.0 mm 
(Grace)) with radiodetection (Ludlum Measurments Inc., Model 2200). A 20 minutes gradient 
was used at a flow rate of 6 mL/min (from 10 to 95% acetonitrile in 20 minutes; 0.1% formic 
acid). Radioactivity in cell lysates was acquired on an automatic gamma counter (COBRA, 
Perkin Elmer).  
 
Animal models 
FVB mice (female; age: 5 weeks; weight: 20–25 g) were purchased from Janvier, and were 
housed and handled according to guidelines approved by the European Ethics Committee and 
acclimatized for at least 1 week before the experiments. All animals were kept under 
environmentally controlled conditions (12-h normal light/dark cycles, 20°C–24°C, and 40-
70% relative humidity) with food and water ad libitum. The study protocol was approved by 
the Animal Experimental Ethical Committee of Ghent University (ECD12/62). 
 
Chemistry 
A summary of the (radio)synthesis is displayed in Figure 8.1.  
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Figure 8.1: Overview of the (radio)synthesis of the technetium labeled chenodeoxycholic acid analogue, 
[99mTc]DTPA-CDCA ([99mTc]-3a) and cholic acid analogue, [99mTc]DTPA-CA ([99mTc]-3b). Reagents and 
conditions: (a) dimethoxypropane, methanol, hydrochloric acid, 91% (1a), 83% (1b); (b) ethylenediamine, 
methanol, 98% (2a), 98% (2b); (c) dimethylformamide, triethylamine, DTPA(bis)anhydride, 26% (3a) and 16% 
(3b); (d) stannous chloride, pertechnetate ([[99mTc]]O4-), radiochemical purity >95%. 
 
Synthesis of methyl (R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (1a) and 
methyl (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate (1b) 
Chenodeoxycholic and cholic acid (1g, 2.55 and 2.45 mmol respectively) were dissolved in 
MeOH (5mL).  2,2-dimethoxypropane (2.5 mL) and 0.15 mL 12M hydrochloric acid were 
added. The resulting mixture was stirred at room temperature overnight and subsequently 
evaporated under reduced pressure (Rohacova et al., 2009). Next, the residue was dissolved in 
EtOAc, washed with saturated NaHCO3, brine, dried over MgSO4, filtered and evaporated 
under reduced pressure till dryness to obtain 1a and 1b (91% and 83% yield, respectively), 
which were used in the next step without further purification. MRMS (ESI) calculated for 1a 
[C25H42O4] [M+H]+: 407.3161, found: 407.3159; [2M+H]+: 813.6249, found: 813.6251. 
MRMS (ESI) for 1b [C25H42O5]  [M+H]+: 423.3110, found: 423.3118; [2M+H]+: 845,6137, 
found: 845,6198. 
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Synthesis of (R)-N-(2-aminoethyl)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7 
dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamide (2a) and (R)-N-(2-aminoethyl)-4-((3R,5S,7R,8R,9S, 
10S,12S,13R,14S,17R)-3,7,12 -trihydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamide (2b) 
1a and 1b (300 mg, 0.738 mmoles and 0.710 mmol respectively) were dissolved in 10 mL 
MeOH and an excess of ethylenediamine (0.45 mL, 6.711 mmol) was added (Pandey et al., 
2002). The reaction mixtures were stirred overnight at 50°C. The solvents were evaporated 
under reduced pressure and the crude products were purified by column chromatography 
(20% (NH3 7M in MeOH) in DCM (v/v)) to give 2a and 2b. Compounds containing fractions 
were pooled and evaporated under reduced pressure. The resulting residue was stirred in di-
isopropylether overnight, after which the materials were filtered and dried in vacuo to obtain 
2a and 2b in 98% and 98% yield, respectively. MRMS (ESI) for 2a [C26H46N2O4]  [M+H]+: 
435.3581, found: 435.3585. MRMS (ESI) for 2b [C26H46N2O3]  [M+H]+: 451.3531, found: 
451.3488.  
 
Synthesis of (R)-3,6,9-tris(carboxymethyl)-19-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-
3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)-11,16-dioxo-3,6,9,12,15-pentaazaicosanoic acid (3a) and (R)-3,6,9-
tris(carboxymethyl)-11,16-dioxo-19-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-
trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-
3,6,9,12,15-pentaazaicosanoic acid (3b) 
2a and 2b (97 mg;0.450 mmol and 101 mg;0.450 mmol respectively) were coupled to DTPA-
bis-anhydride (120 mg, 0.338 mmol) (Anelli et al., 2004). Towards this end 5.5 µL (0.3 
mmol) of water was added to a solution of DTPA-bis-anhydride and triethylamine (0.2 mL) in 
anhydrous DMF (10 mL). After 2 hours of stirring at room temperature, 2a or 2b was added 
and stirring continued for 72 hours. Then, the pH was adjusted to 7 with 6 M HCl. The 
solvent was evaporated under reduced pressure and the crude product was redissolved in 
50:50 (v:v) MeCN:H2O. Subsequently, the products were purified by RP-flash 
chromatography (Reveleris X2; ELSD detection; column: Reveleris C18, 12g (Grace)) to give 
DTPA-CDCA (3a) and DTPA-CA (3b) in 26% and 16% yield, respectively. MRMS (ESI) for 
3a [C40H67N5O12]  [M+H]+: 810.4859, found: 810.4952. MRMS (ESI) for 3b [C40H67N5O13]  
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[M+H]+: 826.4808, found: 826.4789. The total yield was 23% and 13% yield for 3a and 3b, 
respectively. 
 
Radiosynthesis 
[99mTc]-incorporation was done by a direct labeling method (Sinha et al., 2009) giving 
[99mTc]DTPA-CDCA ([99mTc]-3a) and [99mTc]DTPA-CA ([99mTc]-3b). To 2.25±0.25 mg of 
compound dissolved in 50 µL saline in a shielded lead vial, 60 µL of 10-2 M SnCl2.2H2O 
solution (dissolved in N2 purged 10% acetic acid) was added. Then, pH was adjusted to 6.5 
with 0.2 M NaHCO3, followed by addition of freshly eluted saline solution of sodium 
pertechnetate (185 MBq, 50 µL). Subsequently, the pH was again adjusted to 6.5 with 0.2 M 
NaHCO3. The vial was allowed to incubate for 30 minutes at room temperature. 
Radiochemical purity was determined by means of RP-HPLC. 
 
In vitro uptake assays 
Chinese hamster ovary (CHO) cells, CHO-OCT, Human Embryonic Kidney (HEK), 
HEK293-OATP1B3 cells were purchased from Solvo Biotechnologies (Hungary); CHO-
NTCP and HEK293-OATP1B1 cells were a kind gift from the same company. CHO-NTCP, 
CHO-OCT1, HEK293-OATP1B1 and HEK293-OATP1B3 cells were stably transfected with 
genes encoding human NTCP (SLC10A1), OCT1 (SLC22A1), OATP1B1 (SLCO1B1), and 
OATP1B3 (SLCO1B3), respectively. The cell lines were cultured in a humidified atmosphere 
at 37°C in the presence of 5% CO2. The culture medium of the CHO cells consisted of 
Dulbecco’s modified Eagle’s medium (DMEM)/F12, supplemented with 10% fetal calf 
serum, 2 mM L-glutamine, 0.3 mM L-proline, and antibiotics (Penicillin/Streptomycin; 50 
U/mL; 50 µg/mL). The culture medium of the HEK293 cells consisted of DMEM glutamax; 
high glucose; pyruvate supplemented with 10% fetal calf serum, 5 mL MEM-non essential 
amino acid solution, and antibiotics (Penicillin/Streptomycin; 50 U/mL; 50 µg/mL). 
For transport experiments, all CHO and HEK cells were seeded in 24-well plates (4.0×105 
cells/well; n=3/cell line) in 1 mL of the corresponding culture medium. After 18–24 h, 
medium was removed and cells were washed twice with washing buffer (1 mL sterile 
HBSS+/+ (HBSS with Ca2+ and Mg2+), 10 mM HEPES, pH=7.4, 37°C). Incubation buffers 
(250 µL/well) were obtained by adding the radiolabeled compounds to the washing buffer. 
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Final concentrations of the positive controls were 1 µM [3H]-estradiol-17β-glucuronide 
(E17βG, for OATP1B1), 1 µM [3H]-taurocholic acid (TCA, for NTCP) and 1µM [14C]-tetra-
ethyl-ammonium (TEA, for OCT1). Concentrations of the test compounds ([99mTc]DTPA-
CDCA and [99mTc]DTPA-CA) were 1, 2, 5, 10, 20, 50, 100 µM (for all cell lines). The plates 
were incubated at 4°C or 37°C and 5% CO2 for 5, 10, 20, 30, 60, 90, 120, 180 minutes. The 
incubation was stopped by placing the plates on ice and adding 1 ml of ice-cold HBSS+/+ 
with 1% BSA. Next, the cells were washed twice more with 2 mL HBSS+/+ and the 
supernatant was removed. The cells were lysed with 250 µL mammalian protein extraction 
reagent and the plates were shaken for 10 minutes at 400 rpm at room temperature. A 150 µL 
aliquot of this solution was used for gamma counting. Protein content was determined by 
means of a BCA kit (Thermo Scientific). 
 
In vitro vesicular efflux assay 
HEK293-MRP2, HEK293-BSEP and HEK293-CTRL vesicles were purchased from 
PharmTox (The Netherlands). To determine the involved efflux transporters, ATP-binding 
cassette transporter vesicles transfected with human MRP2 or BSEP were used. Membrane 
vesicles (7.5 µg of protein per well) were incubated at 37°C in a final volume of 30 µL. The 
buffer used was Tris (10 mM)/sucrose (250 mM) with or without 4mM ATP, MgCl2 (10 mM) 
and [99mTc]DTPA-CDCA or [99mTc]DTPA-CA (20 µM) and incubated for 15, 30, 60 or 90 
minutes. The reaction was stopped by addition of 150 µL of ice-cold buffer and the well 
content was transferred to a glass fiber filter plate (Multiscreen HTS plates; Merck Millipore) 
and washed 3 times with buffer. Then, 100 µL 0.1 M NaOH was added and incubated at room 
temperature for 10 minutes to lyse the vesicles. An 80 µL aliquot of this solution was used for 
gamma counting.  
 
Molecular imaging 
Whole-body µSPECT/CT acquisitions were acquired on a USPECTII/CT device (MILabs) 
equipped with a cylindrical collimator containing 75 pinholes of 1 mm diameter (rat whole-
body collimator; spatial resolution, 0.8 mm). All acquisitions were acquired in list mode. 
After an overnight fast (minimum 6 hours), mice (n=6) were anesthetized with a mixture of 
1.5% isoflurane and medical O2 to allow placement of intravenous needle (30G) and 
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polyethylene (PE10) tubing (Becton Dickinson) in a lateral tail vein. The mice were placed in 
a prone position on the mouse scan bed and were imaged while anesthetized, with their body 
temperature maintained during imaging using a heated bed. Subsequently, in untreated mice 
(n=3) a 120 minutes dynamic whole-body SPECT acquisition using 120 time frames of 1 
minute was initiated 5 seconds before the injection of 200 µL of [99mTc]DTPA-CDCA or 
[99mTc]DTPA-CA (37 MBq). Finally, a CT acquisition (5min; tube voltage, 50 kV; tube 
current, 612 µA) was performed for anatomical correlation. The resultant CT scan is 
inherently co-registered with the corresponding µSPECT acquisition. Additionally, an in vivo 
inhibition experiment was performed. Mice (n=3) were injected with rifampicin (100 mg/kg; 
IP) 60 minutes before tracer injection. Another dose of 25 mg/kg rifampicin was co-
administered with the radiotracer (IV) and the same imaging protocol was performed.  
All dynamic SPECT scans were iteratively reconstructed using an ordered subsets expectation 
maximization algorithm (3 iterations; 16 subsets; 0.75 mm voxel size; decay correction), 
including only those photons from the acquired list-mode data with an energy range of 140 
keV±20%. After reconstruction, regions of interest (ROIs) were manually drawn over the 
heart, liver, gallbladder+intestines and urinary bladder using PMod software (PMod 
Technologies) to obtain a time activity curve (TAC) for each ROI. ROI volumes varied 
between 67 and 1578 mm³. Additionally, reconstructions of different phases (early phase: 0 - 
10 minutes; late phase: 10 – 120 minutes) were performed to visualize the distribution of 
[99mTc]MEB as function of time. Three-dimensional projection images of the co-registered 
CT and µSPECT images were performed using ImageJ software.  
 
Statistical analysis 
Statistical analysis was performed using Prism, version 3.0 (GraphPad), and SPSS version 22, 
for Windows (Microsoft). For the in vitro uptake assays, uptake in function of time was 
determined. Additionally, Michaelis Menten constants and associated maximum transport 
rates were calculated by means of GraphPad Prism (nonlinear regression). The time–activity 
curves were described by calculating the maximal tracer amount in the liver and in the 
gallbladder and intestines, the time point at which tracer maximized (time to peak) in the 
liver, and the AUC in the blood, liver and gallbladder and intestines. AUCs were calculated 
using the trapezoidal method. Total, hepatic, biliary and urinary clearance rates were 
calculated.  
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𝑇𝑜𝑡𝑎𝑙 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =
𝐷𝑜𝑠𝑒
𝐴𝑈𝐶𝑏𝑙𝑜𝑜𝑑 ,0→∞
 
𝐻𝑒𝑝𝑎𝑡𝑖𝑐 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =  
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝑙𝑖𝑣𝑒𝑟
𝐴𝑈𝐶𝑏𝑙𝑜𝑜𝑑,0→180
 
𝐵𝑖𝑙𝑖𝑎𝑟𝑦 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =  
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝐺𝐵 + 𝐼
𝐴𝑈𝐶𝑏𝑙𝑜𝑜𝑑 ,0→180
 
𝑈𝑟𝑖𝑛𝑎𝑟𝑦 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =  
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝑢𝑟𝑖𝑛𝑎𝑟𝑦 𝑏𝑙𝑎𝑑𝑑𝑒𝑟
𝐴𝑈𝐶𝑏𝑙𝑜𝑜𝑑,0→180
 
 
Differences between 2 groups were tested for significance using the nonparametric Mann–
Whitney test for 2 groups. All experiments were performed on 3 wells per time point or 
concentration (unless stated otherwise); a p-value of 0.05 or smaller was considered 
significant.  
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Results 
Radiosynthesis 
Radiochemical purities were higher than 95% within 30 minutes. In its final formulation or 
dissolved in the appropriate buffer for the in vitro experiment, the tracers showed no 
alterations in radiochemical purity for up to 4h after the end of the synthesis.  
 
In vitro uptake assays 
The transfected cell lines are fully functional, which is confirmed by the uptake of positive 
controls (cf. Figure 5.5, Chapter 5). The uptake of [3H]-TCA, [14C]-TEA and [3H]-E17-BG is 
respectively 255-, 11-, 256- and 50-fold higher in CHO-NTCP, CHO-OCT1, HEK293-
OATP1B1 and HEK293-OATP1B3 compared to their parent/mock cell line.  
Figure 8.2 shows the in vitro uptake of 20 µM [99mTc]DTPA-CDCA ([99mTc]-3a) and 
[99mTc]DTPA-CA ([99mTc]-3b) after 60 minutes (Figure 8.2 A and C, respectively) and with 
or without rifampicin co-incubation (Figure 8.2 B and D, respectively). Without inhibitor, 
significantly higher uptake is observed for both tracers in HEK293-OATP1B1 and HEK293-
OATP1B3 compared to their controls, HEK293-MOCK. After 60 minutes, the uptake of 
[99mTc]DTPA-CDCA is 534.2±6.0 and 316.8±8.1 pmol/mg protein in OATP1B1 and 
OATP1B3 transfected cell lines, respectively. The uptake in the MOCK transfected cell lines 
was 82.2±4.9 pmol/mg protein. The uptake of [99mTc]DTPA-CA was 212±7.6, 110.9±2.1 and 
50.8±1.7 pmol/mg protein in OATP1B1, OATP1B3 and MOCK transfected cell lines, 
respectively. For both tracers, no significantly higher uptake was observed in NTCP and 
OCT1 transfected cell lines.  
After co-incubation with 100 µM rifampicin, a known OATP inhibitor, the uptake is 
significantly lower for both tracers in the OATP transfected cell lines. The uptake of 
[99mTc]DTPA-CDCA after rifampicin administration amounts to 100.2±13.9 and 87.9±13.4 
pmol/mg protein in OATP1B1 and OATP1B3 cell lines, respectively. The uptake of 
[99mTc]DTPA-CA after rifampicin administration amounts to 72.4±1.6 and 85.8±1.9 pmol/mg 
protein in OATP1B1 and OATP1B3 cell lines, respectively.  
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Figure 8.2: In vitro uptake of 20 µM[99mTc]DTPA-CDCA ([99mTc]-3a) (A) and [99mTc]DTPA-CA ([99mTc]-3b) 
(C) after 60 minutes. Uptake of 20 µM[99mTc]DTPA-CDCA ([99mTc]-3a) and [99mTc]DTPA-CA ([99mTc]-3b) 
after 60 minutes with or without co-incubation with 100 µM rifampicin (B, D, respectively) (n=3). Data are 
mean ± SD. *= significant difference (p ≤ 0.05). 
 
Figure 8.3 depicts uptake kinetics for [99mTc]DTPA-CDCA ([99mTc]-3a, Figure 8.3 A); 
[99mTc]DTPA-CA ([99mTc]-3a), Figure 8.3 B) and [99mTc]MEB (Figure 8.3 C). The uptake 
increased and saturated with increasing concentrations of substrate for all three tracers and for 
both cell lines (OATP1B1 and OATP1B3 transfected cell lines). The Michaelis-Menten 
constants (Km) with associated maximum transport rates (Vmax) were calculated (Table 8.1). 
Both tracers show a higher affinity compared to [99mTc]MEB. The lower Km of [99mTc]DTPA-
CDCA indicates a higher affinity for both OATP1B1 and OATP1B3 compared to 
[99mTc]DTPA-CA. The affinity for OATP1B1 is higher than the affinity for OATP1B3, for all 
the tracers. Vmax values of [99mTc]DTPA-CDCA and [99mTc]DTPA-CA were lower compared 
to Vmax value of [99mTc]MEB, indicating a lower transport capacity, which can also be 
concluded from the in vitro clearance values (Table 8.1). 
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Figure 8.3: In vitro uptake of [99mTc]DTPA-CDCA ([99mTc]-3a, A), [99mTc]DTPA-CA ([99mTc]-3b, B) and 
[99mTc]MEB (C) (n=3). Data are mean ± SD. 
 
Table 8.1: Michaelis Menten constants and associated maximum transport rates of [99mTc]DTPA-CDCA 
([99mTc]-3a) and [99mTc]DTPA-CA ([99mTc]-3b) and [99mTc]MEB. Data are mean ± SD (n=3). 
 Cell line Km (µM) Vmax (pmol/mg 
protein/min) 
Clearance 
(Vmax/Km; 
mL/mg/min) 
[99mTc]DTPA-CDCA HEK293-OATP1B1 8.45±0.75 11.3±0.29 0.0013 
HEK293-OATP1B3 13.7±1.24 9.10±0.27 0.00066 
[99mTc]DTPA-CA HEK293-OATP1B1 61.7±5.25 13.6±0.36 0.00022 
HEK293-OATP1B3 162±16.9 14.1±0.70 0.000087 
[99mTc]MEB HEK293-OATP1B1 958±78.8 (60.5±1.70) x 103 0.063 
HEK293-OATP1B3 3547±294 (90.2±3.97) x 103 0.025 
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In vitro vesicular efflux assay 
To determine the involved efflux transporters, ATP-binding cassette transporter vesicles 
transfected with human MRP2 or BSEP were used. The ATP-dependent [99mTc]DTPA-CDCA 
and [99mTc]DTPA-CA uptake was determined in canalicular inside-out membrane vesicles by 
a rapid filtration method. A time dependent uptake of the tracers was observed in presence of 
ATP in MRP2 vesicles (Figure 8.4). We observed a significantly higher uptake in MRP2 
vesicles in ATP+ conditions compared to ATP- conditions after 15, 30, 60 and 90 minutes for 
[99mTc]DTPA-CDCA; and after 30, 60 and 90 minutes for [99mTc]DTPA-CA (p≤0.05). There 
was no difference in uptake in ATP+ and ATP- conditions for control and BSEP vesicles at 
all time points.  
 
 
Figure 8.4: In vitro vesicular efflux assay. Uptake of 20 µM [99mTc]DTPA-CDCA ([99mTc]-3a, A) and 
[99mTc]DTPA-CA ([99mTc]-3b, B) after 15, 30, 60 and 90 minutes. Data are mean ± SD (n=3). *= significant 
difference (p ≤ 0.05). 
 
Molecular imaging 
In vivo µSPECT imaging of mice revealed uptake of both radiotracers in liver, gallbladder, 
intestines and urinary bladder. Figure 8.5 shows 3D projection images of co-registered CT 
and µSPECT images of [99mTc]DTPA-CDCA (Figure 8.5 A, B) and [99mTc]DTPA-CA 
(Figure 8.5 C, D) during the first 10 minutes (early phase, Figure 8.5 A and C) and during the 
last 110 minutes (late phase, Figure 8.5 B and D). In the early phase, [99mTc]DTPA-CDCA is 
taken up in the liver, gallbladder and urinary bladder. [99mTc]DTPA-CA is taken up in liver 
and urinary bladder. In the late phase, the mean distribution of the tracers show mainly uptake 
in the intestines and urinary bladder. 
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Figure 8.5: Projection images of co-registered CT and µSPECT images of 37 MBq of [99mTc]DTPA-CDCA 
([99mTc]-3a)  (A, B) and [99mTc]DTPA-CA ([99mTc]-3b) (C, D) in a WT mouse during the first 10 minutes (A, C) 
and during the last 110 minutes (B, D) of the dynamic µSPECT acquisition (120 frames, 1 minute/frame).  
 Time activity curves of [99mTc]DTPA-CDCA and [99mTc]DTPA-CA in WT and rifampicin 
treated mice are shown in Figure 8.7 and the corresponding metrics are shown in Table 8.2.  
[99mTc]DTPA-CDCA (Figure 8.7 A) and [99mTc]DTPA-CA (Figure 8.7 C) show a maximal 
liver uptake of respectively 13.83±0.58 MBq and 9.50±1.45 MBq after 12.67±1.53 and 
12.00±1.00 minutes, followed by a decrease to baseline levels, indicating secretion. 
A secretion maximum to gallbladder and intestine of 23.00±2.00 MBq and 17.67±2.61 MBq 
for [99mTc]DTPA-CDCA and [99mTc]DTPA-CA, respectively, indicates secretion of the 
radiotracer to gallbladder and intestines. Additionally, in the urinary bladder, an accumulation 
of activity was observed with a maximal uptake of respectively 5.10±0.71 and 13.00±1.98 
MBq (Figure 8.7 A and B, Table 8.2). After 4 hours, the remaining radioactivity was located 
in the intestines and no activity was observed in the urinary bladder, since the urinary bladder 
was emptied. 
Next, we investigated the effect of rifampicin administration on [99mTc]DTPA-CDCA and 
[99mTc]DTPA-CA transport. Rifampicin is both a substrate and an inhibitor of OATPs and 
MRP2, and therefore, it was selected as test agent. Figure 8.6 shows 3D projection images of 
co-registered CT and µSPECT images of [99mTc]DTPA-CDCA (Figure 8.6 A, B) and 
[99mTc]DTPA-CA (Figure 8.6 C and D) after rifampicin administration during the first 10 
minutes (early phase, Figure 8.6 A and C) and during the last 110 minutes (late phase, Figure 
8.6 B and D). In the early phase, less liver uptake of [99mTc]DTPA-CDCA and [99mTc]DTPA-
CA is observed; mainly the blood pool and heart are visible. Additionally, the urinary bladder 
is visible. In the late phase, the mean distribution of the tracers shows mainly uptake in the 
urinary bladder, in contrast to the WT mouse (Figure 8.5). 
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Figure 8.6: Projection images of co-registered CT and µSPECT images of 37 MBq of [99mTc]DTPA-CDCA 
([99mTc]-3a)  (A, B) and [99mTc]DTPA-CA ([99mTc]-3b) (C, D) in a rifampicin treated WT mouse during the first 
10 minutes (A, C) and during the last 110 minutes (B, D) of the dynamic µSPECT acquisition (120 frames, 1 
minute/frame). 
 
 
Figure 8.7: Time activity curves (TACs) of [99mTc]DTPA-CDCA ([99mTc]-3a) (A, B) and [99mTc]DTPA-CA 
([99mTc]-3b) (C, D) in WT (n=3) (A, C) and RIF treated (n=3; 100 mg/kg IP, 60 minutes before imaging; 25 
mg/kg IV, coinjected with tracer) (B, D) mice after intravenous injection of 37 MBq radiotracer and dynamic 
µSPECT imaging (120 frames; 1 minute/frame). TACheart (blood) is expressed as MBq/mL (left y-axis); all other 
TACs are expressed as MBq (right y-axis). Data are mean±SD. Green= liver, blue= gallbladder+intestines, 
black= urinary bladder, red= blood. 
 
The time-activity curves of the rifampicin treated mice (100 mg/kg intraperitoneally, 25 
mg/kg intravenously) are shown in Figure 8.7 B D. Corresponding metrics are shown in Table 
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8.2. Compared to control mice, the maximum liver uptake was 2.6- and 2.8-fold lower in 
rifampicin treated mice compared to control mice (p≤0.05) for [99mTc]DTPA-CDCA and 
[99mTc]DTPA-CA, respectively. Additionally, the liver AUC was 1.5- and 3.1-fold lower in 
rifampicin treated mice for [99mTc]DTPA-CDCA and [99mTc]DTPA-CA, respectively. In 
rifampicin treated mice the AUC and the maximal tracer activity in the gallbladder and 
intestine for [99mTc]DTPA-CDCA was 7.6 times lower compared to control animals. For 
[99mTc]DTPA-CA, the maximal tracer activity in the gallbladder and intestine was 36 times 
lower and gallbladder/intestine AUC was 32 times lower, when rifampicin treated mice are 
compared to control animals. The mean blood AUC in RIF treated mice was 2.6-fold and 2.1-
fold larger than in their control counterparts. There was no significant difference between 
urinary bladder Cmax and AUC. 
When clearance values are compared (Table 8.2), a significant lower total, hepatic and biliary 
clearance can be observed (p≤0.05). 
Table 8.2: Metrics of the time activity curves of the heart (blood pool), liver, gallbladder/intestines and urinary 
bladder after injection of 37 MBq of tracer. *: 100 mg/kg intraperitioneal 60 minutes before tracer injection; 25 
mg/kg intravenous, coinjected with tracer. (n=3 per group) Data are mean±SD. 
 [99mTc]DTPA-
CDCA 
[99mTc]DTPA-
CDCA + RIF* 
[99mTc]DTPA-CA [99mTc]DTPA-CA 
+ RIF* 
Maximum liver 
uptake (MBq) 
13.8±0.58 5.2±0.40 9.5±1.45 3.37±0.49 
Liver Time to peak 
(min) 
12.7±1.53 N/A 12.0±1.00 N/A 
Liver AUC  
(MBq x min) 
755±81.1 499±157 582±21.5 185±52.0 
Maximum secretion 
to gallbladder + 
intestines  (MBq) 
23.0±2.00 3.30±0.28 17.7±2.61 0.48±0.8 
Gallbladder + 
intestines AUC 
(MBq x min) 
1926±178 253±67.9 1250±171 39.0±15.6 
Urinary bladder 
Cmax (MBq) 
5.10±0.71 10.6±2.05 13.0±1.98 18.5±2.19 
Urinary bladder 
AUC (MBq x min) 
425±85 758±182 1093±80.6 1098±397 
Blood AUC 
(MBq/mL x min) 
426±125 1138±262 353±58.3 742±217 
Total clearance 
(mL/min) 
0.075±0.023 0.015±0.0025 0.10±0.017 0.039±0.017 
Hepatic clearance 
(mL/min) 
0.035±0.014 0.0049±0.0011 0.027±0.0063 0.0047±0.00098 
Biliary clearance 
(mL/min) 
0.057±0.015 0.0030±0.00094 0.049±0.0039 0.00077±0.000061 
Urinary clearance 
(mL/min) 
0.010±0.0011 0.0093±0.00033 0.034±0.0058 0.030±0.00062 
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Discussion 
 [99mTc]MEB is an OATP1 and MRP2 substrate that is used in nuclear medicine to investigate 
the (dys)function of liver and gallbladder. In Chapter 5, we demonstrated the ability of non-
invasively visualizing and quantifying disturbed hepatic transport by drugs or genetic defects 
by means of µSPECT imaging of [99mTc]MEB (Neyt et al., 2013). However, [99mTc]MEB is a 
lidocain analogue and has no similarities with endogenous bile acids. Therefore, in the current 
study, a procedure for the synthesis and radiolabeling of two bile acid analogues was 
developed, which resemble endogenous primary bile acids, for in vitro uptake and efflux 
experiment and in vivo µSPECT studies. These compounds can possibly be used to 
investigate the disturbances of hepatobiliary transport mechanisms by drugs in vivo. DTPA-
chenodeoxycholic acid (DTPA-CDCA, 3a) and DTPA-cholic acid (DTPA-CA, 3b) were 
synthetized from respectively chenodeoxycholic and cholic acid by esterification with 
methanol, exchange of the methylester with ethylenediamine and subsequent coupling with 
DTPA-bis-anhydride as chelating agent. Finally, these bile acid analogues were successfully 
labeled by technetium incorporation. 
In vitro evaluation of both compounds showed that the human uptake transporters OATP1B1 
and OATP1B3 are involved in the uptake of both tracers. For [99mTc]DTPA-CDCA, Km 
values of 8.45±0.75 µM and 13.7±1.24 µM were obtained for OATP1B1 and OATP1B3, 
respectively, while for [99mTc]DTPA-CA, these values were 61.7±5.25 µM and 162±16.9 µM, 
respectively. When these Km values are compared to the Km values of endogenous bile acids, 
values which were in the same range were observed (Km OATP1B1 cholate: 11.4±2.3 µM for 
OATP1B1 (Cui et al., 2001); Km Oatp1 taurocholic acid= 19.4 ±3.3 µM, Km 
taurodeoxycholic acid: 3.5±0.25 µM (Hata et al., 2003)). Additionally, similar transport was 
observed of the previously reported fluorescent tracer cholyl-l-lysyl-fluorescein (CLF) (de 
Waart et al., 2010; Milkiewicz et al., 2001). Indeed, the structures of [99mTc]DTPA-(CD)CA 
are comparable to that of CLF in that, all three structures are primary bile acids with 
modifications on the carboxyl moiety. Km values of CLF were in the same range as 
[99mTc]DTPA-(CD)CA (Km for OATP1B3 of CLF: 4.6±2.7 µM; no Km of OATP1B1 was 
reported). When the newly synthetized tracers were compared with the lidocain analogue 
[99mTc]MEB, which is commonly used in nuclear medicine for hepatobiliary imaging, lower 
Km values were observed (Km values of [99mTc]MEB of 957±78.8 µM and 3547±294 µM; for 
OATP1B1 and OATP1B3, respectively).  
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Vmax values of [99mTc]DTPA-CDCA and [99mTc]DTPA-CA were lower compared to that of 
[99mTc]MEB, indicating that the efficiency of the active transport is much lower for the bile 
acid analogues (Table 8.1). However, the transport rates that are observed for [99mTc]DTPA-
CDCA and [99mTc]DTPA-CA are in the same range as the transport rates of endogenous 
chenodeoxycholic acid and cholic acid (Vmax Oatp1 taurocholic acid: 62±1.4 pmol/mg 
protein/min; Vmax Oatp1 taurodeoxycholic acid: 199±27 pmol/mg protein/min (Hata et al., 
2003)). In conclusion, the synthesized bile acid analogues show more similarities with 
endogenous bile acid transport, in comparison with [99mTc]MEB. 
To summarize, the new tracers have a higher affinity (Km) and a lower transporter capacity 
(Vmax). The clearance (Vmax/Km) is slower for both compounds compared to [99mTc]MEB. 
Additionally, our data confirm previous studies that the side chain of bile acids is essential for 
NTCP transport. Baringhaus et al. (Baringhaus et al., 1999) determined the pharmacophore of 
both NTCP and ASBT (ASBT is the ileal counterpart, NTCP and ASBT are homologous bile 
salt transporters), and found that the 3-OH group is not essential for transport by these 
transporters, in contrast to the acidic side chain. Our data are completely in line with this 
model. In contrast to [99mTc]DTPA-(CD)CA, a fluorescent bile salt conjugate, 
taurocholylchlorambucil, was found to be a substrate for human NTCP (Kullak-Ublick et al., 
1997). This compound is conjugated at the 3-OH position of the bile acid, whereas our 
compounds are conjugated at the side chain. This confirms that the 3-OH position is not 
essential for transport, whereas the side chain is. The less specific bile salt transporters, 
OATP1B1 and OATP1B3, are more likely to be involved in uptake of [99mTc]DTPA-(CD)CA 
into the hepatocyte, which is in line with the broad substrate specificity of these transporters 
(de Graaf et al., 2011). After co-incubation with rifampicin, a known OATP inhibitor, uptake 
of  [99mTc]DTPA-CDCA in OATP1B1 and OATP1B3 transfected cell lines was 5- and 4- fold 
reduced, respectively. Uptake of [99mTc]DTPA-(CD)CA was 2 and 1.3-fold reduced, 
respectively. Consequently, this also confirms that these two transporters are involved in the 
uptake of [99mTc]DTPA-CDCA and [99mTc]DTPA-CA, since rifampicin is a known OATP 
inhibitor (Neyt et al., 2013). 
Finally, a difference in in vitro uptake between the two analogues was observed, probably due 
to the presence or absence of the hydroxyl group at the C12 position. Our findings are in 
agreement with Hata et al. (Hata et al., 2004), who stated that the transport of trihydroxy bile 
acids was below that of dihydroxy bile acids. Indeed, we also reported that the transport of the 
Chapter 8: Synthesis, in vitro and in vivo evaluation of technetium labeled bile acid analogues 
169 
trihydroxy analogue, [99mTc]DTPA-CA is 2.5- and 3-fold lower in OATP1B1 and OATP1B3 
transfected cell lines, respectively, compared to the transport of the dihydroxy analogue 
[99mTc]DTPA-CDCA. This difference in transport was also reflected in the in vivo results. 
Vesicular efflux experiments identified MRP2 as the involved efflux transporter, and not 
BSEP. Uptake in MRP2 transfected inside-out vesicles at 60 minutes was respectively 2- and 
1.5-fold higher in presence of ATP, compared to conditions without ATP. This is in 
accordance with the findings of Gerloff et al. (Gerloff et al., 1998), who demonstrated that 
unconjugated cholate is not transported by rat Bsep. This is also supported by the observation 
that in patients with a defect in bile acid conjugation practically no unconjugated bile acids 
are found in bile (Carlton et al., 2003). Additionally, de Waart et al. (de Waart et al., 2010) 
stated that CLF is no BSEP substrate. There seems to be a negative correlation between BSEP 
substrates and molecular weight. MRP2, in contrast, can accommodate larger molecules than 
BSEP. Since the molecular weight of the bile acid analogues in this study was almost doubled 
due to DTPA coupling to the primary bile acid, efflux transport by MRP2 and not BSEP can 
be explained by the size of the analogues. Our findings are thus completely in line. 
Preclinical in vivo evaluation revealed that both compounds showed uptake in the liver and 
efflux to gallbladder and intestines. [99mTc]DTPA-CDCA showed more uptake in the liver 
and efflux to gallbladder and intestines compared to [99mTc]DTPA-CA that is cleared in a 
higher extent by the kidneys. This is in line with the findings of Hata et al. (Hata et al., 2003), 
who stated that dihydroxy bile acids show better transport compared to trihydroxy bile acids. 
Additionally, our in vitro data also support these in vivo findings: uptake of [99mTc]DTPA-CA 
was lower compared to [99mTc]DTPA-CDCA in transfected OATP1B1 and OATP1B3 cells. 
No enterohepatic recirculation was observed for both compounds. Asbt is the ileal counterpart 
(homologous bile salt transporters) of Ntcp (Dawson et al., 2009), and consequently, these in 
vivo data, together with the finding that rifampicin can inhibit transport of both tracers, 
support the finding that Ntcp is not involved in transport of [99mTc]DTPA-(CD)CA. Since 
there is no recirculation of these bile acids analogues, the radiation dose is reduced.  
Our in vitro data also supports the in vivo findings of the current study and a previous study in 
which we investigated the hepatobiliary transport of [99mTc]MEB (Neyt et al., 2013). We 
observed lower Vmax values for [99mTc]DTPA-(CD)CA compared to [99mTc]MEB. In vivo, we 
also observed slower transport compared to [99mTc]MEB.  The time to peak in the liver was 
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2.5 minutes for [99mTc]MEB, whereas the time to peak was 12.0 and 12.7 minutes for 
[99mTc]DTPA-CDCA and [99mTc]DTPA-CA, respectively. 
Determination of the influence of newly synthetized drugs on liver transporters is important to 
detect possible pharmacological inhibition that can lead to hepatotoxicity. To assess the effect 
of pharmacological inhibition on transporter activity, rifampicin was administered as model 
drug, by both the intraperitoneal and the intravenous routes. This double administration led to 
impaired uptake of both tracers. This was reflected in a low maximum uptake value in the 
liver and elevated blood concentrations. These tracers allow the detection and quantification 
of impaired hepatobiliary transport. 
To conclude, the current study showed that [99mTc]DTPA-CDCA as an imaging probe shows 
better in vitro and in vivo characteristics compared to [99mTc]DTPA-CA. It is mainly taken up 
in the hepatocytes by OATP1B1 and OATP1B3; and is secreted into bile canaliculi via 
MRP2. Dynamic µSPECT imaging can be a useful noninvasive method of visualizing and 
quantifying hepatobiliary transporter functionality and disturbances thereof in vivo, which 
could predict drug pharmacokinetics. 
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Drug induced liver injury (DILI) is the most frequent single cause of safety-related 
withdrawal of drugs from the market (for example iproniazid, troglitazone, benoxaprofen, 
etc.). Additionally, it is a major cause of attrition in the drug development process. Therefore, 
it is important to assess these interactions early in the drug development process.  
Drug-induced cholestasis is a type of DILI that can result from defects in bile formation in the 
hepatocytes or flow at the bile duct level and the retention of bile acids leads to liver injury. It 
presents as an acute or chronic illness that will fade out after termination of the medication. 
Many cases of drug-induced cholestasis are a result from functional inhibition of 
hepatobiliary transporter by the drug or its metabolites. When hepatobiliary uptake 
transporters are inhibited, it can cause drug-drug interactions, bilirubinemia or 
hypercholanemia. For example, OATPs mediate the uptake of antibiotics, statins, 
chemotherapeutic agents, which are associated with cholestatic liver injury. A significant 
increase in statin concentration in blood is observed after cyclosporine administration, due to 
OATP1B1 inhibition. Additionally, OATPs are associated with drug-induced 
hyperbilirubinemia, which causes transient jaundice due to impaired bilirubin clearance. 
Drugs that can cause hyperbilirubinemia are for example atazanavir, rifampicin, cyclosporine 
A, saquinavir, etc. Drug interference with MRP2 can cause hyperbilirubinemia. BSEP 
inhibition is also a major cause of drug-induced cholestasis: cyclosporine A, glibenclamide, 
troglitazone, rifampicin, etc. for example exibit cis-inhibition of BSEP in a concentration 
dependent manner. Inhibition of NTCP can lead to hypercholanemia. As stated before, it is 
important to detect these interactions from early on. 
Therefore, in this work our aim was to develop non-invasive predictive methods to visualize 
and quantify disturbed hepatobiliary transport by drugs in mice as an alternative to the 
existing invasive techniques. Rifampicin was used as model compound, since it is a known in 
vitro and in vivo OATPs/Oatps and in vitro Mrp2 inhibitor. Rifampicin is both substrate and 
inhibitor of OATP/Oatps. 1 oral dose of 10 mg/kg in mice ensures plasma and liver 
concentrations of 11,9 and 35 µM, respectively. Double administration of rifampicin (100 
mg/kg i.p. and 25 mg/kg i.v.), which was used in this work, ensures high rifampicin levels in 
blood and liver during the dynamic SPECT measurements, which in turn ensures Oatp and 
Mrp2 inhibition.  
In this work, our goal was to answer four research questions. 
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Question 1: Is it possible to visualize and quantify altered hepatobiliary transport in 
mice? (Chapter 5) 
We proposed a non-invasive method to visualize and quantify altered hepatobiliary 
transporter function by means of SPECT imaging of [99mTc]MEB in mice. Out of dynamic 
SPECT measurements, time activity curves (TACs) of the liver, gallbladder+intestines and 
blood pool were calculated and several metrics were obtained derived from these curves. The 
maximal liver uptake, time-to-peak in the liver and the area under the blood curve (AUCblood) 
could be used to quantify normal and disturbed hepatic uptake of [99mTc]MEB from the liver 
sinusoids into the hepatocytes via Oatp. The maximal activity in the gallbladder+intestines, 
emergence time of the gallbladder and AUCgallbladder+intestines could be used to describe and 
quantify normal and altered efflux from the hepatocytes to the gallbladder and intestines, via 
Mrp2. Repeated measurements were performed and interanimal and intra-animal variation 
was lower than 13% for all metrics. Experiments performed in Oatp1a/1b and Mrp2 knock-
out (KO) mice showed the critical roles of Oatp1a/1b and Mrp2, respectively, in the hepatic 
handling of [99mTc]MEB. Differences in metrics between Oatp1a1/1b KO and Mrp2 KO mice 
on the one hand and WT mice on the other hand are shown in Table 9.1. Pharmacological 
inhibition was achieved by rifampicin administration, a known Oatp and Mrp2 inhibitor. 
Rifampicin is both a substrate and inhibitor of Oatp. Therefore, a certain amount of rifampicin 
is able to enter the hepatocytes, where it can inhibit Mrp2, which was demonstrated by an 
accumulation of [99mTc]MEB in the liver. A comparison of the metrics of rifampicin treated 
mice with their vehicle controls is also shown in Table 9.1. To the best of our knowledge, we 
were the first to demonstrate in vivo Mrp2 inhibition. Our method offers a novel approach for 
in vivo visualizing and quantifying disturbed hepatobiliary transport, and the differentiation 
between uptake and efflux alterations. We demonstrated the feasibility of visualizing and 
quantifying the effect of Oatp1a/1b and Mrp2 modulation by various drugs in vivo, with 
rifampicin as model drugs. Additionally, we were able to show that slight alterations in 
transporter activity can be detected with the proposed imaging method. Therefore, this 
method offers a promising approach to investigate the interaction between new chemical 
entities and hepatobiliary transporters. 
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Table 9.1: Summary of results: comparison of Oatp1a/1b KO, Mrp2 KO and rifampicin treated mice with their 
control mice (vehicle controlled or WT mice). GB: gallbladder, GB+I: gallbladder+intestines, *: could not be 
observed, nd: not determined.  
 AUCblood Maximal 
activity 
liver 
Time-
to-
peak 
liver 
AUCliver Mean 
emergence 
time GB 
Maximal 
activity 
GB+I 
AUCGB+I k12 k21 k20 
Oatp1a/1b 
KO 
↑ ↓ * ↓ * * * nd nd nd 
Mrp2 KO = = = ↑ ↑ ↓ ↓ = = ↓ 
Rifampicin 
treated 
↑ ↓ ↓ ↑ ↑ ↓ ↓ ↓ ↑ ↓ 
 
Question 2: Can this quantification be further refined by kinetic modeling of 
[99mTc]MEB? (Chapter 6) 
Normal and disturbed hepatobiliary transport of [99mTc]MEB in mice were absolutely 
quantified by calculating kinetic parameters from a two-tissue compartmental model. Tracer 
kinetic modeling of [99mTc]MEB was performed and the following kinetic parameters were 
calculated: k12 that is a measure for the hepatic uptake of [99mTc]MEB from the liver sinusoids 
into the hepatocytes via Oatp, k21 that is a measure for the basolateral efflux of [99mTc]MEB 
and k20 that is a measure for the canalicular efflux of [99mTc]MEB from the liver to the 
gallbladder and intestines via Mrp2. Discrimination on a quantitative level between 
pharmacological inhibition of uptake and efflux was possible. Similar results were obtained 
compared to the study in Chapter 5: Mrp2 KO mice showed normal uptake and decreased 
efflux of [99mTc]MEB. Rifampicin treated mice showed decreased uptake and efflux of 
[99mTc]MEB. A comparison of the k-values of Mrp2 KO and rifampicin treated mice with 
their controls is shown in Table 9.1. Kinetic modeling enables a more robust estimation of 
disturbed hepatobiliary transport and estimation of k21, which is a measure for basolateral 
efflux. Additionally, a non-invasive image derived method was evaluated to obtain the input 
function, using [99mTc]tetrofosmin to visualize the left ventricle. A comparison between the 
image derived input function and the sampling blood curve showed similar curves. We can 
conclude that these kinetic parameters can also be used to describe disturbed hepatobiliary 
transport.  
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Question 3: Is a humanized mouse model useful for the prediction of disturbed human-
type hepatobiliary transport? (Chapter 7) 
It was demonstrated that the heterozygous mice, i.e. the mice that exhibit the liver disease 
caused by the uPA transgene, had an impaired Oatp and Mrp2 transporter function that was 
reflected in a lower maximal liver uptake, a decreased AUC liver and a decreased 
AUCgallbladder+intestines. The older the mice get, the better the liver function, due to a spontaneous 
somatic deletion of the transgene. Thus, the liver disease in itself causes an impaired liver 
function. Chimeric, “humanized” mice exhibited normal uptake values, indicating normal 
hepatic blood flow and functional human hepatic uptake transporters of [99mTc]MEB, namely 
OATP1B1/3. However, impaired liver efflux of [99mTc]MEB compared to WT mice was 
observed. The degree of impaired efflux was dependent on the human albumin level in mouse 
serum sample and the weight of the animal. The higher the human serum albumin level, the 
higher the repopulation index of the human hepatocytes and the more the efflux was impaired. 
This impaired efflux function can be caused by a pronounced interspecies difference in the 
biliary excretion of Mrp2/MRP2 at the level of the protein (Vmax) or at the level of the 
intrinsic transporter affinity (km) of the substrates, or a combination of both factors. It was 
concluded that the chimeric “humanized” mouse model could be useful to study 
pharmacologically disturbed hepatobiliary transport. However, the selection of mice must be 
handled with care, due to differences between several groups of humanized mice. Molecular 
SPECT imaging can be a useful screening method to select a homogenous group of 
humanized mice. 
 
Question 4: Can bile acid analogues serve as biomarkers for DILI? (Chapter 8) 
Technetium labeled diethylene triamine pentaacetic acid chenodeoxycholic acid 
([99mTc]DTPA-CDCA) and technetium labeled diethylene triamine pentaacetic acid cholic 
acid ([99mTc]DTPA-CA) were successfully synthesized and radiolabeled with radiochemical 
purities higher than 95% within 30 minutes. Both tracers remain stable in their final 
formulation or dissolved in the appropriate buffer for up to 4 hours. In vitro cellular uptake 
assays showed that OATP1B1 and OATP1B3 were involved in the uptake of both tracers. km 
values were in the same range of endogenous bile acids. When these bile acid analogues were 
compared to [99mTc]MEB,  lower km values were observed, indicating that the active 
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components are larger for the bile acid analogues compared to [99mTc]MEB, resulting in a 
higher affinity. Vmax values were lower compared to  [99mTc]MEB, which indicates that the 
efficiency of the active transport is much lower for the bile acid analogues. However, 
transport rates were in the same range as endogenous bile acids. When these bile acid 
analogues were compared to each other, less uptake was observed in the cholic acid analogue. 
This was also shown in the in vivo results and indicates that the transport of trihydroxy bile 
acids, like cholic acid, was below that of dihydroxy bile acids, like chenodeoxycholic acid. 
Vesicular efflux experiments identified MRP2 as the involved efflux transporter. In vivo 
evaluation in mice showed that both tracers are taken up in the liver and are then transported 
to gallbladder and intestines. Additionally, urinary clearance was observed and was larger in 
the cholic acid analogue, compared to the chenodeoxycholic acid analogue. After 
administration of rifampicin, almost no hepatic uptake and efflux was observed, due to Oatp 
and Mrp2 inhibition. Slower transport of both compounds compared to [99mTc]MEB was also 
observed in vivo that was in line with the in vitro findings. To the best of our knowledge, 
these were the first radiolabeled bile acid analogues that were fully characterized both in vitro 
and in vivo.  
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The drug development process is lengthy, costly and takes about 14 years from synthesis to 
marketing approval (Figure 10.1). Therefore, new strategies that aid the early detection of 
promising candidates or early termination of candidates that are unlikely to be successful, 
could improve the drug development process.  
 
 
Figure 10.1: The drug development pipeline (source: Janssen Pharmaceutica) 
 
Drug induced liver injury (DILI) is a form of acquired liver disease and is a major cause of 
safety-related withdrawal of drugs from the market (Figure 10.2). Additionally, it is a major 
cause of attrition during the drug development process. Although DILI is a rare event, it still 
represents a significant health problem because of its unpredictable nature, poorly understood 
pathogenesis and potential to cause a fatal outcome. Since DILI poses a significant burden to 
patient safety and to the cost of health care systems, it is crucial to assess the hepatotoxic 
potential of new candidate drugs early in the drug development process. It is important to 
improve the currently available prediction methods to identify and mitigate potential 
compound-related safety issues. This will result in safer drugs and a more efficient drug 
development process (Regev et al., 2014; Stevens et al., 2009). 
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Figure 10.2: Summary of target organ contributions to drug withdrawals from 1975-2007. Target organs were 
identified on the basis of the reasons for withdrawal. CV: cardiovascular; CNS: central nervous system; GI: 
gastrointestinal (adapted from Stevens et al., 2009).  
 
Drug-induced cholestasis is one of the major mechanisms in DILI and many cases are a result 
from functional inhibition of hepatobiliary transporters by the drug or its metabolites. 
Cholestasis occurs when there is a disturbance, metabolic or mechanical, in bile acid 
homeostasis. The accumulation of bile acids in hepatocytes can become cytotoxic and cause 
liver injury. Table 10.1 provides an overview of drugs that are associated with induced 
cholestatic syndromes (de Lima Toccafondo Vieira et al., 2014; Schadt et al., 2016; Padda et 
al., 2011; Maddrey et al., 2005). 
Table 10.1: Drugs associated with induced cholestatic syndromes. Listed drugs with at least 1000 reported cases 
of liver adverse events in the WHO database (adapted from de Lima Toccafondo Vieira et al., 2014 ). 
Clinical manifestation List of causative drugs 
Bland cholestasis Anabolic steroids, azathioprine, cetirizine, cyclosporine A, glimepiride, 
nevirapine, tamoxifen 
Cholestatic hepatitis Acitretin, amoxicillin-clavulanic acid, atorvastatin, azathioprine, bupropion, 
captopril, celecoxib, carbamazepine, chlorpromazine, fenofibrate, 
gabapentin, glimepiride, isoniazid, itraconazole, metformin, methyldopa, 
macrolide antibiotics, orlistat, propafenone, propylthiouracil, risperidone, 
terbinafine, ticlopidine, tricyclic antidepressants, troglitazone 
Cholestatic hepatitis 
associated with bile duct 
injury  
Amoxicillin-clavulanic acid, dextropropxyphene, flucoxacillin, pioglitazone 
Vanishing bile duct syndrome Amitriptyline, amoxicillin/clavulan ic acid, azathioprine, barbiturates, 
carbamazepine, chlorpromazine, cimetidine, ciprofloxacin, clindamycin, 
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diazepam, erythromycin, estradiolb, flucloxacillin, glibenclamide, 
haloperidol, ibuprofen, imipramine, methyltestosterone, phenytoin, 
terbinafine, tetracyclines, trimethoprim sulfamethoxazole 
Unconjugated 
hyperbilirubinemia 
Cyclosporine A, indinavir, rifampicin 
 
Currently, interactions of candidate drugs with hepatic transporters are investigated by means 
of in vitro, in silico and invasive, expensive and time-consuming in vivo experiments. An 
overview of the available methods is given in Table 10.2. 
 
Table 10.2: Current methods for the identification of drugs with cholestatic poten tial (adapted from de Lima 
Toccafondo Vieira et al., 2014). 
In vitro methods  Vesicular transport assay using membrane vesicles  
 Transfected cell lines 
 Suspended hepatocytes 
 In vitro biliary clearance technique using accumulation studies in 
sandwich-cultured hepatocytes (human and preclinical species) 
 Sandwich-cultured hepatocyte uptake and efflux assays  
 Ex vivo liver perfused technique  
 Xenobiotic metabolism 
In vivo based-methods  Blood chemistry (bile acids, bilirubin, etc.) 
 Hepatobiliary transporters rodent wild-type and knock-out models 
 Bile duct-cannulated rodent models  
In silico methods  Structure-activity relationship (SAR) and quantitative SAR modeling 
 3D-pharmacophore modeling 
 Chemical category approach 
 Analogue/read-across approach 
 
In vitro methods are valuable to provide an efficient development of safer drugs by 
identifying hepatotoxic potential during early stages. Additionally, these assays contribute to 
the understanding of the pathogenic mechanisms, and can assist in the design and testing of 
alternative compounds. An ideal in vitro model resembles the in vivo situation with relevant 
liver functions and mechanisms of hepatotoxicity. In vitro high-throughput assays allow early 
estimation of the potential cytotoxic effect that might otherwise go undetected during 
preclinical development (de Lima Toccafonda Vieira et al., 2014). 
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Two different types of in vitro assay systems can be distinguished: membrane-based and cell-
based assays. Membrane based assays use for example membranes isolated from baculovirus-
infected cells overexpressing BSEP/Bsep. BSEP inhibition was considered as the major 
mechanism of drug induced cholestasis and therefore, the majority of the in vitro models rely 
on detection of BSEP inhibition. However, other mechanisms (for example inhibition of other 
bile acid transporters) are involved. Therefore, cell lines transfected with human hepatic 
transporters were widely used. Additionally, cell-based assays were introduced as in vitro 
model to assess drug-induced toxicity caused by bile acid accumulation as a result of 
disturbed bile acid homeostasis, such as suspended hepatocytes and sandwich-cultured human 
hepatocytes (SCHH). SCHH allow simultaneous evaluation of hepatic uptake and efflux 
transport at the basolateral membrane, as well as biliary secretion at the canalicular membrane 
(Oorts et al., 2016; de Lima Toccafonda Vieira et al., 2014; Annaert et al., 2005; Wolf et al., 
2010; Nakanishi et al., 2011).  
In silico methods use computational modeling algorithms to gain insight into transporter-
substrate interactions. These models can identify chemical components that are important for 
interaction with hepatic transporters. 
During drug development, preclinical in vivo safety experiments are required. In these toxicity 
studies, increasing amounts of potential new drugs are administered to animals. Blood and 
bile samples are subsequently taken to measure bile acid and bilirubin concentrations in blood 
and bile (Bergman et al., 2010). These in vivo experiments require liver tissue and bile 
samples and are therefore very invasive. In addition, these studies cannot distinguish between 
uptake or efflux interactions.  
 
In this thesis, non-invasive in vivo methods were proposed as an alternative to the invasive, 
time-consuming and expensive in vivo models that are currently available to study drug 
induced cholestasis. The presented methods offer pharmaceutical companies a powerful non-
invasive tool to visualize and quantify possible interactions of new candidate drugs with 
hepatic transporters and to identify drug-drug interactions by means of molecular SPECT 
imaging. 
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Our methods are innovative, since we are using a combination of dynamic SPECT imaging 
and biomarkers (mebrofenin and bile acid analogues, both labeled with technetium) for 
visualizing and quantifying normal and disturbed hepatobiliary transport. Additionally, we 
were able to quantitatively discriminate between uptake and efflux alterations. We identified 
several parameters that were able to quantify alterations in hepatic uptake and/or efflux using 
[99mTc]MEB, [99mTc]DTPA-CDCA and [99mTc]DTPA-CA. Here, [99mTc]DTPA-CDCA and 
[99mTc]DTPA-CA were the first radiolabeled bile acid analogues that were completely 
characterized both in vitro and in vivo.  
Previously, Frisch et al. (Frisch et al., 2013), Jia et al. (Jia et al., 2014) and Schacht et al. 
(Schacht et al., 2016) also developed radiolabeled bile acid analogues to study drug-induced 
cholestasis or FXR-related diseases. However, no inhibitors were evaluated and no in vitro 
characterization was done. In this context, our technetium labeled bile acid analogues are the 
first analogues that were fully evaluated.  
The non-invasive SPECT imaging protocol of [99mTc]MEB can also be applied for the 
screening of the chimeric, “humanized” mouse model to carefully select a homogenous group 
of mice that can be used for the assessment of new candidate drugs in pharmacokinetic and 
metabolism studies. To detect small alterations between two groups, it is important to have a 
homogenous group of mice (Sanoh et al., 2014; Jaiswal et al., 2014). This chimeric model 
also offers advantages compared to normal mice, due to the preclinical species specificity 
issue in which many hepatotoxicants remain undetected in preclinical toxicity studies.  
Besides drug induced cholestasis, the bile acid analogues proposed in this thesis can also be 
used for other applications like functional liver assessment in cirrhosis, fibrosis, radiation 
induced liver injury, etc. Additionally, these analogues can be used to evaluate specific 
tumors. For example, OATP1B1 and OATP1B3 is downregulated in liver tumors, and 
OATP1B3 is frequently expressed in cancers of the gastrointestinal tract, breast, prostate and 
lung  and may be assoiciated with different clinical outcomes. For example, OATP expression 
in breast cancer is significantly associated with a hormone-dependent growth mechanism of 
the breast cancer, but patients expressing this OATP had a better prognosis. This can be 
explained by the fact that OATP also transports anticancer drugs, and this leads to a better 
response to anticancer therapy. Therefore, identification of OATP expression in these tumors 
can be beneficial and since [99mTc]DTPA-CDCA and [99mTc]DTPA-CA are substrates of 
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OATP1B1 and OATP1B3, these tracers can be used to visualize these tumors (Yamaguchi et 
al., 2006; Abe et al., 2001; Buxohofer-Ausch et al., 2013). 
However, there is still a need to investigate drug-induced cholestasis that is caused by NTCP 
and/or BSEP inhibition. The bile acid analogues used in this thesis are OATP and MRP2 
substrates, possibly due to large modifications that were done on the structure of the bile acids 
to allow 99mTc labeling. Therefore, 18F labeled bile acid analogues that require only minor 
modification on the bile acid structure are currently in development at our laboratory by Stef 
De Lombaerde and are very promising. These tracers can be used to assess pharmacological 
inhibition of NTCP and BSEP. An additional advantage of these bile acid analogues is their 
applicability in PET imaging. Dynamic PET imaging is more feasible in humans compared to 
dynamic SPECT and absolute quantification can be easily achieved. A disadvantage is the 
need of a cyclotron and the shorter half-life of the 18F isotope.  
 
To conclude, the future perspectives of this work are:  
(1) Mechanistic evaluation of new candidate drugs for OATP and/or MRP2 interactions 
by means of µSPECT imaging of [99mTc]MEB, [99mTc]DTPA-CDCA or 
[99mTc]DTPA-CA in normal or “humanized” mice. 
(2) Screening of “humanized” mice to obtain a homogenous animal group for further 
studies. 
(3) Evaluation of [99mTc]DTPA-CA and [99mTc]DTPA-CDCA for cancers that have 
decreased or increased OATP1 expression. 
(4) Synthesis, in vitro and in vivo evaluation of 18F labeled bile acid analogues, in order to 
search for NTCP and BSEP biomarkers. 
(5) Evaluation of radiolabeled bile acid analogues for functional liver assessment in liver 
diseases.  
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Summary 
The liver is an important organ for homeostasis. Its most important functions include 
glycogen storage, production of plasma proteins and bile acids, elimination of endogenous 
substances and secretion of toxic compounds like drugs, carcinogens, etc. Drugs can interfere 
with these important functions, which can lead to drug induced liver injury. Drug induced 
liver injury is a major cause for the withdrawal of drugs from the market or for the 
termination of the development of a new candidate drug. Additionally, up to 15% of the cases 
of acute liver failure in Europe and the United States is caused by drug induced liver injury. 
An example of interference of new candidate drugs with liver functionality is inhibition of 
hepatic transporters. Therefore, new strategies are needed to identify and characterize 
interactions of new candidate drugs with hepatic transporters early in the developmental 
process. In this thesis, we propose non-invasive methods to assess altered transporter function, 
as an alternative of the invasive, time-consuming and expensive preclinical in vivo tests. 
Chapter 1 provided an overview of the function of the liver, with a focus on the enterohepatic 
cycling of bile acids and their biosynthesis, the most common bile acid transporters and an 
introduction on drug induced liver injury. Additionally, the main characteristics of molecular 
imaging, and more specifically, preclinical functional SPECT and PET imaging were given. 
Dynamic imaging and tracer kinetic modeling was also discussed. Chapter 2 focused on 
functional liver imaging and hepatobiliary imaging agents for MR, optical imaging 
(fluorescence), PET and SPECT imaging. Bile acid analogues were discussed in detail. The 
scope and aims of this thesis were outlined in Chapter 3. 
In Chapter 4, the calibration curves of the NaI(Tl) scintalliation detector and SPECT camera 
were given. These calibration curves were used in the experimental sections to calculate exact 
radioactivity amounts and concentrations from the output of these two devices.  
Chapter 5 proposed a non-invasive in vivo method to visualize and quantify normal and 
disturbed hepatobiliary transport using [99mTc]mebrofenin ([99mTc]MEB), a tracer that is 
routinely used in the clinic to study function and dysfunction of the liver by planar 
scintigraphy. Wild type, bile duct ligated (mechanical inhibition), Oatp1a/1b knock-out (KO), 
Mrp2 KO and rifampicin treated (pharmacological inhibition) mice were evaluated by means 
of dynamic SPECT imaging after [99mTc]MEB injection. It was demonstrated that the 
transport activities of Oatp1a/1b (hepatic uptake) and Mrp2 (biliary efflux) could be 
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quantified simultaneously in vivo. Moreover, pharmacological modulation of these activities 
was demonstrated in a dose-dependent manner using rifampicin as a model drug.  
In Chapter 6, the quantification of normal and disturbed hepatobiliary transport was further 
refined by using tracer kinetic modeling of [99mTc]MEB. A two-tissue compartmental model 
was proposed and the dynamic SPECT data of WT, Mrp2 KO and rifampicin treated mouse 
was analyzed. Additionally, a non-invasive image-derived method was evaluated to obtain the 
blood input function and showed similar metrics compared to manual blood sampling, which 
is the gold standard. The kinetic parameters were also able to quantify altered hepatobiliary 
transport by Oatp and Mrp2, and to discriminate between altered uptake and efflux.  
Chapter 7 characterized [99mTc]MEB transport in chimeric mice with a humanized liver. 
These mice were transplanted with human hepatocytes and due to their liver disease and 
immunodeficiency successful engraftment was possible. SPECT imaging demonstrated that 
humanized mice showed normal hepatic uptake of [99mTc]MEB. However, efflux to 
gallbladder and intestines was impaired compared to WT mice. Additionally, when the 
different groups (based on different human albumin levels and different weights) of 
humanized mice were compared, differences were also observed. Consequently, [99mTc]MEB 
SPECT imaging was proposed as non-invasive method to select a homogenous group of 
humanized mice for metabolization studies.  
In Chapter 8, two primary bile acid analogues were synthesized and evaluated both in vitro 
and in vivo to study the effect of pharmacological inhibition on bile acid transport. 
Additionally, these compounds were compared to [99mTc]MEB. A technetium labeled 
chenodeoxycholic and cholic acid analogue were evaluated: technetium labeled diethylene 
triamine pentaacetic acid chenodeoxycholic acid ([99mTc]DTPA-CDCA) and technetium 
labeled diethylene triamine pentaacetic acid cholic acid ([99mTc]DTPA-CA). OATP1B1/3 and 
MRP2 were identified as the involved transporters of both compounds. In vivo SPECT 
evaluation showed uptake in the liver and efflux to gallbladder and intestines. 
Pharmacological inhibition with rifampicin blocked almost all the transport of the 
compounds. 
A general conclusion and an overview of the broader international context, relevance, and 
future perspectives were given in Chapter 9 and Chapter 10, respectively. 
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Samenvatting 
De lever is een belangrijk orgaan voor homeostase. De meest belangrijke functies van de lever 
zijn glycogeen opslag, productie van plasmaproteïnen en galzuren, eliminatie van endogene 
stoffen en secretie van toxische stoffen zoals geneesmiddelen, carcinogenen, etc. 
Geneesmiddelen kunnen interfereren met deze belangrijke functies, en dat kan dan leiden tot 
geneesmiddel geïnduceerde leverschade. Geneesmiddel geïnduceerde leverschade is één van 
de voornaamste oorzaken van het uit de handel nemen van geneesmiddelen of van de 
vroegtijdige stopzetting van de ontwikkeling van nieuwe geneesmiddelkandidaten. 
Daarenboven is meer dan 15% van de gevallen van acute leverschade in Europa en de 
Verenigde Staten een gevolg van geneesmiddel geïnduceerde leverschade. Een voorbeeld van 
interferentie van geneesmiddelen met leverfunctionaliteit is via inhibitie van transporters die 
aanwezig zijn in de lever. Bijgevolg is er een nood aan nieuwe strategieën om interactie van 
mogelijks nieuwe geneesmiddelen met deze transporters vroegtijdig te identificeren en te 
kwantificeren. In deze thesis worden niet-invasieve methodes om normaal en verstoord 
hepatobiliair transport te onderzoeken voorgesteld, als alternatief voor de bestaande invasieve, 
tijdrovende en dure preklinische in vivo experimenten. 
Hoofdstuk 1 gaf een overzicht van de leverfuncties. De nadruk lag op de enterohepatische 
cyclus van galzuren en hun biosynthese, de meest voorkomende galzuurtransporters en een 
introductie in verband met geneesmiddel geïnduceerde leverschade. Daarenboven werden de 
voornaamste eigenschappen van moleculaire beeldvorming besproken, en meer specifiek, van 
preklinische functionele SPECT en PET beeldvorming. Dynamische beeldvorming en 
kinetische modelering aan de hand van tracers werd ook uiteen gezet. In Hoofdstuk 2 lag de 
focus op functionele lever beeldvorming en hepatobiliary speurstoffen voor MR, optische 
beeldvorming (fluorescentie), PET en SPECT beeldvorming. Galzuuranalogen werden in 
detail besproken. In Hoofdstuk 3 werden de doelstellingen van deze thesis overlopen. 
In Hoofdstuk 4 werd een overzicht gegeven van de kalibratie curves van de NaI(Tl) 
scintillatie detector en de SPECT camera. Deze kalibratiecurves werden in de experimentele 
hoofdstukken gebruikt worden om de output van de meettoestellen om te zetten naar exacte 
hoeveelheden en concentraties radioactiviteit.  
Hoofdstuk 5 beschreef een niet-invasieve in vivo methode om normaal en verstoord 
hepatobiliair transport te visualiseren en te kwantificeren gebruik makende van 
[99mTc]mebrofenin ([99mTc]MEB). [99mTc]MEB wordt routinematig gebruikt in de nucleaire 
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geneeskunde om de functie en disfunctie van de lever te onderzoeken met behulp van planaire 
scintigrafie. Wild type muizen, muizen met een galwegligatie (mechanische inhibitie), 
Oatp1a/1b knock-out (KO), Mrp2 KO en rifampicine behandelde (farmacologische inhibitie) 
muizen werden onderzocht met behulp van dynamische SPECT beeldvorming na 
[99mTc]MEB injectie. Het werd aangetoond dat het mogelijk is om de transportactiviteiten van 
Oatp1a/1b (lever opname) en Mrp2 (biliaire efflux) simultaan te kwantificeren in vivo. 
Daarenboven kon farmacologische modulatie van deze transporters aangetoond worden op 
een dosisafhankelijke manier met rifampicine als modelgeneesmiddel. 
In Hoofdstuk 6 werd nagegaan of de kwantificatie van normaal en verstoord hepatobiliair 
transport kon uitgebreid worden via kinetische modelering van [99mTc]MEB. Een twee 
compartimenteel model werd voorgesteld en de dynamische SPECT data van WT, Mrp2 KO 
en rifampicine behandelde dieren werden geëvalueerd met behulp van dit model. 
Daarenboven werd een niet-invasieve methode geëvalueerd om de bloedcurve te bekomen 
van [99mTc]MEB. Deze curve werd vergeleken met degene die verkregen werd na manuele 
bloedname, welke de gouden standaard is, en gelijkaardige curves werden bekomen. De 
kinetische parameters die berekend werden met behulp van het model konden gebruikt 
worden om normaal en verstoord hepatobiliair transport te kwantificeren. Daarnaast was deze 
methode ook in staat verstoorde opname en efflux van elkaar te onderscheiden.  
Hoofdstuk 7 karakteriseerde [99mTc]MEB transport in een chimeer muismodel met een 
gehumaniseerde lever. Deze muizen werden getransplanteerd met humane levercellen, en 
door het feit dat ze immunodeficiënt zijn en een leverziekte hebben, was succesvolle 
transplantatie mogelijk. Na SPECT beeldvorming werd aangetoond dat deze muizen normale 
opname vertoonden van [99mTc]MEB.  Efflux naar galblaas en darmen was echter verstoord in 
vergelijking met wild type muizen. Daarenboven werd er een verschil in efflux waargenomen 
tussen de verschillende groepen (indeling gebaseerd op hun verschillend humaan 
albuminegehalte en gewicht) van gehumaniseerde muizen. Bijgevolg werd SPECT 
beeldvorming van [99mTc]MEB voorgesteld als niet-invasieve method om een homogene 
groep van gehumaniseerde muizen te selecteren voor metabolisatie studies.  
In Hoofdstuk 8 werden twee primaire galzoutanalogen gesynthetiseerd en in vitro en in vivo 
geëvalueerd. Daarnaast werden beide stoffen vergeleken met [99mTc]MEB. Een technetium 
gelabeld chenodeoxycholzuur and cholzuur analoog werden geëvalueerd: technetium gelabeld 
diethylene triamine pentaacetic acid chenodeoxycholic acid ([99mTc]DTPA-CDCA) en 
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technetium gelabeld diethylene triamine pentaacetic acid cholic acid, ([99mTc]DTPA-CA). 
OATP1B1/3 en MRP2 werden geïndentificeerd als betrokken transporters van beide stoffen.  
SPECT evaluatie toonde opname in de lever en efflux naar galblaas en darmen aan. 
Farmacologische inhibtie met rifampicine blokkeerde bijna al het levertransport van de 
stoffen.  
Een algemene conclusie en een overzicht van de bredere internationale context, relevantie en 
toekomstperspectieven zijn beschreven in Hoofdstuk 9 en Hoofdstuk 10, respectievelijk.  
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